"1","04-02-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2","04-02-12","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-AMIODARONE","MODIFICATION DU NOM DU PRODUIT DE RIVA-AMIODARONE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"3","04-02-06","TRANSKARYOTIC THERAPIES INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE SUBSTITUTION ENZYMATIQUE","",""
"4","04-01-23","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"5","04-01-23","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER","TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ","",""
"6","04-01-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: 70MG/75ML (FOR THE APPROVED INDICATION: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND IN MEN)","NOUVELLE FORMULE : 70MG/75ML (POUR L'INDICATION APPROUVÉE : TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES FEMMES POSTMÉNOPAUSIQUES ET CHEZ LES HOMMES)","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7","04-01-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ZENECA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"8","04-01-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ZENECA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9","04-01-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"10","04-03-15","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT, ANTIPARKISONIAN AGENT","ANTIVIRAL, ANTIPARKINSONIEN","",""
"11","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"12","04-03-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","AGONISTE ALPHA2-ADRÉNORÉCEPTEUR RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"13","04-03-02","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"14","04-02-12","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM BACLOFEN","MODIFICATION DU NOM DU PRODUIT DE BACLOFEN","MUSCLE RELAXANT ANTISPASTIC AGENT","RELAXANT MUSCULAIRE - ANTIPASMODIQUE","",""
"15","04-01-29","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOSUPPRESSANT","AGENT IMMUNOSUPPRESSEUR","",""
"16","04-03-10","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA INC.","CANADA","CANADA","1","CHANGE IN FORMULATION AND MANUFACTURING PROCESS","CHANGEMENT À LA FORMULATION ET AU PROCÉDÉ DE FABRICATION","ANTIANDROGEN","ANTIANDROGÈNE","",""
"17","04-03-03","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEACHAM INC.","CANADA","CANADA","1","","","Congestive heart failure agent","Agent pour l'insuffisance cardiaque congestive","",""
"18","03-12-17","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"19","04-03-03","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"20","03-12-09","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","ADDITION OF NEW STRENGTH","ADDITION D'UNE NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"21","03-11-04","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMACEUTICALS","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC AND B-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE B-LACTAMASES","",""
"22","03-10-24","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH TO INCLUDE THE INDICATION FOR REDUCING RISK OF A FIRST NON-FATAL MYOCARDIAL INFARCTION IN THE INFORMATION FOR THE CONSUMER SECTION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SECTION RENSEIGNEMENTS AU CONSOMMATEUR, POUR INCLURE L'INDICATION DE RÉDUCTON DU RISQUE D'UN PREMIER INFARCTUS NON MORTEL DU MYOCARDE","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"23","03-10-17","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN","",""
"24","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"25","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"26","03-09-29","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1, RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - ANTIMIGRAINEUX","",""
"27","03-09-11","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"28","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLOCORT 0.1% CREAM","STIEFEL CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","COTICOSTÉROÏDE TOPIQUE","",""
"29","03-08-27","GILEAD SCIENCES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"30","04-03-03","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"31","04-02-26","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"32","04-02-18","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPROBAY","BAYER AG","GERMANY","ALLEMAGNE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"33","04-02-18","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"34","04-02-18","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"35","04-02-18","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"36","04-02-18","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"37","03-08-25","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"38","04-02-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"39","04-02-18","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"40","04-02-18","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"41","04-02-18","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"42","04-02-18","DR REDDYS LABORATORIES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"43","04-02-12","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"44","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"45","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"46","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"47","04-01-29","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"48","03-08-13","SANGSTAT MEDICAL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","EXPANSION DU PROCÉDÉ DE FABRICATION","IMMUMOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"49","04-01-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PRODUCT MONOGRAPH RE: FIRST-LINE TREATMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR LE TRAITEMENT DE PREMIÈRE LIGNE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER & ANGIOTENSIN II AT1 RECEPTOR BLOCKER + DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II & ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II + DIURÉTIQUE","",""
"50","04-01-26","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"51","04-01-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"52","04-01-23","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"53","04-01-19","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"54","04-01-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"55","04-01-12","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"56","03-08-11","CHIRON CANADA ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REGULATORY RELIEF FROM IN-PROCESS AND FINAL PRODUCT RELEASE TESTING AND MODIFICATIONS TO LOT RELEASE PROTOCOL","MODIFICATION DE LA MÉTHODE DE FABRICATION","IMMUNOMODULATOR","AGENT IMMUNOMODULATEUR","",""
"57","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"58","04-03-03","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"59","04-03-15","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONE REPLACEMENT THERAPY","TRAITEMENT HORMONAL SUBSTITUTIF","",""
"61","04-03-09","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 2MG/PAD, 5.7MG/PAD; NEW INDICATION: FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS, 3.8MG/PAD, 5.7MG/PAD, 7.6MG/PAD","NOUVELLES CONCENTRATIONS : 2MG/PAD, 5.7MG/PAD; NOUVELLE INDICATION : POUR LA PRÉVENTION DE L'OSTÉOPOROSE POSTMÉNOPAUSIQUE, 3.8MG/PAD, 5.7MG/PAD, 7.6MG/PAD","ESTROGEN","OESTROGÈNE","",""
"62","04-03-01","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"63","04-02-03","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH INHIBITOR","INHIBITEUR DE LA POUSSE DES CHEVEUX","",""
"64","04-01-28","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"65","04-01-20","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTER AND GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT, ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTIPAGÉTIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"66","04-01-08","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: PSORIATIC ARTHRITIS","NOUVELLE INDICATION : POLYARTHRITE PSORIASIQUE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"67","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE, ADJUVANT ANESTHÉSIQUE","",""
"68","03-06-20","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVEAU DOSAGE","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION  INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"69","04-03-15","ORGANON SANOFI-SYNTHELABO CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE ACTION AND CLINICAL PHARMACOLOGY SECTION OF THE PRODUCT MONOGRAPH WITH REGARDS TO EXTENDED PROPHYLAXIS OF THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY","MISE À JOUR À LA RUBRIQUE PHARMACOLOGIE DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE LE TRAITEMENT PROLONGÉ DE TROUBLES THROMBOEMBOLIQUES CHEZ LES PERSONNES SUBISSANT UNE CHIRURGIE POUR FRACTURE DE LA HANCHE","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"70","03-07-21","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"71","04-03-10","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL","",""
"72","04-02-27","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"73","04-02-26","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER S.C.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"74","04-02-17","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONAGONIST ESTROGEN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES OESTROGÈNES SANS EFFET AGONISTE CONNUS","",""
"75","04-02-12","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"76","03-06-11","INTERMUNE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"77","04-02-03","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN INJECTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"78","04-01-15","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOFRACORT","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIBIOTIC, CORTICOSTEROID","ANTIBIOTIQUE, CORTICOSTÉROÏDE","",""
"79","03-05-20","CLONMEL HEALTHCARE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"80","04-01-14","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","BANAMINE INJECTION","SCHERING CANADA INC.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"81","03-05-12","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"82","03-05-02","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS","MODIFICATION DE LA FABRICATION","IMMUNOMODULATORY AGENT","AGENT IMMUNOMODULATEUR","",""
"83","03-08-25","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO ALLOW A FLEXIBLE STARTING DOSE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT POUR PERMETTRE UNE DOSE DE DÉPART FLEXIBLE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"84","03-04-25","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CIE., MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"85","03-04-14","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC AGENT","INHIBITEUR DE LA FIBRINOLYSE","",""
"86","03-04-09","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","NEW INDICATION","NOUVELLE INDICATION","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"87","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"88","03-03-20","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE ADMINISTRÉ PAR VOIE INTRAVEINEUSE","",""
"89","03-02-25","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"90","04-03-09","LG LIFE SCIENCES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"91","04-02-17","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS, DIVISION OF WARNER LAMBERT CO. CANADA INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"92","03-02-17","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"93","04-01-27","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR CONTRAST-ENHANCED MAGNETIC RESONANCE ANGIOGRAPHY (CE-MRA)","NOUVELLE INDICATION : AUGMENTATION DE CONTRASTE DE L'ANGIOGRAPHIE PAR RÉSONANCE MAGNÉTIQUE","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"94","04-03-05","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"95","04-01-27","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY CORTICOSTEROID FOAM","ANTI-INFLAMMATOIRE RECTAL CORTICOSTÉROÏDE","",""
"96","03-02-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"97","04-03-04","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURER NAME CHANGE","MODIFICATION DU NOM DU FABRICANT","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"98","03-02-11","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLOCORT 0.1% CREAM","STIEFEL CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"99","04-03-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"100","04-03-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"101","04-03-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"102","04-02-16","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"103","04-02-16","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"104","04-02-10","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPANSION OF INDICATION FOR CROHN'S DISEASE","EXPANSION DE L'INDICATION POUR LA MALADIE DE CROHN","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"105","04-01-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"106","04-01-14","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"107","04-01-09","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"108","04-01-08","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF HUMAN ALBUMIN","SOURCE D'ALBUMINE HUMAINE ALTERNATIVE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"109","04-01-12","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 0.4%; NEW NAME: ACULAR LS; NEW INDICATION: FOR THE REDUCTION OF OCULAR PAIN AND OCULAR SYMPTOMS OF FOREIGN BODY SENSATION, BURNING/STINGING, TEARING, AND PHOTOPHOBIA FOLLOWING REFRACTIVE SURGERY","NOUVELLE CONCENTRATION : 0.4%; NOUVEAU NOM : ACULAR LS; NOUVELLE INDICATION : RÉDUCTION DE LA DOULEUR OCULAIRE ET DES SYMPTÔMES OCULAIRES DE SENSATION DE PRÉSENCE DE CORPS ÉTRANGER DE BRÛLURE/PICOTEMENT, LARMOIEMENT ET DE PHOTOPHOBIE SUITE À UNE CHIRURGIE RÉFRINGENTE","TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE NON-STÉROÏDIEN TOPIQUE","",""
"110","04-03-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN: 750MG ONCE DAILY FOR FIVE DAYS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP)","RÉVISION À LA POSOLOGIE : 750MG UNE FOIS PAR JOUR POUR 5 JOURS POUR LE TRAITEMENT DE LA PNEUMONIE COMMUNAUTAIRE ACQUISE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"111","04-03-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF CHRONIC BACTERIAL PROSTATITIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA PROSTATITE BACTÉRIENNE CHRONIQUE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"112","03-01-21","GLADES, DIVISION OF STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"113","03-01-06","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM ATENOLOL","MODIFICATION DU NOM DU PRODUIT DE ATENOLOL","ß-Adrenergic Receptor Blocking Agent","Inhibiteur des récepteurs ß-adrénergiques","",""
"114","03-01-03","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE B-LACTAMASES","",""
"115","04-02-23","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 30MG","NOUVELLE CONCENTRATION : 30MG","LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"116","04-02-11","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"117","04-02-06","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF NOSOCOMIAL PNEUMONIA USING A ONCE DAILY 750 MG DOSE FOR 7 TO 14 DAYS","NOUVELLE INDICATION : TRAITEMENT DE LA PNEUMONIE NOSOCOMIALE UTILISANT UNE DOSE DE 750 MG POUR UNE DURÉE DE 7 À 14 JOURS","ANTI-BACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"118","04-01-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"119","04-01-29","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF EROSIVE AND NON-EROSIVE GERD IN CHILDREN AGED 1-17 YEARS","NOUVELLE INDICATION : POUR LE TRAITEMENT DU REFLUX GASTROOESOPHAGIEN PATHOLOGIQUE ÉROSIF ET NON-ÉROSIF CHEZ LES ENFANTS ÂGÉS DE 1 À 17 ANS","H+, K+ -ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+ -ATPASE","",""
"120","03-12-23","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"121","04-01-02","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PREMIX PRESENTATIONS","AJOUT DE PRÉMÉLANGES","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"122","04-03-19","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A NEW STRENGTH","AJOUT D'UNE NOUVELLE CONCENTRATION","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"123","04-03-03","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"124","04-02-26","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"125","03-12-09","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"126","04-02-26","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"127","04-02-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"128","04-01-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"129","04-01-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"130","04-02-23","GALEN (CHEMICALS) LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROGROGESTATIVE","",""
"131","04-01-28","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","LIQUAMYCIN LP","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"132","06-01-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRA PHARMA INC.","CANADA","CANADA","1","","","H+, K+ -ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+ -ATPASE","",""
"133","04-01-23","VALEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"134","04-01-12","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"135","03-11-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 400/12 MCG PER DOSE","NOUVELLE CONCENTRATION: 400/12 MCG PER DOSE","CORTICOSTEROID AND BRONCHODILATOR FOR INHALATION","CORTICOSTÉROÏDE ET BRONCHODILATATEUR POUR INHALATION","",""
"136","04-01-05","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SANDOSTATIN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"137","04-03-12","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC AGENT","HÉMATOPOÏÉTIQUE","",""
"138","04-03-09","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"139","04-03-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"140","04-02-17","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"141","04-02-12","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY, POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLITIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"142","04-02-12","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"143","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL INJECTION","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"144","03-11-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"145","04-02-05","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY, POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"146","04-01-29","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW REDIPEN DELIVERY SYSTEM","NOUVELLE PRÉSENTATION (REDIPEN)","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"147","04-01-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"148","04-01-23","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE, REFORMULATION OF DRUG PRODUCT","SITE ALTERNATIF DE FABRICATION DU PRODUIT MÉDICAMENTEUX, REFORMULATION DU PRODUIT MÉDICAMENTEUX","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"149","04-01-14","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"150","04-01-09","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE","",""
"151","03-11-04","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ELEVATED INTRAOCULAR PRESSURE THERAPY (RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST)","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE (AGONISTE ALPHA2-ADRÉNORÉCEPTEUR RELATIVEMENT SÉLECTIF)","",""
"152","04-01-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"153","04-03-15","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR","INHIBITEUR DE LA PROLACTINE","",""
"154","04-02-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"155","03-09-05","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: TABLET 24 MG","NOUVEAU DOSAGE: COMPRIMÉ DE 24 MG","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"156","04-02-12","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH BASED ON THE 2003 GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE","CHANGEMENTS À LA RUBRIQUE POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT POUR TENIR COMPTE DES LIGNES DIRECTRICES DE 2003 SUR LA GESTION DE LA DYSLIPIDÉMIE ET LA PRÉVENTION DES MALADIES CARDIOVASCULAIRES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"157","04-02-09","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","REVISION TO LABEL CLAIM","RÉVISION À LA RÉCLAME SUR L'ÉTIQUETTE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"158","04-01-23","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH TO INCLUDE STATEMENT RE THE MANAGEMENT OF PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS","MONOGRAPHIE RÉVISÉE DU PRODUIT INCLUANT UN ÉNONCÉ SUR LA GESTION DES PERSONNES PRÉSENTANT UN RISQUE ÉLEVÉ DE TROUBLES CARDIOVASCULAIRES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"159","04-01-15","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"160","04-03-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"161","04-03-08","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS REGARDING SAFETY OF SILDENAFIL IN SUBJECTS WITH TREATED HYPERTENSION, CORONARY ARTERY DISEASE AND STABLE ANGINA","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'INNOCUITÉ DU SILDÉNAFIL CHEZ LES PERSONNES TRAITÉES POUR HYPERTENSION, INSUFFISANCE CORONAIRE ET ANGOR STABLE","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"162","03-09-05","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM HELICIDE","MODIFICATION DU NOM DU PRODUIT DE HELICIDE","HELICOBACTER PYLORI ERADICATION THERAPY IN CONJUNCTION WITH OMEPRAZOLE","TRAITEMENT D'ÉRADICATION DE L'HELICOBACTER PYLORI EN UTILISANT PARALLÈLEMENT L'OMÉPRAZOLE","",""
"163","04-03-02","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES)","",""
"164","04-03-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INCORPORATE RELEVANT CLINICAL TRIAL INFORMATION INTO THE PRODUCT MONOGRAPH","INCLURE À LA MONOGRAPHIE DU PRODUIT LES RENSEIGNEMENTS PERTINENTS AUX ESSAIS CLINIQUES","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"165","04-02-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW CONTAINER CLOSURE SYSTEM: NUTROPIN AQ PEN CARTRIDGE","NOUVEAU DISPOSITIF DE FERMETURE DES CONTENANTS : NUTROPIN AQ PEN CARTRIDGE","GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"166","04-02-12","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","0","","","DIAGNOSTIC ULTRASOUND CONTRAST AGENT","AGENT DE CONTRASTE POUR L'ÉCHOGRAPHIE","",""
"167","03-08-22","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","ZONE DE FABRICATION ADDITIONNELLE","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"168","04-02-10","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","THERAPEUTIC RADIOPHARMACEUTICAL","THÉRAPEUTIQUE RADIOPHARMACEUTIQUE","",""
"169","04-02-02","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRO-DUODÉNAL","",""
"170","04-03-18","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION WITH IMPROVED STABILITY AT AMBIENT CONDITIONS","CHANGEMENT À LA COMPOSITION AVEC STABILITÉ AMÉLIORÉE AUX CONDITIONS AMBIANTES","ANDROGEN","ANDROGÈNE","",""
"171","03-08-22","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","ZONE DE FABRICATION ADDITIONNELLE","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"172","04-02-26","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TRAZODONE","MODIFICATION DU NOM DU PRODUIT DE TRAZODONE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"173","04-04-01","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"174","03-07-21","ESP PHARMA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"175","04-02-25","VETOQUINOL N.-A. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","TRIVETRIN INJECTION","SCHERING CANADA INC.","CANADA","CANADA","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"176","04-02-23","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR TREATMENT OF RHEUMATOID ARTHRITIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ARTHRITE RHUMATOÏDE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"177","04-01-23","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"178","04-01-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"179","04-01-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","REAGENT FOR PREPARATION OF A RADIODIAGNOSTIC AGENT","RÉACTIF POUR LA PRÉPARATION D'UN AGENT RADIODIAGNOSTIQUE","",""
"180","04-01-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"181","04-01-19","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"182","04-01-14","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"183","04-03-17","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMP CYCLIQUE","",""
"184","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"185","04-02-26","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN SOLID ORGAN TRANSPLANT PATIENTS AT RISK","NOUVELLE INDICATION : COMME PRÉVENTION DE L'INFECTION AU CYTOMÉGALOVIRUS CHEZ LES RÉCIPIENDAIRES DE GREFFES D'ORGANES SOLIDES ET QUI SONT VULNÉRABLES À L'INFECTION","ANTIVIRAL AGENT","ANTIVIRAL","",""
"186","04-02-12","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE REDUCTION OF TRANSMISSION OF GENITAL HERPES","NOUVELLE INDICATION : POUR LA RÉDUCTION DE LA TRANSMISSION DE L'HERPÈS GÉNITAL","ANTIVIRAL AGENT","ANTIVIRAL","",""
"187","04-03-02","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: NASAL SPRAY","NOUVELLE FORME POSOLOGIQUE : VAPORISATEUR NASAL","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"188","02-12-16","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE","",""
"189","02-12-16","ENZON, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"190","02-11-28","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"191","02-11-20","SANGSTAT MEDICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","AGENT IMMUNOSUPPRESSEUR","",""
"192","02-11-20","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","BURROUGHS WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"193","02-11-05","AVENTIS BEHRING LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTI-HEMOPHILIC FACTOR (HUMAN)","FACTEUR ANTIHÉMOPHILIQUE (HUMAINE)","",""
"194","02-11-04","PANGEO HEALTH SCIENCES DIV. OF/DE PANGEO PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTICOAGULANT","ANTICOAGULANT ORAL","",""
"195","02-11-01","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"196","02-10-24","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"197","02-10-15","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"198","02-09-30","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"199","02-08-29","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"200","02-08-20","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ACCELERATED DOSING IN PEDIATRIC PATIENTS FOR ACUTE OTITIS MEDIA: 30 MG/KG SINGLE DOSE FOR 1 DAY, 10 MG/KG ONCE DAILY FOR 3 DAYS, PRODUCT MONOGRAPH REVISIONS","POSOLOGIE ACCÉLÉRÉE POUR L'OTITE MOYENNE AIGÜE CHEZ LES PATIENTS PÉDIATRIQUES : 1 DOSE UNIQUE DE 30 MG/KG POUR UNE JOURNÉE, DOSE DE 10 MG/KG UNE FOIS PAR JOUR POUR 3 JOURS, RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"201","02-07-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"202","02-07-30","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"203","02-07-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - PEDIATRIC USE","NOUVELLE INDICATION : POUR L'USAGE EN PÉDIATRIE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"204","02-05-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PROPHYLAXIS OF PLASMODIUM FALCIPARUM MALARIA","NOUVELLE INDICATION : PROPHYLAXIE DE LA MALARIA À PLASMODIUM FALCIPARUM","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"205","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASES","",""
"206","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"207","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"208","02-05-15","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"209","02-05-15","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESIVE AGENT","IMMUNOSUPPRESSEUR","",""
"210","02-04-16","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARHYTHMIQUE","",""
"211","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"212","02-04-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN-875","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"213","02-04-03","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","AGENT ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"214","02-03-20","WAMPOLE BRANDS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE, NON-STÉROÏDIEN, ANALGÉSIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"215","02-06-26","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR REDUCING THE RISK OF A FIRST NON-FATAL MYOCARDIAL INFARCTION IN INDIVIDUALS DEEMED TO BE AT SUFFICIENT RISK OF SUCH AN EVENT BY THEIR PHYSICIAN","NOUVELLE INDICATION : POUR RÉDUIRE LE RISQUE D'UN PREMIER INFARCTUS DU MYOCARDE NON FATAL CHEZ LES INDIVIDUS QUI, SELON L'ESTIMATION DU MÉDECIN, PRÉSENTENT UN RISQUE SUFFISANT D'UN TEL PROBLÈME","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"216","02-03-11","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"217","02-02-21","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"218","02-02-20","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARHYTHMIQUE","",""
"219","02-02-19","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"220","02-02-19","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: RAISES HDL-CHOLESTEROL AND THEREFORE LOWERS THE LDL-C/HDL-C AND TOTAL-C/HDL-C RATIOS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND COMBINED (MIXED) HYPERLIPIDEMIA (FREDRICKSON TYPE IIA AND IIB DYSLIPIDEMIA)","NOUVELLE INDICATION : AUGMENTE LE LDL CHOLESTÉROL ET, PAR CONSÉQUENT, RÉDUIT LES RAPPORTS CDL-C/HDL-C ET C/HDL-C TOTAL CHEZ LES PATIENTS PRÉSENTANT UNE HYPERCHOLESTÉROLÉMIE PRIMAIRE ET HYPERLIPIDÉMIE COMBINÉE MIXTE (DYSLIPIDÉMIE DE TYPE IIA ET IIB DE FREDRICKSON)","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"221","02-02-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN-125F AND CLAVULIN-250F","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIBIOTIC AND ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"222","03-07-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: SEPARATE PRODUCT MONOGRAPH FOR SENCORCAINE FORTE FROM THAT OF THE OTHER SENSORCAINE PRODUCTS","MONOGRAPHIE RÉVISÉE: MONOGRAPHIE DU PRODUIT SENSORCAINE FORTE SÉPARÉE DES AUTRES PRODUITS SENSORCAINE","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"223","02-02-04","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 70MG; NEW DOSING REGIMEN: ONCE WEEKLY; FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND IN MEN","NOUVELLE CONCENTRATION : 70MG; NOUVEAU SCHÉMA POSOLOGIQUE : UNE FOIS PAR SEMAINE; POUR LE TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES FEMMES POSTMÉNOPAUSÉES ET LES HOMMES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"224","03-04-25","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROPHYLACTIC MANAGEMENT OF STEROID-RESPONSIVE BRONCHIAL ASTHMA IN PEDIATRIC PATIENTS BETWEEN 5 AN 11 YEARS OLD","NOUVELLE INDICATION: GESTION PROPHYLACTIQUE DE L'ASTHME BRONCHIQUE RÉCEPTIF AUX STÉROÏDES CHEZ LES PATIENTS PÉDIATRIQUES DE 5 À 11 ANS","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION","",""
"225","03-04-23","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","CRYSTAAL A DIVISION OF BIOVAIL CORPORATION CANADA","CANADA","CANADA","1","","","B-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"226","03-04-02","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIRECT THROMBIN INHIBITOR","INHIBITEUR DIRECT DE LA THROMBINE","",""
"227","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHISTAMINIC, ANTI-INFLAMMATORY, LEUKOTRIENE INHIBITOR AGENT","ANTI-HISTAMINIQUE, ANTI-INFLAMMATOIRE, AGENT INHIBITEUR DE LEUCOTRIÈNE","",""
"228","02-02-04","WELLSPRING PHARMACEUTICAL CANADA CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MUCOLYTIC, ANTIDOTE FOR ACETAMINOPHEN POISONING","MUCOLYTIQUE, ANTIDOTE CONTRE LES INTOXICATIONS PAR L'ACÉTAMINOPHÈNE","",""
"229","03-03-14","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HELICOBACTER PYLORI ERADICATION THERAPY IN CONJUNCTION WITH OMEPRAZOLE","TRAITEMENT D'ÉRADICATION DE L'HELICOBACTER PYLORI EN UTILISANT PARALLÈLEMENT L'OMÉPRAZOLE","",""
"230","02-01-14","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL POUR SOINS DENTAIRES","",""
"231","03-03-14","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM WELLBUTRIN SR","CHANGEMENT DU NOM DU PRODUIT DE WELLBUTRIN SR","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"232","03-03-14","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ZYBAN","CHANGEMENT DU NOM DU PRODUIT DE ZYBAN","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"233","03-03-14","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"234","02-01-02","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW-DOSE 81MG","BAYER INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM SAFEWAY COATED DAILY LOW-DOSE ASA","MODIFICATION DU NOM DU PRODUIT DE SAFEWAY COATED DAILY LOW-DOSE ASA","ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"235","03-03-14","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"236","02-01-02","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT, ANTIPARKINSONIAN AGENT","AGENT ANTIVIRAL, AGENT ANTIPARKINSONIEN","",""
"237","02-10-25","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCEDURE","CHANGEMENT À LA PROCÉDURE DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"238","02-09-10","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE SITE DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"239","02-09-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"240","02-08-28","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC AGENT AID","AGENT POUR USAGE DIAGNOSTIQUE","",""
"241","02-07-25","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","AGENT DE CONTRASTE INTRAVEINEUX PAR ULTRASON","",""
"242","02-06-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","MILIEU DE CONTRASTE INTRAVEINEUX POUR ULTRASON","",""
"243","02-05-24","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOMODULATORY AGENT","AGENT D'IMMUNOMODULATEUR","",""
"244","02-05-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT (TISSUE PLASMINOGEN ACTIVATOR)","AGENT FIBRINOLYTIQUE (ACTIVATEUR DU PLASMINOGÈNE TISSULAIRE)","",""
"245","02-01-23","WELLSPRING PHARMACEUTICAL CANADA CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"246","03-12-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TAZIDIME","CHANGEMENT DU NOM DU PRODUIT DE TAZIDIME","ANTIBIOTIC","ANTIBIOTIQUE","",""
"247","03-12-22","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE VULGARIS THERAPY","TRAITEMENT DE L'ACNÉ VULGAIRE","",""
"248","03-12-19","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"249","03-11-28","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C CAPSULES","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"250","03-11-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOESCHT MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"251","03-11-12","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"252","03-10-17","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"253","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"254","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VAGINAL ANTIBACTERIAL PREPARATION","AGENT ANTIBACTÉRIEN","",""
"255","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"256","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"257","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"258","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"259","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS DE LA DOPAMINE","",""
"260","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"261","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE ORAL","",""
"262","03-09-15","LUNDBECK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: ADDITION OF STATEMENTS TO THE DOSAGE AND ADMINISTRATION SECTION","MONOGRAPHIE RÉVISÉE DU PRODUIT: AJOUT D'ÉNONCÉS À LA RUBRIQUE POSOLOGIE ET ADMINISTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"263","03-10-08","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML)","NOUVELLE INDICATION: DIAGNOSTIC RÉCENT DE LEUCÉMIE CHRONIQUE MYÉLOÏDE","PROTEIN TYROSINE-KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"264","03-12-05","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDE DE LA PROTÉASE VIH-1","",""
"265","03-12-02","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"266","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"267","03-08-05","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 500 MG TABLET STRENGTH AND NEW DOSING REGIMEN (THREE DAY TREATMENT) FOR ACUTE BACTERIAL EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ADULTS","NOUVEAU COMPRIMÉ DE 500 MG ET NOUVELLE POSOLOGIE (TRAITEMENT D'UNE DURÉE DE TROIS JOURS) POUR EXACERBATIONS BACTÉRIENNES AIGUES DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE CHEZ L'ADULTE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"268","03-09-05","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION FOR 500MG TABLET","NOUVELLE FORMULATION POUR LES COMPRIMÉS DE 500MG","ANTIBIOTIC","ANTIBIOTIQUE","",""
"269","03-09-05","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"270","03-09-05","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"271","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"272","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"273","04-03-23","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"274","04-03-22","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"275","04-03-26","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO UPDATE THE INDICATIONS IN THE PRODUCT MONOGRAPH","MISE À JOUR DES INDICATIONS DE LA MONOGRAPHIE DU PRODUIT","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"276","04-03-26","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A NEW 80 MG STRENGTH AND REVISED DOSAGE RECOMMENDATIONS","AJOUT D'UNE NOUVELLE CONCENTRATION DE 80 MG ET RÉVISION AUX RECOMMENDATIONS RELATIVES À LA POSOLOGIE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"277","04-03-23","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"278","04-03-23","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN PATIENTS AT HIGH RISK OF CORONARY EVENTS REGARDLESS OF LIPID STATUS","NOUVELLE INDICATION : CHEZ LES PATIENTS À RISQUE ÉLEVÉ DE MANIFESTATIONS CORONAIRES, SANS ÉGARD AU TAUX DES LIPIDES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"279","04-03-25","QLT INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PRESUMED OCULAR HISTOPLASMOSIS","NOUVELLE INDICATION : HISTOPLASMOSE OCCULAIRE PRÉSUMÉE","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION AND PATHOLOGIC MYOPIA","AGENT PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE ET POUR LA MYOPIE PATHOLOGIQUE","",""
"280","04-03-24","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"281","04-03-24","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"282","04-03-24","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"283","04-03-25","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"284","04-03-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 80 MG EXTENDED RELEASE TABLET","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À ACTION PROLONGÉE DE 80 MG","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"285","04-03-22","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE","HOFFMAN-LA ROCHE LIMITED","CANADA","CANADA","1","","","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"286","04-03-24","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"287","04-03-24","ALPHARMA APS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"288","04-03-23","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antileukemic Agent","Antileucémique","",""
"289","04-03-23","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"290","04-03-26","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCEDURE","MODIFICATION À LA MÉTHODE DE FABRICATION","COAGULATION FACTOR","AGENT DE COAGULATION","",""
"291","04-03-25","WYETH CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: SOLUTION IN GELATIN CAPSULE","NOUVELLE FORME POSOLOGIQUE : SOLUTION DANS UNE CAPSULE EN GÉLATINE","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT","",""
"292","04-03-31","ACTELION PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOSYCERAMIDE SYNTHASE INHIBITOR","INHIBITEUR DE LA GLUCOSYCERAMIDE SYNTHASE","",""
"293","04-03-29","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DILANTIN","PARKE-DAVIS DIVISION WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"294","04-03-29","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION AND INDICATION: SUSTAINED-RELEASE CAPSULES TO PROLONG THE TIME TO RECURRENCE OF SYMPTOMATIC ATRIAL ARRHYTHMIAS IN PATIENTS WITHOUT SIGNIFICANT STRUCTURAL HEART DISEASE AND WITH A HISTORY OF SYMPTOMATIC ATRIAL FIBRILLATION","NOUVELLE FORMULE ET INDICATION : CAPSULES À LIBÉRATION SOUTENUE POUR PROLONGER LE TEMPS DE RÉCURRENCE DE L'ARYTHMIE AURICULAIRE SYMPTOMATIQUE CHEZ LES PERSONNES QUI NE PRÉSENTENT PAS DE MALADIE CARDIAQUE STRUCTURELLE IMPORTANTE ET AYANT UNE HISTOIRE DE FIBRILLATION AURICULAIRE SYMPTOMATIQUE","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"295","04-03-29","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"296","04-03-29","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER S.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"297","04-04-01","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLET","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À DISSOLUTION ORALE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"298","04-04-01","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT AGENT","ANTIDÉPRESSEUR","",""
"299","04-03-31","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"300","04-03-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION OF TABLETS","REFORMULATION DES COMPRIMÉS","5-HT1, RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"301","04-03-31","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"302","04-03-30","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONE REPLACEMENT THERAPY","TRAITEMENT HORMONAL SUSTITUTIF","",""
"303","04-03-29","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR RELIEF OF MIGRAINES","NOUVELLE INDICATION : POUR LE SOULAGEMENT DES MIGRAINES","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"304","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"305","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"306","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"307","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"308","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"309","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"310","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"311","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"312","04-04-01","AVENTIS PASTEUR SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"313","02-12-09","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"314","02-11-25","ASTRAZENECA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","NEW INDICATION: FOR IMMEDIATE THERAPY IN SOME PATIENTS WITH LOCALIZED (T1-T2) PROSTATE CANCER WHO ARE INAPPROPRIATE FOR SURGERY OR RADIOTHERAPY; NEW STRENGTH: 150MG","NOUVELLE INDICATION : POUR LE TRAITEMENT IMMÉDIAT DES PATIENTS QUI PRÉSENTENT UN CANCER LOCALISÉ (T1-T2) DE LA PROSTATE ET POUR QUI LA CHIRURGIE OU LA RADIOTHÉRAPIE SERAIT INAPPROPRIÉE; NOUVEAU DOSAGE : 150 MG","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"315","02-10-09","THE MEDICINES COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIRECT THROMBIN INHIBITOR","INHIBITEUR DIRECT DE LA THROMBINE","",""
"316","02-07-30","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","STIMULANT DES RÉCEPTEURS ALPHA2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"317","02-07-29","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","STIMULANT DES RÉCEPTEURS ALPHA2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"318","02-07-29","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","STIMULANT DES RÉCEPTEURS ALPHA2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"319","02-07-19","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy","Thérapie pour réduire la pression intra-oculaire","",""
"320","02-06-17","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Relatively Selective Alpha2-Adrenoceptor Agonist, Elevated Intraocular Pressure Therapy","Stimulant des récepteurs Alpha2-adrénergiques relativement sélectif, Thérapie pour réduire la pression intra-oculaire","",""
"321","02-06-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: NEW SAFETY INFORMATION ON USE IN PATIENTS WITH LIVER OR RENAL IMPAIRMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : NOUVELLE MISE EN GARDE POUR LE TRAITEMENT DES PATIENTS PRÉSENTANT UN TROUBLE DE LA FONCTION HÉPATIQUE OU RÉNALE","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"322","02-05-31","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"323","02-05-30","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA LTD.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"324","02-05-30","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle Relaxant, Antispastic Agent","Relaxant Musculaire, Antispasmodique","",""
"325","02-05-24","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY, PROSTAMIDE ANALOGUE","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE, PROSTAMIDE ANALOGUE","",""
"326","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCALLY ACTING ANALGESIC AGENT","ANALGÉSIQUE LOCAL","",""
"327","02-04-29","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPROSALIC LOTION","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID AND KERATOLYTIC","CORTICOSTÉROÏDE TOPIQUE ET KÉRATOLYTIQUE","",""
"328","02-03-01","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH: NEW DOSING RECOMMENDATIONS FOR USE IN PATIENTS WITH LIVER OR RENAL IMPAIRMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : NOUVELLES RECOMMENDATIONS PORTANT SUR LA POSOLOGIE POUR LE TRAITEMENT DES PATIENTS SOUFFRANT D'INSUFFISANCE RÉNALE OU HÉPATIQUE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"329","03-09-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIACALCIN NS","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"330","02-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID AND BRONCHODILATOR FOR INHALATION","CORTICOSTÉROÏDE ET BRONCHODILATATEUR POUR INHALATION","",""
"331","03-08-27","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA PNEUMONIE ACQUISE DANS LA COMMUNAUTÉ","ANTIBIOTIC","ANTIBIOTIQUE","",""
"332","02-12-13","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"333","02-07-12","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS, NEW MANUFACTURING FACILITY","CHANGEMENT DANS LE PROCÉDÉ DE FABRICATION; NOUVEL ÉTABLISSEMENT DE FABRICATION","LUNG SURFACTANT (BOVINE)","SURFACTANT PULMONAIRE (BOVIN)","",""
"334","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"335","03-08-13","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE AND CHANGES TO THE DOSAGE AND ADMINISTRATION SECTION TO REFLECT THE MAINTENANCE DOSING SCHEDULE FOR ADULT PATIENTS WITH RENAL IMPAIRMENT","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT ET MODIFICATIONS APPORTÉES À LA RUBRIQUE POSOLOGIE POUR INCLURE UN SCHÉMA POSOLOGIQUE CHEZ LES PATIENTS DONT LA FONCTION RÉNALE EST ANORMALE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"336","02-12-11","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"337","03-08-13","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GNRH ANTAGONIST","GNRH (ANTAGONISTE)","",""
"338","02-12-09","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"339","02-11-08","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY AND COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"340","03-08-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","HOFFMANN-LAROCHE LIMITED","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"341","02-10-15","ORYX PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"342","02-10-08","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSING REGIMEN: STARTING DOSE OF 16MG ONCE DAILY WHEN USED AS MONOTHERAPY, AND A MAXIMUM DAILY DOSE OF 32MG","NOUVELLE POSOLOGIE : COMMENÇANT À 16MG UNE FOIS PAR JOUR EN MONOTHÉRAPIE, AVEC DOSE MAXIMALE QUOTIDIENNE DE 32MG","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"343","02-09-19","ORBUS PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"344","02-09-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA INC.","CANADA","CANADA","1","","","ANTI-ANDROGEN","ANTIANDROGÈNE","",""
"345","02-08-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS À LA RUBRIQUE DOSAGE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"346","02-08-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"347","03-08-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"348","02-08-02","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","E.R. SQUIBB & SONS, INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"349","02-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"350","02-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"351","02-07-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"352","02-06-17","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT MUSCULAIRE SQUELETTIQUE","",""
"353","02-06-17","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"354","02-06-13","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ACUTE OTITIS EXTERNA; NEW ROUTE OF ADMINISTRATION: OTIC","NOUVELLE INDICATION : OTITE AIGUË EXTERNE; NOUVELLE VOIE D'ADMINISTRATION : OTIQUE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"355","02-06-04","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"356","02-05-28","PHARMACIA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","NEW INDICATION: TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS","NOUVELLE INDICATION : TRAITEMENT DE LA POLYPOSE ADÉNOMATEUSE FAMILIALE","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"357","03-08-07","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"358","02-05-15","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL AGENT WITH TOPICAL CORTICOSTEROID","ANTIBACTÉRIEN, ANTIFONGIQUE, CORTICOSTÉROÏDE TOPIQUE","",""
"359","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"360","03-08-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"361","03-08-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"362","02-05-13","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"363","02-05-10","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR EN MATIÈRE D'INNOCUITÉ DE LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"364","02-05-08","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"365","02-05-08","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"366","02-05-01","ABIOGEN PHARMA S.P.A","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"367","02-05-01","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"368","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Anti-Inflammatory Steroid","Corticostéroïde anti-inflammatoire topique","",""
"369","03-07-22","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"370","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"371","03-07-11","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"372","03-07-11","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE TREATMENT OF ESOPHAGEAL CANDIDIASIS","NOUVELLE INDICATION POUR LE TRAITEMENT DE LA CANDIDIASE OESOPHAGIENNE","ANTIFUNGAL","ANTIFONGIQUE","",""
"373","03-07-11","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE TREATMENT OF INVASIVE CANDIDIASIS","NOUVELLE INDICATION POUR LE TRAITEMENT DE LA CANDIDIASE ENVAHISSANTE","ANTIFUNGAL","ANTIFONGIQUE","",""
"374","03-07-07","PHARMACIA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","NEW STRENGTH: 400 MG - FOR THE TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS (FAP)","NOUVELLE CONCENTRATION: 400 MG - POUR LE TRAITEMENT DE LA POLYPOSE ADÉNOMATEUSE FAMILIALE","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"375","03-06-20","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION; CHANGE IN METHOD OF MANUFACTURING","MODIFICATION DE LA PRÉPARATION; MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"376","03-06-17","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CLARIFICATION OF MONITORING FREQUENCY WHEN SWITCHING CLOZAPINE BRANDS","CLARIFICATION À LA FRÉQUENCE DU SUIVI LORS D'UN CHANGEMENT DE MARQUE DE LA CLOZAPINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"377","02-04-19","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIJEX","ABBOTT LABORATORIES, LIMITED","CANADA","CANADA","1","","","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"378","02-04-10","GUILFORD PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"379","03-06-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CLARIFICATION OF MONITORING FREQUENCY WHEN SWITCHING CLOZAPINE BRANDS","CLARIFICATION À LA FRÉQUENCE DU SUIVI LORS DU CHANGEMENT DE MARQUE DE COMMERCE DE LA CLOZAPINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"380","02-04-10","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REDUCTION OF ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES, UNSTABLE ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION, WITHOUT ST SEGMENT ELEVATION","NOUVELLE INDICATION : RÉDUCTION DES ACCIDENTS DE THROMBOSE ATHÉROSCLÉREUSE CHEZ LES PATIENTS QUI PRÉSENTENT DES SYNDRÔMES CORONAIRES AIGUS, DE L'ANGINE INSTABLE OU UN INFARCTUS DU MYOCARDE SANS ONDE Q, ET QUI NE PRÉSENTENT PAS D'AUGMENTATION DU SEGMENT ST","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"381","02-04-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SEVERE HEART FAILURE","NOUVELLE INDICATION : TRAITEMENT DE L'INSUFFISANCE CARDIAQUE GRAVE","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"382","02-03-20","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN THE DOSING REGIMEN TO ONCE DAILY","CHANGEMENT AU SCHÉMA POSOLOGIQUE À UNE FOIS PAR JOUR","TOPICAL ANTIPSORIATIC AGENT, VITAMIN D ANALOGUE, CORTICOSTEROID","AGENT ANTIPSORIASIQUE TOPIQUE, ANALOGUE DE LA VITAMIN D, CORTICOSTÉROÏDE","",""
"383","03-06-13","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"384","03-05-16","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"385","02-03-11","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"386","02-02-21","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"387","02-02-19","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"388","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"389","02-02-04","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM PMS-CARBAMAZEPINE","MODIFICATION DU NOM DU PRODUIT DE PMS-CARBAMAZEPINE","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"390","02-02-04","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"391","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"392","02-01-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C CAPSULES","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"393","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"394","02-09-30","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"395","02-08-15","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE SITE DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"396","02-06-14","MEDIMMUNE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FRACTIONATION SITE","NOUVEAU SITE DE FRACTIONNEMENT","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"397","03-05-14","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","SANDOZ CANADA INC.","CANADA","CANADA","1","CLARIFICATION OF MONITORING FREQUENCY WHEN SWITCHING CLOZAPINE BRANDS","ÉCLAIRCISSEMENTS À LA FRÉQUENCE DES ACTIVITÉS DE SUIVI, AU COURS D'UN CHANGEMENT DE MARQUE DE CLOZAPINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"398","02-05-31","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEAU SITE DE FABRICATION","DIAGNOSTIC IMAGING AGENT","AGENT D'IMAGERIE DIAGNOSTIQUE","",""
"399","02-05-02","BERNA BIOTECH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"400","02-03-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","PROPHYLACTIC VACCINE","VACCIN PROPHYLACTIQUE","",""
"401","03-04-08","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX","FACTEUR IX ANTIHÉMORRAGIQUE DE COAGULATION SANGUINE","",""
"402","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"403","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"404","03-04-03","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CLONAZEPAM","MODIFICATION DU NOM DU PRODUIT DE CLONAZEPAM","ANTICONVULSANT","ANTICONVULSIVANT","",""
"405","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"406","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"407","02-03-08","CYTOGEN CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"408","03-04-03","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES / PROGESTIN","HORMONES OESTROGÈNES / PROGESTATIF","",""
"409","02-12-24","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DESFERAL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"410","02-12-10","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC, ANTIBIOTIC","ANTIMITOTIQUE, ANTIBIOTIQUE","",""
"411","03-11-25","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGENIC HORMONES, PROGESTIN","HORMONES OESTROGÈNES, PROGESTATIF","",""
"412","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES / PROGESTIN","HORMONES OESTROGÈNES / PROGESTATIF","",""
"413","02-10-17","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC AGENT AID","AGENT POUR USAGE DIAGNOSTIQUE","",""
"414","02-10-17","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"415","02-09-23","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DTIC","BAYER INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"416","02-08-27","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH XELODA (CAPECITABINE) FOR THE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING CHEMOTHERAPY","NOUVELLE INDICATION : CONJOINTEMENT AU XELODA (CAPÉCITABINE) POUR LE TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER AVANCÉ OU MÉTASTATIQUE DU SEIN APRÈS ÉCHEC D'UNE CHIMIOTHÉRAPIE INCLUANT L'ANTHRACYCLINE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"417","02-08-01","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVASCULAR X-RAY CONTRAST MEDIUM-MD-60, IONIC, WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE-MD-76","AGENT DE CONTRASTE RADIOLOGIQUE INTRAVASCULAIRE-MD-60, AGENT IONIQUE DE CONTRASTE RADIO-OPAQUE HYDROSOLUBLE POUR USAGE INTRAVASCULAIRE-MD-76","",""
"418","02-07-30","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PRSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"419","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"420","03-03-26","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL","ANTIFONGIQUE TOPIQUE","",""
"421","03-02-13","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"422","03-02-21","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"423","03-02-20","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"424","03-02-20","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"425","03-02-19","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"426","03-02-17","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"427","03-02-13","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"428","03-02-13","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"429","03-02-04","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CARBAMAZEPINE CR","MODIFICATION DU NOM DU PRODUIT DE CARBAMAZEPINE CR","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"430","03-01-31","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT / SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA","ANTICONVULSIVANT / SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU","",""
"431","03-01-31","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"432","03-01-03","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"433","03-11-25","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"434","03-10-28","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM CANADA","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM DIPYRIDAMOLE FOR INJECTION","MODIFICATION DU NOM DU PRODUIT DE DIPYRIDAMOLE FOR INJECTION","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"435","03-10-17","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN DEXTROSE QUICKMIX","MODIFICATION DU NOM DU PRODUIT DE TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN DEXTROSE QUICKMIX","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"436","02-07-16","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"437","02-06-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RADIOPAQUE CONTRAST MEDIA","AGENT DE CONTRASTE OPACIFIANT","",""
"438","02-06-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RADIOPAQUE CONTRAST MEDIA","AGENT DE CONTRASTE OPACIFIANT","",""
"439","02-06-10","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE AND ADMINISTRATION FOR POST-OPERATIVE INITIATION OF THROMBOPROPHYLAXIS IN PATIENTS UNDERGOING ELECTIVE HIP SURGERY AT HIGHER RISK OF PERIOPERATIVE BLEEDING","DOSAGE ET ADMINISTRATION RÉVISÉS POUR L'AMORCE POST-OPÉRATOIRE DE LA THROMBOPROPHYLAXIE CHEZ LES PATIENTS QUI SUBISSENT UNE CHIRURGIE ÉLECTIVE DE LA HANCHE ET QUI PRÉSENTENT UN RISQUE HÉMORRAGIQUE POST-OPÉRATOIRE ACCRU","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"440","02-06-06","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"441","02-06-06","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST MEDIUM","AGENT DE CONTRASTE","",""
"442","03-10-17","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN DEXTROSE QUICKMIX","MODIFICATION DU NOM DU PRODUIT DE TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN DEXTROSE QUICKMIX","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"443","02-06-06","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF PROSTATIC CARCINOMA","THÉRAPIE DU CARCINOME PROSTATIQUE","",""
"444","02-05-24","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAL ENTRY BLOCKING AGENT","AGENT BLOQUANT D'ENTRÉE VIRALE","",""
"445","02-05-22","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIAZEM CD","HOECHST MARION ROUSSEL CANADA","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","AGENT ANTIHYPERTENSEUR, AGENT ANTIANGINEUX","",""
"446","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"447","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"448","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"449","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"450","02-02-19","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MONOTHERAPY IN THE TREATMENT OF PARIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF A PREVIOUS CHEMOTHERAPY REGIMEN","NOUVELLE INDICATION : MONOTHÉRAPIE POUR LE TRAITEMENT OU RÉCIDIVE DE L'ÉPITHÉLIOME ÉPIDERMOÏDE MÉTASTATIQUE DE LA TÊTE ET DU COU, SUITE À L'ÉCHEC DU TRAITEMENT PAR CHIMIOTHÉRAPIE","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"451","03-10-17","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMINE D","",""
"452","02-01-10","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTIANGINAL AGENT","AGENT ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"453","02-08-02","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"454","03-10-10","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"455","02-04-19","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURER","CHANGEMENT DU FABRICANT","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"456","02-11-29","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"457","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"458","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"459","02-09-20","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"460","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"461","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"462","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"463","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"464","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT WITH A MUCOSAL PROTECTIVE AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE, AGENT PROTECTEUR DE LA MUQUEUSE","",""
"465","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT / ANTITHROMBOTIC AGENT","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"466","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"467","03-09-10","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"468","03-09-05","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"469","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"470","03-09-04","AXXESS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE","BENZODIAZÉPINES","",""
"471","03-08-25","AXXESS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL AGENT FOR SCLERODERMA TREATMENT","TRAITEMENT DE LA SCLÉRODERMIE","",""
"472","03-08-13","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"473","03-08-11","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"474","03-07-30","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH BASED ON RESULTS FROM FOUR STUDIES","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT BASÉE SUR LES RÉSULTATS DE QUATRE ÉTUDES","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"475","03-07-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYPE I AND II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE TYPE I ET II DE LA 5-ALPHA RÉDUCTASE","",""
"476","03-07-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"477","03-07-11","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"478","03-06-09","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS MONOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER, WHERE THERE IS AN INCREASED CARDIAC RISK","NOUVELLE INDICATION: EN MONOTHÉRAPIE CHEZ LES PATIENTS PRÉSENTANT UN CANCER DU SEIN AVEC MÉTASTASES, ET À RISQUE ACCRU DE TROUBLE CARDIAQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"479","03-05-16","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT FOR BOOSTER VACCINATION","AGENT D'IMMUNISATION ACTIF POUR LE RAPPEL DE VACCINATION","",""
"480","03-04-23","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, RELAXANT","ANXIOLYTIQUE, SÉDATIF","",""
"481","03-04-02","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: ALLERGIC RHINITIS","NOUVELLE INDICATION: RHINITE ALLERGIQUE","ANTIHISTAMINE H1 - RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"482","03-03-28","DIMETHAID HEALTH CARE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY - ANALGESIC","ANTI-INFLAMMATOIRE TOPIQUE - ANALGÉSIQUE","",""
"483","03-03-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","HISTAMINE H1 - RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"484","03-03-14","IVAX PHARMACEUTICALS INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INOTROPIC","INOTROPE","",""
"485","03-03-11","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COLLAGENASE INHIBITOR FOR PERIODONTAL USE","INHIBITEUR DE LA COLLAGÉNASE POUR USAGE PÉRIODONTIQUE","",""
"486","03-02-13","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / RELAXANT","ANXIOLYTIQUE / RELAXANT","",""
"487","03-01-31","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC PROFIBRINOLYTIC ANTI-INFLAMMATORY ENZYME","ENZYME ANTITHROMBOTIQUE PROFIBRINOLYTIQUE ANTI-INFLAMMATOIRE","",""
"488","03-01-22","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM DOMPERIDONE","CHANGEMENT DU NOM DU PRODUIT DE DOMPERIDONE","Modifier of Upper Gastrointestinal Motility","Modificateur de la motilité des voies digestives supérieures","",""
"489","02-07-04","BRISTOL-MYERS SQUIBB PHARMA. GROUP, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS; PRODUCT MONOGRAPH UPDATE: REVISED DOSING OF THE CAPSULES AND TABLETS TO RECOMMEND TAKING ON AN EMPTY STOMACH","NOUVELLES CONCENTRATIONS; MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : FORMULATION RÉVISÉE DES CAPSULES ET COMPRIMÉS POUR RECOMMANDER DE LES INGÉRER À JEUN","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"490","02-06-03","MILLENNIUM PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATION AND A NEW DOSING REGIMEN IN THE TREATMENT OF PATIENTS UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY","INDICATION ADDITIONNELLE ET NOUVEAU SCHÉMA POSOLOGIQUE POUR LE TRAITEMENT DES PATIENTS QUI SUBISSENT UNE ANGIOPLASTIE TRANSLUMINAIRE PERCUTANÉE","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"491","02-04-03","MILLENNIUM PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"492","02-04-03","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 25MCG/DAY","NOUVELLE CONCENTRATION : 25MCG/JOUR","ESTROGEN","OESTROGÈNE","",""
"493","02-12-24","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF FIVE-YEAR CLINICAL DATA TO PRODUCT MONOGRAPH","AJOUT DE DONNÉES CLINIQUES DE CINQ ANS À LA MONOGRAPHIE DU PRODUIT","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"494","02-12-20","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE, ADJUVANT ANESTHÉSIQUE","",""
"495","02-12-06","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"496","02-11-28","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","",""
"497","02-10-23","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU RPODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"498","02-09-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROPHYLACTIC MANAGEMENT OF STEROID-RESPONSIVE BRONCHIAL ASTHMA IN PEDIATRIC PATIENTS (12 MONTHS TO 16 YEARS)","NOUVELLE INDICATION : GESTION PROPHYLACTIQUE DES PATIENTS PÉDIATRIQUES ÂGÉS DE 12 MOIS À 16 ANS ATTEINTS D'ASTHME BRONCHIQUE RÉAGISSANT BIEN À L'ADMINISTRATION DE STÉROÏDES","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"499","02-09-25","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"500","02-08-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DOSING REGIMEN OF 200MCG TWICE DAILY FOR CHILDREN AGED 4 YEARS AND ABOVE WHO REQUIRE A HIGHER DOSE TO CONTROL ASTHMA","SCHÉMA POSOLOGIQUE ALTERNATIF DE 200MCG PAR JOUR POUR LES ENFANTS ÂGÉS DE 4 ANS ET PLUS QUI ONT BESOIN D'UNE DOSE PLUS ÉLEVÉE POUR CONTRÔLER LEUR ASTHME","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE","",""
"501","02-08-29","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"502","02-08-20","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE DOSAGE & ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH REGARDING ELDERLY AND POOR RISK PATIENTS","CHANGEMENTS À LA RUBRIQUE POSOLOGIE DE LA MONOGRAPHIE DU PRODUIT POUR LES PERSONNES ÂGÉES ET LES INDIVIDUS À PAUVRE RISQUE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"503","02-08-20","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 10MG TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS DE 10MG","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"504","02-07-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SIBELIUM","JANSSEN PHAMACEUTICA","CANADA","CANADA","1","","","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"505","02-07-02","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"506","02-06-19","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GRANULOCYTE COLONY STIMULATING FACTOR, HAEMATOPOIETIC AGENT","FACTEUR STIMULANT DE COLONIES DE GRANULOCYTES, AGENT HÉMATOPOÏÉTIQUE","",""
"507","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"508","02-06-13","ORGANON SANOFI-SYNTHELABO CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"509","02-06-06","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 150","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"510","02-06-05","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"511","02-06-05","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 100 MG","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"512","02-06-05","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"513","02-05-24","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"514","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"515","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN-PROGESTIN","OESTROGÈNE-PROGESTÉRONE","",""
"516","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN-ESTROGEN","PROGESTÉRONE-OESTROGÈNE","",""
"517","03-11-19","MILLENNIUM PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR TREATMENT OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION","NOVELLES INDICATIONS POUR LE TRAITEMENT DES PATIENTS SUBISSANT UNE INTERVENTION CORONAIRE","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"518","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"519","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"520","04-04-08","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"521","04-04-05","DUSA PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTODYNAMIC THERAPY PHOTOSENSITIZER","SENSIBILISATEUR POUR THÉRAPIE PHOTODYNAMIQUE","",""
"522","04-04-08","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN + PROGESTIN","OESTROGÈNE + PROGESTATIF","",""
"523","04-04-07","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"524","04-04-05","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES","PREGESTIN","PROGESTATIF","",""
"525","04-04-05","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARUTHMIQUE","",""
"526","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"527","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"528","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"529","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"530","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"531","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"532","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AROMATASE INACTIVATOR / ANTI-TUMOR AGENT","INACTIVATEUR DE L'AROMATASE / ANTITUMORAL","",""
"533","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"534","03-09-04","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISIONS TO PRODUCT MONOGRAPH - PHARMACOKINETICS AND HIGH DOSE","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT - PHARMACOCINÉTIQUE ET DOSE ÉLEVÉE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"535","03-09-04","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - EARLY RHEUMATOID ARTHRITIS","NOUVELLE INDICATION - STADE INITIAL DE DÉVELOPPEMENT DE L'ARTHRITE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"536","03-08-01","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"537","03-07-29","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION -JUVENILE RHEUMATOID ARTHRITIS","NOUVELLE INDICATION - ARTHRITE RHUMATOÏDE JUVÉNILE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"538","03-07-14","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"539","02-05-24","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"540","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"541","03-06-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTOR & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT, ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTI PAGETIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"542","02-05-24","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"543","02-05-10","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"544","02-05-08","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL, ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE, ANTIBACTÉRIEN, ANTIFONGIQUE","",""
"545","02-05-08","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL, ANTIFUNGAL AGENT FOR AURAL USE","CORTICOSTÉROÏDE TOPIQUE, ANTIBACTÉRIEN, ANTIFONGIQUE POUR USAGE AURICULAIRE","",""
"546","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"547","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK SHARP & DOHME","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"548","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"549","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant, Antiobsessional Agent","Antidépresseur, Agent Antiobsessionnel","",""
"550","02-04-02","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"551","02-04-02","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","Histamine H2 Receptor Antagonist","Antagoniste des récepteurs histaminiques H2","",""
"552","02-03-11","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"553","02-02-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTISPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"554","02-02-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL ANTIBOULIMIQUE","",""
"555","02-01-31","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT : MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"556","02-01-31","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT : MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"557","02-01-11","ORYX PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"558","02-06-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"559","02-10-10","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"560","02-12-10","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM GABAPENTIN","MODIFICATION DU NOM DU PRODUIT DE GABAPENTIN","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"561","02-10-24","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"562","02-07-30","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"563","02-07-16","FIRST HORIZON PHARMACEUTICAL CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC","ANTICHOLINERGIQUE","",""
"564","02-05-27","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"565","02-05-27","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PARAMAGNETIC, INTRAVASCULAR CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","PARAMAGNÉTIQUE, AGENT DE CONTRASTE INTRAVASCULAIRE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"566","02-05-27","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT RADIOPHARMACEUTIQUE DE DIAGNOSTIC","",""
"567","02-05-01","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"568","02-05-01","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONIST","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (GNRH)","",""
"569","02-04-16","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: 5-DAY TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS","NOUVELLE INDICATION : TRAITEMENT DE 5 JOURS DE LA BRONCHITE CHRONIQUE EN POUSSÉE ÉVOLUTIVE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"570","02-03-20","TEVA PHARMACEUTICALS USA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORMAT: PRE-FILLED SYRINGE","NOUVELLE FORME POSOLOGIQUE : SERINGUE PRÉREMPLIE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"571","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - FOR DIAGNOSTIC USE","AGENT RADIOPHARMACEUTIQUE - POUR USAGE DIAGNOSTIQUE","",""
"572","02-01-25","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HUPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIQUE ORAL (SULFONYLUREA)","",""
"573","02-01-21","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN COMBINATION WITH CISPLATIN FOR PATIENTS WITH STAGE IV (LOCALLY ADVANCED OR METASTATIC) TRANSITIONAL CELL CARCINOMA (TCC) OF THE BLADDER","NOUVELLE INDICATION : À ÊTRE UTILISÉ CONJOINTEMENT À LA CISPLASTINE POUR LE TRAITEMENT DU CARCINOME DE LA VESSIE DE TYPE TRANSITIONNEL PHASE IV","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"574","02-01-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON TABLETS 80MG","SERVIER CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC AGENT","AGENT HYPOGLYCÉMIANT ORAL","",""
"575","02-12-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI CANADA INC.","CANADA","CANADA","1","","","ANTI-RHEUMATIC, ANTIMALARIAL","ANTI-INFLAMMATOIRE, ANTIPALUDÉEN","",""
"576","02-12-04","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DOSING SCHEDULE (ADULT PRESENTATION)","PLAN POSOLOGIQUE ALTERNATIF (PRÉSENTATION ADULTE)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"577","02-10-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"578","02-10-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","INJECTABLE VACCINE","VACCIN INJECTABLE","",""
"579","02-07-08","BIOTIME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","EXPANSION DU VOLUME DE PLASMA","",""
"580","02-05-30","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: IMMEDIATE RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS À LIBÉRATION IMMÉDIATE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"581","02-05-28","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PURIFICATION AND FORMULATION FACILITY, THIMEROSAL-FREE FORMULATION - 10MCG/ML (ADULT PRESENTATION) - 40MCG/ML (DIALYSIS FORMULATION)","NOUVEAU SITE DE FORMULATION DE PURIFICATION, FORMULATION SANS THIMÉROSAL - 10MCG/ML (PRÉSENTATION ADULTE) - 40MCG/ML (FORMULATION POUR LA DIALYSE)","VACCINE FOR IMMUNIZATION - HEPATITIS B","VACCIN POUR L'IMMUNISATION CONTRE L'HÉPATITE B","",""
"582","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"583","02-05-02","BERNA BIOTECH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"584","02-04-16","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSING SCHEDULE AND BOOSTER WORDING","NOUVEAU PLAN POSOLOGIQUE ET PERSISTANCE DE L'EFFICACITÉ","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"585","02-04-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF INGREDIENT","DIFFÉRENTE SOURCE DE L'INGRÉDIENT","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"586","02-03-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","PROPHYLACTIC VACCINE","VACCIN PROPHYLACTIQUE","",""
"587","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"588","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"589","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"590","02-01-10","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST HEPATITIS A VIRUS","AGENT D'IMMUNISATION ACTIVE CONTRE LE VIRUS DE L'HÉPATITE A","",""
"591","02-12-10","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIAGNOSTIC AGENT FOR THE DELINEATION OF LYMPHATIC VESSELS","AGENT DIGNOSTIQUE POUR LA DÉLINÉATION DES VAISSEAUX LUMPHATIQUE","",""
"592","02-11-05","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND RENAL DISEASE TO REDUCE THE RATE OF PROGRESSION OF NEPHROPATHY","NOUVELLE INDICATION : TRAITEMENT DES PATIENTS HYPERTENSIFS QUI SOUFFRENT DE DIABÈTE MELLITUS TYPE 2 ET DE MALADIE RÉNAL DANS LE BUT DE RÉDUIRE LE TAUX DE PROGRESSION DE LA NÉPHROPATHIE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"593","02-10-17","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE FORME POSOLOGIQUE ET NOUVELLES CONCENTRATIONS","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"594","02-10-16","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IFEX","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"595","02-09-13","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"596","02-09-10","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","REAGENT FOR PREPARATION OF A RADIODIAGNOSTIC AGENT","RÉACTIF POUR LA PRÉPARATION D'AGENTS RADIODIAGNOSTIQUES","",""
"597","02-08-21","BIOGEN CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION FROM SINGLE PRODUCT FACILITY TO MULTI-PRODUCT FACILITY","CONVERSION D'UNE INSTALLATION À PRODUIT UNIQUE À UNE INSTALLATION MULTI-PRODUITS","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"598","02-08-09","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: INTRAVENOUS CONTRAST ENHANCEMENT IN COMPUTED TOMOGRAPHY OF THE BODY IN ADULTS - ISOVUE 370 (76%) INJECTION; NEW DOSAGE FOR INTRAVENOUS CONTRAST ENHANCEMENT IN COMPUTED TOMOGRAPHY OF THE BODY IN ADULTS: 100-150ML ADMINISTRED BY RAPID INTRAVENOUS BOLUS INJECTION OR INFUSION - ISOVUE 300 (61%) INJECTION","NOUVELLE INDICATION : AMÉLIORATION DU CONTRASTE INTRAVEINEUX POUR LA TOMOGRAPHIE PAR ORDINATEUR DU CORPS CHEZ L'ADULTE - INJECTION INTRAVEINEUSE D'ISOVUE 370 (76%); NOUVEAU DOSAGE POUR L'AMÉLIORATION DU CONTRASTE INTRAVEINEUX POUR LA TOMOGRAPHIE PAR ORDINATEUR DU CORPS CHEZ L'ADULTE : 100-150ML ADMINISTRÉ PAR INJECTION INTRAVEINEUSE BOLUS RAPIDE OU PAR PERFUSION - INJECTION D'ISOVUE 300 (61%)","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"599","02-08-07","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"600","02-07-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","BRONCHODILATATOR","BRONCHODILATATEUR","",""
"601","02-07-10","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT","BOEHRINGER INGELHEIM (CANADA) INC.","CANADA","CANADA","1","","","TOPICAL ANTICHOLINERGIQUE","ANTICHOLINERGIQUE TOPIQUE","",""
"602","02-07-04","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN HIV-INFECTED PEDIATRIC PATIENTS; REVISED FORMULATION OF THE 100MG CAPSULES","NOUVELLE INDICATION : POUR LES PATIENTS PÉDIATRIQUES INFECTÉS AU VIH; FORMULATION RÉVISÉE DES CAPSULES DE 100MG","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"603","02-07-02","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE NON IONIQUE","",""
"604","02-07-02","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVASCULAR X-RAY CONTRAST MEDIUM","SUBSTANCE DE CONTRASTE DE RADIOGRAPHIE INTRAVASCULAIRE","",""
"605","02-06-25","BIOGEN CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION FROM SINGLE PRODUCT FACILITY TO MULTI PRODUCT FACILITY","CONVERSION D'UNE INSTALLATION À PRODUIT UNIQUE À UNE INSTALLATION MULTI-PRODUITS","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"606","02-06-19","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"607","02-06-19","VITA HEALTH PRODUCTS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"608","02-06-17","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"610","02-05-14","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"611","03-05-26","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS REGARDING THE ADMINISTRATION OF DISPERSED TABLETS THROUGH NASO-GASTRIC TUBES","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'ADMINISTRATION DES COMPRIMÉS DISPERSÉS PAR TUBES NASO-GASTRIQUES","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"612","02-05-14","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITION OF 400MG CAPLET AS A NON-PRESCRIPTION PRODUCT","AJOUT D'UN COMPRIMÉ DE 400MG COMME PRODUIT SANS ORDONNANCE","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"613","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"614","02-05-02","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE ADMINISTRÉ PAR VOIE NASALE","",""
"615","02-05-01","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"616","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal Anti-Inflammatory Analgesic Agent","Analgésique anti-inflammatoire non stéroïdien","",""
"617","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"618","02-04-30","MCNEIL CONSUMER HEALTHCARE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"619","02-04-16","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF ALTERNATE MANUFACTURING SITE","AJOUT D'UN AUTRE SITE DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"620","03-05-12","MERCK FROSST/SCHERING PHARMA GP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLESTEROL ABSORPTION INHIBITOR","INHIBITEUR DE L'ABSORPTION DU CHOLESTÉROL","",""
"621","02-04-03","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"622","02-02-14","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"623","02-02-04","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"624","02-01-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","AGENT DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"625","02-01-18","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN LABELS TO INCLUDE DOSING FOR CHILDREN LESS THAN 24 MONTHS AND CHANGE TO PRODUCT MONOGRAPH TO INCLUDE DOSING FOR CHILDREN LESS THAN SIX MONTHS","MODIFICATION À L'ÉTIQUETAGE POUR INCLURE LA POSOLOGIE POUR LES ENFANTS DE MOINS DE 24 MOIS ET MODIFICATION À LA MONOGRAPHIE DU PRODUIT POUR INCLURE LA POSOLOGIE POUR LES ENFANTS DE MOINS DE 6 MOIS","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"626","03-05-12","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"627","02-11-27","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KETALAR","PFIZER CANADA INC.","CANADA","CANADA","1","","","GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL","",""
"628","02-11-04","PANGEO HEALTH SCIENCES DIV. OF/DE PANGEO PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC, ANTIALLERGIC AGENT","AGENT PROPHYLACTIQUE DE L'ASTHME INFANTILE, AGENT ANTIALLERGIQUE","",""
"629","02-05-27","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: OPHTHALMIC SOLUTION","NOUVELLE FORME POSOLOGIQUE : SOLUTION OPHTALMIQUE","TOPICAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE TOPIQUE","",""
"630","02-04-03","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIZORAL CREAM","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"631","03-04-14","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIVELLE 100","CIBA PHARMACEUTICALS, CIBA GEIGY CANADA LTD.","CANADA","CANADA","1","","","ESTROGEN THERAPY","THÉRAPIE D'OESTROGÈNE","",""
"632","02-12-20","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"633","03-02-28","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH INCLUDING REDUCED DOSAGE REGIMEN FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT INCLUANT UNE POSOLOGIE RÉDUITE POUR LES PERSONNES ATTEINTES DE DÉFICIENCE RÉNALE GRAVE","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"634","02-12-11","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION (TABLETS 250MG, 500MG, 750MG; INJECTION 25MG/ML, 5MG/ML IN 5% DEXTROSE): COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (MILD TO MODERATE), EXCLUDING BURNS, DUE TO ENTEROCOCCUS FAECALIS, METHICILLIN-SENSITIVE STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PYOGENES, PROTEUS MIRABILIS, OR STREPTOCOCCUS AGALACTIAE; NEW DOSING REGIMEN OF 750MG ONCE DAILY FOR TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"635","02-12-11","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW TABLET STRENGTH 750MG","NOUVELLE CONCENTRATION DU COMPRIMÉ 750MG","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"636","02-12-10","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"637","03-12-09","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"638","02-10-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2A ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER","ANALOGUE DE LA PROSTAGLANDINE F2A ET INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"639","02-09-11","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"640","03-11-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"641","02-08-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"642","02-07-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"643","02-06-28","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTITHROMBOTIC","AGENT ANTITHROMBOTIQUE","",""
"644","02-05-22","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP AND DOHME","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"645","03-11-06","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK FROSST CANADA AND COMPANY","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"646","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"647","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Glaucoma Therapy, Noncardioselective Beta-Adrenoceptor Blocking Agent","Traitement du glaucome, Inhibiteur non cardiosélectif des récepteurs Bêta-Adrénergiques","",""
"648","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC - ANABOLIC STEROID","ANDROGÈNE - STÉROÏDE ANABOLISANT","",""
"649","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"650","02-04-16","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"651","02-03-20","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"652","02-03-11","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"653","03-09-19","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION AND FILL-BY-MASS","NOUVELLE FORMULATION ET REMPLISSAGE BASÉ SUR LA MASSE","GONADOTROPHIN","GONADOTROPHINE","",""
"654","02-02-27","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"655","02-02-27","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"656","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"657","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"658","02-02-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: TOPICAL ANALGESIA ON INTACT SKIN PRIOR TO VACCINATION WITH VACCINES THAT HAVE BEEN SHOWN NOT TO INTERACT WITH EMLA IN CLINICAL TRIALS","NOUVELLE INDICATION : ANALGÉSIE TOPIQUE AVENT LA VACCINATION AVEC DES VACCINS, QUI LORS DES ESSAIS CLINIQUES, N'ONT PAS DÉMONTRÉ D'INTERACTION ANTAGONISTE AVEC L'EMLA","TOPICAL ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE TOPIQUE POUR ANALGÉSIE DERMIQUE","",""
"659","02-02-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"660","02-02-06","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: CAPLETS","NOUVELLE FORME POSOLOGIOQUE : CAPLETS","ORAL ANTIDIARRHEAL, ANTIFLATULENT","ANTIDIARRHÉIQUE ORAL, ANTIFLATULENT","",""
"661","02-01-21","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN >= 14 YEARS OF AGE","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ACNÉ VULGAIRE MODÉRÉ CHEZ LES FEMMES DE 14 ANS ET PLUS","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"662","03-09-11","LABORATOIRES FOURNIER S.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTEND THE CLINICAL INDICATION TO INCLUDE ADULT PATIENTS WITH TYPE 2 DIABETES, WHO ARE AT RISK OF CORONARY ATHEROSCLEROSIS","AJOUTER AUX INDICATIONS CLINIQUES LE TRAITEMENT DES ADULTES SOUFFRANT DE DIABÈTE DE TYPE 2 AVEC RISQUE D'ATHÉROSCLÉROSE CORONARIENNE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"663","03-09-05","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"664","02-12-16","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERGLYCEMIC","ANTIHYPERGLYCÉMIANT","",""
"665","02-12-10","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"666","02-12-06","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"667","02-09-20","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE SITE DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"668","02-10-24","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"669","02-10-17","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"670","02-10-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"671","02-10-09","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANITMETABOLITE/ANTIRHEUMATIC","ANTIMÉTABOLITE/ANTIRHUMATISMALE","",""
"672","02-09-26","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE/AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"673","02-09-25","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"674","02-09-19","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"675","02-07-19","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF NEW STRENGTH","ADDITION D'UNE NOUVELLE CONCENTRATION","BETA-ADRENOCEPTOR AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"676","02-07-02","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","IONIC, WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","IONIQUE, SUBSTANCE DE CONTRASTE RADIO-OPAQUE HYDROSOLUBLE POUR USAGE INTRAVASCULAIRE","",""
"677","02-06-26","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVASCULAR X-RAY CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE INTRAVASCULAIRE","",""
"678","02-06-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERIE CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"679","02-06-21","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL RADIOPAQUE CONTRAST MEDIUM FOR DILUTION","AGENT DE CONTRASTE RADIOLOGIQUE ORAL","",""
"680","02-06-20","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RETROGRADE CYSTOGRAPHY AND CYSTOURETHROGRAPHY X-RAY CONTRAST","AGENT DE CONTRASTE RADIOLOGIQUE CYSTOGRAPHIE RÉTROGRADE ET CYSTOURÉTROGRAPHIE","",""
"681","02-06-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION OF THE 2MG TABLET; NEW DRUG PRODUCT MANUFACTURING SITE; NEW DRUG SUBSTANCE MANUFACTURING SITE","REFORMULATION DU COMPRIMÉ DE 2 MG; NOUVEAU SITE DE FABRICATION DU PRODUIT; NOUVEAU SITE DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTINEOPLASTIC (ALKYLATING) AGENT","ANTINÉOPLASIQUE","",""
"682","02-05-28","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"683","02-05-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEPTAZANE","WYETH-AYERST CANADA","CANADA","CANADA","1","","","CARBONIC ANHYDRASE INHIBITOR","INHIBITEUR DE L'ANHYDRASE CARBONIQUE","",""
"684","02-05-15","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION TO MULTI-PRODUCT FAMILY","CONVERSION À UN ÉTABLISSEMENT MULTI-PRODUITS","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"685","02-05-15","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"686","02-05-10","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"687","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE FREDERICK","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"688","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA","CANADA","CANADA","1","","","ORAL ANTIHYPERGYLCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"689","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"690","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"691","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"692","02-03-08","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF SOLAR LENTIGINES AND RELATED HYPERPIGMENTED LESIONS","AGENT POUR LE TRAITEMENT DES LENTIGINES SOLAIRES ET LÉSIONS CONNEXES DE PIGMENTATION EXCESSIVE","",""
"693","02-03-07","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPO-MEDROL","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"694","02-02-27","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"695","02-02-27","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"696","02-02-04","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","UROPROTECTOR","UROPROTECTEUR","",""
"697","02-02-04","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA AGENT","AGENT ANTIROSACÉE","",""
"698","02-01-22","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"699","02-01-07","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"700","02-01-07","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT (HEPATOBILIARY IMAGING)","AGENT RADIODIAGNOSTIQUE (IMAGE HÉPATOBILIAIRE)","",""
"701","02-12-24","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: ADDITION OF 20MG ONCE DAILY DOSE FOR THE INITIATION OF THERAPY IN MILD TO MODERATE ESSENTIAL HYPERTENSION PATIENTS","RÉVISION DE LA MONOGRAPHIE DU PRODUIT: AJOUT D'UNE DOSE DE 20 MG PAR JOUR POUR LA THÉRAPIE INITIALE DE L'HYPERTENSION ESSENTIELLE LÉGÈRE OU MOYENNE","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"702","02-12-10","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM NEFAZODONE","MODIFICATION DU NOM DU PRODUIT DE NEFAZODONE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"703","02-12-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME CANADA","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"704","02-12-06","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"705","02-11-29","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC AGENT FOR THE RELIEF OF SELECTED SYMPTOMS IN PATIENTS WITH ORGANIC BRAIN SYNDROME/PERIPHERAL VASODILATOR","AGENT SYMPATHICOMIMÉTIQUE POUR LE SOULAGEMENT DE SYMPTÔMES PRÉCIS CHEZ LES PERSONNES PRÉSENTANT UN SYNDROME CÉRÉBRAL ORGANIQUE/VASODILATATEUR PÉRIPHÉRIQUE","",""
"706","02-11-13","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - ENTERIC COATED TABLETS","NOUVELLE FORM POSOLOGIQUE - COMPRIMÉS GASTRO-RÉSISTANTS","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"707","02-09-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME CANADA","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"708","02-09-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"709","02-08-20","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONAL CONTRACEPTIVE","CONTRACEPTIF HORMONAL","",""
"710","02-08-07","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"711","02-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"712","02-07-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXID","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"713","02-06-20","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"714","02-05-27","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVENTYL","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"715","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AND ANTIHYPERTENSIVE AGENT","ANTIANGINEUX ET ANTIHYPERTENSEUR","",""
"716","02-05-02","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"717","02-04-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"718","02-03-07","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"719","02-02-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE ORAL","",""
"720","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"721","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"722","02-01-25","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"723","02-01-25","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"724","02-01-23","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"725","02-01-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOGADON","ICN CANADA LIMITED","CANADA","CANADA","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"726","02-01-18","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"727","02-12-16","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","DOSAGE ADDITIONNEL","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"728","02-07-10","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"729","02-05-15","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"730","02-05-10","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"731","02-03-11","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND INDICATION - POWDER FOR ORAL SUSUPENSION TO BE USED IN THE TREATMENT OF PEDIATRIC PATIENTS ONE YEAR AND OLDER","NOUVELLE PRÉSENTATION ET INDICATION - POUDRE POUR SUSPENSION ORALE POUR LE TRAITEMENT DES ENFANTS ÂGÉSDE UN AN ET PLUS","ANTIVIRAL AGENT","ANTIVIRAL","",""
"732","02-02-21","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"733","02-02-08","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH ANTI-DIABETIC AGENTS TO IMPROVE BLOOD GLUCOSE CONTROL IN OVERWEIGHT OR OBESE TYPE 2 DIABETES PATIENTS","NOUVELLE INDICATION: POUR ÊTRE UTILISÉ EN ASSOCIATION AVEC DES AGENTS ANTI-DIABÉTIQUES POUR AMÉLIORER LE CONTRÔLE DU GLUCOSE SANGUIN CHEZ LES SUJETS OBÈSES OU QUI PRÉSENTENT UN DIABÈTE DE TYPE 2","ANTI-OBESITY AGENT/GASTROINTESTINAL LIPASE INHIBITOR","AGENT ANTIOBÉSITÉ/INHIBITEUR DES LIPASES GASTRO-INTESTINALES","",""
"734","02-02-04","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"735","02-11-28","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"736","02-11-08","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"737","02-11-05","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"738","03-09-04","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: ADVERSE EFFECTS FOLLOWING DISCONTINUATION OF TREATMENT","MONOGRAPHIE RÉVISÉE DU PRODUIT: EFFETS INDÉSIRABLES SUITE À L'ABANDON DU TRAITEMENT","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","",""
"739","02-11-04","PANGEO HEALTH SCIENCES DIV. OF/DE PANGEO PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASCULAR HEADACHE PROPHYLAXIS","PROPHYLAXIE DES CÉPHALÉES VASCULAIRES","",""
"740","02-10-18","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"741","02-10-18","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"742","02-10-16","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 8MG TABLET","NOUVELLE CONCENTRATION: COMPRIMÉ DE 8MG","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"743","02-10-09","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"744","02-09-27","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"745","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"746","02-09-10","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","TROUSSE RADIODIAGNOSTIQUE","",""
"747","02-09-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","NEUROLEPTIQUE","",""
"748","02-08-29","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION","NOUVELLE INDICATION: POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE LÉGÈRE À MODÉRÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"749","02-08-20","ALTANA PHARMA AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"750","02-07-30","ALTANA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"751","02-07-16","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"752","01-12-31","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"753","02-07-12","MM THERAPEUTICS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"754","02-07-10","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A CAUTIONARY STATEMENT TO THE DOSAGE & ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","AJOUT D'UNE MISE EN GARDE SOUS LES RUBRIQUES POSOLOGIE ET MODE D'ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"755","02-06-19","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE REGARDING USE IN PATIENTS WITH HEPATIC IMPAIRMENT AND/OR RENAL INSUFFICIENCY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR LE TRAITEMENT DES PATIENTS PRÉSENTANT UN PROBLÈME DE LA FONCTION HÉPATIQUE ET/OU INFUFFISANCE RÉNALE","CHOLINOMIMETIC AGENT","AGENT CHOLINOMIMÉTIQUE","",""
"757","02-05-31","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER PLUS ANTIVIRAL AGENT","MODULATEUR DES RÉACTIONS BIOLOGIQUES, ANTIVIRAL","",""
"758","01-12-20","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ALTI-AMOXI CLAV 125F AND ALTI-AMOXI CLAV 250F","MODIFICATION DU NOM DU PRODUIT DE ALTI-AMOXI CLAV 125F ET ALTI-AMOXI CLAV 250F","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"759","02-05-30","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"760","01-11-30","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"761","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT, ANTIPARKINSONIAN AGENT","ANTIVIRAL, ANTIPARKINSONIEN","",""
"762","02-05-17","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN THE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA","NOUVELLE INDICATION: POUR LE TRAITEMENT DU SARCOME DE KAPOSI RELIÉ AU SIDA","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"763","02-05-15","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT (HUMANIZED MONOCLONAL ANTIBODY)","AGENT D'IMMUNISATION PASSIVE (ANTICORPS MONOCLONAUX HUMANISÉE)","",""
"764","01-11-21","GLAXOSMITHKLINE INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"765","02-05-01","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLYCOSAMINOGLYCAN SUBSTITUTE","SUCCÉDANÉ DE GLYCOSAMINOGLYCANNE","",""
"766","02-04-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF POSTTRAUMATIC STRESS DISORDER","NOUVELLE INDICATION: TRAITEMENT SYMPTOMATIQUE DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","ANTIDEPRESSANT-ANTIOBSESSIONAL-ANTIPANIC-ANXIOLYTIC AGENT-SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER)-POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"767","02-03-22","SIGMA-TAU PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"768","02-03-08","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEDIAPRED","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"769","02-03-07","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"770","02-02-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ORAP","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","NEUROLEPTIQUE","",""
"771","02-02-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTIONS CAUSED BY PNEUMOCCI","AGENT D'IMMUNISATION ACTIVE CONTRE LES INFECTIONS SYSTÉMIQUES À PNEUMOCOQUES","",""
"772","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"773","02-02-04","BLES BIOCHEMICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (BOVINE)","SURFACTANT PULMONAIRE (BOVINE)","",""
"774","02-01-11","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"775","02-01-11","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"776","02-12-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"777","02-12-09","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 35MG FILM-COATED TABLETS; NEW DOSING REGIMEN: ONCE A WEEK FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS","NOUVELLE CONCENTRATION: COMPRIMÉS DE 35MG ENROBÉS D'UNE PELLICULE; NOUVELLE POSOLOGIE: UNE FOIS PAR SEMAINE POUR LE TRAITEMENT DE L'OSTÉOPOROSE POST-MÉNOPAUSIQUE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"778","02-11-06","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - FOR USE IN THE TREATMENT OF PATIENTS WITH CD20 POSITIVE, DIFFUSE LARGE B-CELL NOON-HODGKIN'S LYMPHOMA COMBINATION WITH CHOP CHEMOTHERAPY","NOUVELLE INDICATION: POUR LE TRAITEMENT DES PATIENTS AVEC LYMPHOME NON HODGKINIEN DIFFUS À GRANDES CELLULES DE PHÉNOTYPE B CD20-POSITIVES EN COMBINATIONS AVEC LE TRAITEMENT CHIMIOTHÉRAPEUTIQUE CHOP","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"779","02-08-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"780","02-08-13","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"781","02-08-13","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"782","02-06-26","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"783","02-03-11","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","NEW PRODUCT NAME","NOUVEAU NOM DU PRODUIT","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"784","02-02-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORAL SOLUTION","NOUVELLE FORME POSOLOGIQUE: SOLUTION ORALE","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"785","02-01-23","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH AND LABEL REVISIONS","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT ET DE L'ÉTIQUETTE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"786","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"787","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-FOR DIAGNOSTIC USE","RADIOPHARMACEUTIQUE-POUR USAGE DIAGNOSTIQUE","",""
"788","02-12-09","RATIOPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","HYPNOTIC","HYPNOTIQUE","",""
"789","02-05-27","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"790","02-08-07","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF BONE METASTASES DUE TO PROSTATE CANCER IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY","NOUVELLE INDICATION: TRAITEMENT DES MÉTASTASES OSSEUSES SECONDAIRES À UN CANCER DE LA PROSTATE CONJOINTEMENT À UNE THÉRAPIE UNIFORME ANTINÉOPLASIQUE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"791","02-07-30","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","HYPNOTIC AGENT","HYPNOTIQUE","",""
"792","02-04-19","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","AGENT HYPNOTIQUE","",""
"793","02-01-31","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: SAFETY UPDATE - INCREASE IN THE INFUSION DILUTION VOLUMEFROM 50 TO 100 ML","RÉVISION À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ - AUGMENTATIONDU VOLUME DE DILUTION DE L'INFUSION DE 50 À 100 ML","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"794","02-05-01","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTICOAGULANT","ANTICOAGULANT","",""
"795","02-04-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLES CONCENTRATION","ANTICOAGULANT","ANTICOAGULANT","",""
"796","02-01-02","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"797","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIDEX OINTMENT, TOPSYN GEL","SYNTEX CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"798","02-12-13","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE TO IN-PROCESS CONTROL","MODIFICATION DES CONTRÔLES EN COURS DE PRODUCTION","DIAGNOSTIC RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE À USAGE DIAGNOSTIQUE","",""
"799","01-11-21","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"800","02-11-29","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"801","01-11-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO REINSTATE 50MG/VIAL INJECTION WHICH WAS ORIGINALLY CLEARED MARCH 24, 1974 BUT NEVER SOLD IN CANADA","RÉTABLIR LE VIAL DE 50 MG POUR INJECTION QUI AVAIT ÉTÉ APPROUVÉ INITIALEMENT LE 24 MARS 1974 MAIS QUI N'A JAMAIS ÉTÉ COMMERCIALISÉ AU CANADA","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"802","02-11-28","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPRURITIC/ANTIHISTAMINIC","ANTIPRURIGINEUX/ANTIHISTAMINIQUE","",""
"803","02-11-20","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"804","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"805","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"806","02-10-23","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISIONS TO PRODUCT MONOGRAPH-CHANGE IN AGE INDICATION FROM AGED 12 TO 54 YEARS TO READ AGED 11 TO 54 YEARS; THE SAFETY OF ADACEL WHEN CONCURRENTLY ADMINISTERED WITH HEPATITIS B VACCINE","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT: -MODIFICATION DE L'ÂGE D'INDICATION DE ÂGÉ DE 12 À 54 ANS À ÂGÉ DE 11 À 54 ANS; SÉCURITÉ D'ADACEL LORSQU'ADMINISTRÉ CONJOINTEMENT AVEC LE VACCIN DE L'HÉPATITE B","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"807","02-10-15","ORYX PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"808","02-10-15","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"809","01-10-17","GLAXO WELLCOME BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"810","02-10-04","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYKLOKAPRON","PHARMACIA AND UPJOHN INC.","CANADA","CANADA","1","","","ANTIFIBRINOLYTIC AGENT","AGENT ANTIFIBRINOLYTIQUE","",""
"811","01-10-12","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"812","01-10-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"813","02-09-09","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"814","02-06-19","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 500MG","NOUVELLE CONCENTRATION: 500MG","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"815","01-10-09","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVEAUX DOSAGES","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"816","02-04-03","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY, DOCOSANOID","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE, DOCOSANOÏDE","",""
"817","02-12-11","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"818","03-09-03","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"819","02-11-29","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"820","02-11-29","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"821","03-09-03","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"822","02-11-04","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"823","01-09-21","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAINTENANCE OF REMISSION OF MILD TO MODERATE ULCERATIVE COLITIS","NOUVELLE INDICATION : MAINTIEN DE LA RÉMISSION DE LA COLITE ULCÉREUSE BÉNIGNE À MODÉRÉE","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASSE DU TUBE DIGESTIF","",""
"824","03-08-25","AXXESS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"825","02-06-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FULLY REFRIGERATOR-STABLE VACCINE","RÉFRIGÉRATEUR-VACCIN STABLE","ACTIVE IMMUNIZING AGENT AGAINST VARICELLA","AGENT D'IMMUNISATION ACTIVE CONTRE LA VARICELLE","",""
"826","02-05-31","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"827","02-05-15","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"828","03-08-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"829","02-05-03","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"830","02-04-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"831","02-04-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","NOUVEAU PROCÉDÉ DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"832","03-07-21","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"833","02-10-04","UNITED THERAPEUTICS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"834","01-09-10","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON JUNE 4, 1999","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 JUIN 1999","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"835","02-09-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT/SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"836","01-09-10","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON JUNE 4, 1999","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 JUIN 1999","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"837","01-09-10","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON JUNE 4, 1999","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 JUIN 1999","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"838","02-07-25","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT RADIODIAGNOSTIQUE","",""
"839","02-06-20","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADIITION OF A NEW STRENGTH","ADDITION D'UNE NOUVELLE CONCENTRATION","TESTOSTERONE REPLACEMENT THERAPY","TRAITEMENT DE REMPLACEMENT DE LA TESTOSTÉRONE","",""
"840","02-06-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (LH-RH)","",""
"841","02-06-05","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PHOTODAMAGED SKIN","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA PEAU ENDOMMAGÉE SUITE À UNE EXPOSITION AU SOLEIL OU À LA LUMIÈRE ULTRAVIOLETTE","ANTI-PSORIASIS AGENT, ANTI-ACNE AGENT, AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","ANTIPSORIASIQUE, ANTIACNÉ, AGENT POUR LE TRAITEMENT DE LA PEAU ENDOMMAGÉE SUITE À UNE EXPOSITION AU SOLEIL OU À LA LUMIÈRE ULTRAVIOLETTE","",""
"842","02-05-31","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","THYROID STIMULATING HORMONE","HORMONE STIMULATRICE DE LA THYROÏDE","",""
"843","02-05-15","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TOPICAL TREATMENT OF ACNE VULGARIS","NOUVELLE INDICATION: POUR LE TRAITEMENT TOPIQUE DE L'ACNÉ SIMPLE","ANTI-PSORIASIS AGENT, ANTI-ACNE AGENT","ANTIPSORIASIQUE, ANTIACNÉ","",""
"844","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"845","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"846","02-05-02","BERNA BIOTECH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"847","01-08-28","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","USE OF PARAMETRIC RELEASE INSTEAD OF STERILITY TESTING FOR FINISHED PRODUCT TESTING","USAGE DE LA DIFFUSION PARAMÉTRIQUE PLUTÔT QUE DE L'ÉPREUVE DE STÉRILITÉ POUR UN TEST DE PRODUIT COMPLÉTÉ","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"848","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"849","02-04-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"850","02-04-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODULIN","AXCAN PHARMA INC.","CANADA","CANADA","1","","","LOWER GASTROINTESTINAL TRACT MOTILITY REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"851","02-03-14","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW GELATIN CAPSULE MANUFACTURER","NOUVEAU FABRICANT DE GÉLATINE EN CAPSULE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"852","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"853","02-03-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT4 RECEPTOR PARTIAL AGONIST","RÉCEPTEUR AGONISTE PARTIEL 5-HT4","",""
"854","02-03-11","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"855","02-02-28","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGING PRODUCT NAME FROM DETROL SR TO UNIDEL. ALSO INVOLVES SPLITTING OF APPROVED PRODUCT MONOGRAPH FOR DETROL AND DETROL SR","MODIFICATION DU PRODUIT DE DETROL SR À UNIDET. DE PLUS, IMPLIQUE LA SÉPARATION DE LA MONOGRAPHIE APPROUVÉE DU PRODUIT POUR DETROL ET DETROL SR","ANTICHOLINERGIC-ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"856","02-02-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"857","02-02-21","MEDI PHYSICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"858","02-02-19","ELAN PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTIPASTIC AGENT","AGENT ANTISPASMODIQUE","",""
"859","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (MYOCARDIAL IMAGING)","AGENT RADIODIAGNOSTIQUE DE L'INFARCTUS MYOCARDIQUE","",""
"860","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-DIAGNOSTIC AGENT","RADIOPHARMACEUTIQUE-AGENT DIAGNOSTIQUE","",""
"861","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (BREAST IMAGING)","AGENT RADIODIAGNOSTIQUE POUR L'IMAGE DU SEIN","",""
"862","02-02-06","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC HORMONE","HORMONE ANDROGÉNIQUE","",""
"863","02-12-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA CO.","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"864","02-11-15","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","NEW INDICATIONS: FOR THE TREATMENT OF PANIC DISORDER AND OBESSESIVE COMPULSIVE DISORDER","NOUVELLES INDICATIONS: POUR LE TRAITEMENT DES TROUBLES PANIQUE ET OBSESSIVO-COMPULSIF","ANTIDEPRESSANT, ANTIPANIC, AND ANTIOBSESSIONAL AGENT","ANTIDÉRESSEUR, ANTIPANIQUE ET ANTIOBSESSIONAL","",""
"865","02-12-13","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"866","02-11-28","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"867","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"868","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"869","02-10-31","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"870","02-10-31","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (LIVER AND SPLEEN IMAGING)","AGENT RADIODIAGNOSTIQUE (POUR L'IMAGE DU FOIE ET DE LA RATE)","",""
"871","02-10-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES)","",""
"872","02-10-01","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS AU DOSAGE ET À LA SECTION DE L'ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"873","02-09-10","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT RADIODIAGNOSTIQUE","",""
"874","02-10-09","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"875","02-09-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"876","02-09-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"877","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"878","01-08-17","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"879","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE-OXYDASE","",""
"880","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"881","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPROTOZOAL AGENT","AGENT ANTIPROTOZOAIRE","",""
"882","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"883","01-08-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"884","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"885","01-07-11","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASE","",""
"886","01-06-20","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTODYNAMIC THERAPY PHOTOSENSITIZER","SENSIBILISATEUR POUR THÉRAPIE PHOTODYNAMIQUE","",""
"887","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"888","02-03-01","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE WHERE THE USE OF A COMBINATION PRODUCT IS CONSIDERED TO BE APPROPRIATE","NOUVELLE INDICATION: POUR UNE THÉRAPIE D'ENTRETIEN DE L'ASTHME CHEZ LES PATIENTS QUI PRÉSENTENT UNE OBSTRUCTION RÉVERSIBLE DES VOIES RESPIRATOIRES CHEZ QUI UN PRODUIT MIXTE EST JUGÉ ADÉQUAT","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"889","03-07-11","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"890","02-08-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR/BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR/STIMULANT DES RÉCEPTEURS BÊTA2-ADRÉNERGIQUES","",""
"891","02-07-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIMAR","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","SYNTHETIC SALMON CALCITONIN","CALCITONINE DE SAUMON SYNTHÉTIQUE","",""
"892","02-07-16","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR/BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES BETA2-ADRÉNERGIQUE","",""
"893","02-05-30","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator/Beta2-Adrenergic Stimulant","Bronchodilatateur/Stimulant des Beta2-adrénergique","",""
"894","03-05-08","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"895","02-06-04","AVENTIS BEHRING GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"896","01-06-07","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","NEW DOSAGE FORM (POWDER FOR SUSPENSION)","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC, ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASES","",""
"897","02-05-31","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"898","02-05-31","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"899","01-06-07","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR REDUCING THE RISK OF VASCULAR MORTALITY IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL INFARCTION","NOUVELLE INDICATION : POUR RÉDUIRE LE RISQUE DE MORTALITÉ VASCULAIRE CHEZ LES PATIENTS SUSPECTS D'INFARCTUS AIGÜE DU MYOCARDE","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"900","03-04-25","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - UPDATED TO CONFORM TO INNOVATOR","RÉVISION À LA MONOGRAPHIE DU PRODUIT - POUR ÊTRE CONFORME À L'INNOVATEUR","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"901","02-05-28","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"902","03-04-23","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"903","01-06-04","TEXAS BIOTECHNOLOGY CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"904","02-05-10","IVAX PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES)","",""
"905","01-05-30","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"906","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"907","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS, CROHN'S DISEASE AND RHEUMATOID ARTHRITIS","TRAITEMENT DE LA MALADIE INTESTINALE INFLAMMATOIRE, DE LA COLITE ULCÉREUSE, DE LA MALADIE DE CROHN ET DE L'ARTHRITE RHUMATOÏDE","",""
"908","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"909","02-05-01","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"910","01-05-17","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITION OF 325 MG DAILY IN THE RECOMMENDED DOSAGE FOR UNSTABLE ANGINA OR PREVIOUS MYOCARDIAL INFARCTION.  REVISED INDICATION FOR REDUCING THE RISK OF RECURRENT TRANSIENT ISCHEMIC ATTACKS AND FOR SECONDARY PREVENTION OF ATHEROTHROMBOTIC CEREBRAL INFARCTION TO INCLUDE WOMEN AS WELL AS MEN","AJOUT D'UNE DOSE DE 325 MG PAR JOUR À LA DOSE RECOMMANDÉE DANS LE CAS D'ANGOR INSTABLE AVEC ANTÉCÉDENTS D'INFARCTUS DU MYOCARDE.  INDICATION RÉVISÉ POUR LA RÉDUCTION DU RISQUE D'ACCIDENTS ISCHÉMIQUES TRANSITOIRES ET POUR LA PRÉVENTION SECONDAIRE D'INFARCTUS CÉRÉBRAL ATHÉROTHROMBOTIQUE CHEZ LA FEMME AUSSI BIEN QUE CHEZ L'HOMME","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE, ANTIANGRÉGANT PLAQUETTAIRE","",""
"911","01-05-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"912","02-03-21","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR/BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES","",""
"913","01-05-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"914","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-DIAGNOSTIC AGENT","RADIOPHARMACEUTIQUE-AGENT DIAGNOSTIQUE","",""
"915","03-04-23","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"916","02-01-28","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"917","03-03-28","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"918","02-01-23","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"919","01-04-27","BAXTER HEALTHCARE CORPORATION, HYLAND IMMUNO","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DRUG SUBSTANCE MANUFACTURING SUITE","NOUVELLE SUITE DE FABRICATION POUR LES SUBSTANCES MÉDICALES","ANTIHEMOPHILIC","ANTIHÉMOPHILIQUE","",""
"920","03-03-04","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"921","03-02-27","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"922","03-02-17","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"923","02-08-29","DENTSPLY CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"924","03-01-22","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM FLUOXETINE","CHANGEMENT DU NOM DU PRODUIT DE FLUOXETINE","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"925","03-12-17","ASTRAZENECA CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITOR","INHIBITEUR DE L'ACTIVITÉ TYROSINE KINASE DU RÉCEPTEUR DE FACTEUR DE CROISSANCE ÉPIDERMIQUE","",""
"926","03-12-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING","NOUVELLES INDICATIONS: LA PRÉVENTION ET LE TRAITEMENT DE LA NAUSÉE POST-OPÉRATOIRE ET DU VOMISSEMENT","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"927","03-11-19","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"928","03-11-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON TABLETS 80MG","SERVIER CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"929","03-11-06","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH REGARDING THE POTENTIAL FOR INTERACTIONS WITH OPIOID ANALGESICS","MISES À JOUR DE LA MONOGRAPHIE EN MATIÈRE D'INTERACTION POSSIBLE AVEC LES ANALGÉSIQUES OPIOÏDES","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"930","03-11-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"931","03-10-02","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"932","00-12-21","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR CONCENTRATE","FACTEUR DE COAGULATION CONCENTRÉ","",""
"933","00-12-19","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"934","00-12-11","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANTI-HISTAMINIC, LEUKOTRIENE INHIBITOR AGENT","ANTI-INFLAMMATOIRE, ANTI-HISTAMINIQUE, INHIBITEUR DE LEUCOTRIÈNE","",""
"935","00-12-11","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MUCOMYST","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","MUCOLYTIC, ANTIDOTE FOR ACETAMINOPHEN POISONING","AGENT MUCOLYTIQUE, ANTIDOTE CONTRE LES INTOXICATIONS PAR L'ACÉTAMINOPHÈNE","",""
"936","00-12-08","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"937","00-12-05","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"938","00-12-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"939","00-11-28","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMIKIN","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"940","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"941","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIHEMORRHAGIC","ANTIHÉMORRAGIQUE","",""
"942","00-11-10","JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTI-PYRETIC & PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE & INHIBIEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"943","00-10-27","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTIPLATELET ANTIBODY","ANTICORPS ANTIPLAQUETTAIRE","",""
"944","00-10-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"945","00-10-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"946","00-09-11","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"947","00-08-02","HANSAMED LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"948","00-08-02","HANSAMED LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"949","00-07-27","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"950","03-08-01","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"951","00-07-24","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"952","00-07-21","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SECONDARY HYPERPARATHYROIDISM","NOUVELLE INDICATION: HYPERPARATHYROÏDE SECONDAIRE","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMIN D","",""
"953","00-07-21","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: SOLUTION FOR INJECTION 2MCG/ML","NOUVELLE FORM POSOLOGIQUE: SOLUTION POUR INJECTION","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMIN D","",""
"954","00-07-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYEST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHIQUE","",""
"955","00-07-04","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"956","00-06-16","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"957","00-06-12","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING-INCREASE IN FINAL PRODUCT LOT SIZE, -CHANGE IN STABILITY TESTING PROGRAMME","CHANGEMENT DANS LA FABRICATION - AUGMENTATION DE LA QUANTITÉ DU PRODUIT FINAL - CHANGEMENT AU NIVEAU DU PROGRAMME D'ÉTUDES DE STABILITÉ","IMMUNOMODULATOR","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"958","00-06-12","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"959","00-05-29","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: HORMONAL TREATMENT OF ADVANCED BREAST CANCER IN POST MENOPAUSAL WOMEN","NOUVELLE INDICATION : TRAITEMENT HORMONAL POUR LE CANCER DU SEIN À UN STAGE AVANCÉ CHEZ LES FEMMES MÉNOPAUSÉES","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"960","00-05-26","CATALYTICA PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE-OXYDASE","",""
"961","00-05-19","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"962","00-04-26","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING -NEW SITE FOR PRODUCTION OF DRUG SUBSTANCE","MODIFICATION DE LA MÉTHODE DE FABRICATION - NOUVEL EMPLACEMENT POUR LA FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILIQUE","",""
"963","00-04-26","SEQUUS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"964","00-04-20","MEDIMMUNE ONCOLOGY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR","",""
"965","00-04-20","MEDIMMUNE ONCOLOGY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"966","00-04-19","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"967","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"968","00-04-11","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"969","00-04-11","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"970","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC-ANTIHYPERTENSIVE","DIURÉTIQUE-ANTIHYPERTENSEUR","",""
"971","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"972","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"973","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT DI'IMMUNISATION ACTIVE","",""
"974","00-03-30","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"975","00-03-30","ZIMMER OF CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"976","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNE AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"977","00-03-10","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"978","00-03-03","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"979","00-02-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL DENTAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"980","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"981","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"982","00-02-11","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSTINE VR STERILE SOLUTION","PHARMACIA & UPJOHN","CANADA","CANADA","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"983","00-02-09","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Intravenous Skeletal Neuromuscular Blocking Agent","Inhibiteur neuromusculaire squelettique intraveineuse","",""
"984","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN","",""
"985","00-01-24","ROBERTS PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF THROMBOCYTHEMIA SECONDARY TO MYELOPROLIFERATIVE DISORDERS","NOUVELLE INDICATION : TRAITEMENT DE LA THROMBOCYTHÉMIE SECONDAIRE AUX TROUBLES MYÉLOPROLIFÉRATIFS","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"986","00-01-19","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"987","00-11-10","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVEATED INTRAOCULAR PRESSURE THERAPY","AGONISTE DES RÉCEPTEURS 2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF - THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"988","00-10-05","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"989","00-09-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"990","00-08-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STADOL NS","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"991","00-06-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"992","00-06-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"993","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"994","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH ANALOGUE)","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"995","00-04-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"996","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASMODIQUE","",""
"997","00-04-19","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE AGENT","ANXIOLYTIQUE, SÉDATIF","",""
"998","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"999","00-04-13","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1000","00-03-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1001","00-03-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1002","00-03-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1003","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1004","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1005","03-05-02","STERIMAX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARASONE","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID AND ANTIBIOTIC","CORTICOSTÉROÏDE TOPIQUE ET ANTIBIOTIQUE","",""
"1006","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1007","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1008","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1009","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1010","00-03-08","BIOCHEM PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1011","03-04-08","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE FORME POSOLOGIQUE ET CONCENTRATION","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"1012","00-02-29","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1013","00-02-24","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT-SEDATIVE-ANAESTHETIC","PRÉMÉDICATION-SÉDATIF-ANESTHÉSIQUE","",""
"1014","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"1015","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1016","00-02-07","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1017","03-03-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT THERAPY IN PRE- AND PERIMENOPAUSAL WOMEN WITH EARLY BREAST CANCER, WHOSE TUMOUR CONTAINS ESTROGEN AND/OR PROGESTERONE RECEPTORS","NOUVELLE INDICATION: THÉRAPEUTIQUE AUXILIAIRE CHEZ LA FEMME PRÉ OU PÉRI-MÉNOPAUSALE AVEC CANCER PRIMAIRE DU SEIN DONT LA TUMEUR CONTIENT DES RÉCEPTEURS D'OESTROGÈNE ET/OU DE PROGESTÉRONE","LUTEINIZING HORMONE - RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉOSTIMULINE","",""
"1018","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORITCOSTÉROÏDE","",""
"1019","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1020","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1021","03-03-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING RECOMMENDATIONS FOR HEPATIC AND RENAL IMPAIRMENT","RECOMMANDATIONS MODIFIÉES À LA POSOLOGIE POUR LE TRAITEMENT DE LA DÉFICIENCE HÉPATIQUE ET RÉNALE","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"1022","00-12-28","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH; PRODUCT MONOGRAPH UPDATED","NOUVEAU DOSAGE; MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1023","03-03-04","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"1024","00-12-19","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"1025","00-12-11","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"1026","00-12-01","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"1027","00-11-28","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"1028","00-11-01","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"1029","00-11-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIALLERGENIC AGENT","ANTIALLERGIQUE","",""
"1030","00-10-27","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1031","00-10-17","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À ACTION CONTRÔLÉE","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1032","00-10-16","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES/PROGESTIN","HORMONES OESTROGÈNES/PROGESTATIF","",""
"1033","00-09-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-ACNE","TRAITEMENT DE L'ACNÉ","",""
"1034","00-09-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1035","00-09-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"1036","00-09-06","ZYMCAN PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1037","00-09-06","NU-PHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1038","00-08-31","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-CLONAZEPAM","MODIFICATION DU NOM DE RHO-CLONAZEPAM","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1039","03-12-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1040","00-08-15","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1042","00-08-01","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AN ADJUNCT IN THE MANAGEMENT OF OSTEOLYSIS RESULTING FROM BONE METASTASES OF MALIGNANT TUMORS","NOUVELLE INDICATION : ADJUVANT À LA GESTION DE L'OSTÉOLYSE RÉSULTANT DES MÉTASTASES OSSEUSES DE TUMEURS MALIGNES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1043","00-07-24","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF DIAPER RASH INFECTED WITH CANDIDA ALBICANS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ÉRYTHÈME FESSIER INFECTÉ PAR C.ALBICANS","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1044","00-07-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER","NOUVELLE INDICATION : TRAITEMENT DE PREMIÈRE LIGNE DES PATIENTS ATTEINTS D'UN CANCER COLO-RECTAL MÉTASTATIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1045","00-07-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW MANUFACTURING SITE, REVISED FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION, FORMULATION REVISÉE","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"1046","00-06-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DU RÉCEPTEUR DOPAMINERGIQUE","",""
"1047","00-06-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OVULATORY AGENT","AGENT OVULATOIRE","",""
"1048","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1049","00-06-12","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN","UPJOHN CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1050","00-06-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIDEX ORAL RINSE","PROCTER & GAMBLE INC.","CANADA","CANADA","1","","","ANTIGINGIVITIS","ANTIGINGIVITE","",""
"1051","00-04-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"1052","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1053","00-08-04","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION:  ADJUNCTIVE TREATMENT TO ANTIBIOTICS FOR ACUTE EPISODES OF SINUSITIS IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER","NOUVELLE INDICATION : TRAITMENT ADJUVANT AUX ANTIBIOTIQUES POUR LES ÉPISODES AIGUËS DE SINUSITE CHEZ LES ADULTES ET LES ENFANTS DE 12 ANS ET PLUS","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1054","00-04-12","SMITHKLINE BEECHAM CONSUMER HEALTHCARE, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH - NEW STRENGTH FOR THE TREATMENT OF HEARTBURN","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE - NOUVELLE CONCENTRATION POUR SOULAGER LES BRÛLURES D'ESTOMAC","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1055","03-12-04","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1056","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1057","00-04-11","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1058","00-04-11","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1059","00-04-04","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN REVISED INDICATION: TREATMENT OF PSORIASIS NEW INDICATION: COMBINATION THERAPY - USE WITH TOPICAL CORTICOSTEROIDS, CYCLOSPRORIN A, ACITRETIN AND/OR PHOTOTHERAPY (PUVA OR UVB)","SCHÉMA POSOLOGIQUE RÉVISÉ; INDICATION RÉVISÉE : TRAITEMENT DU PSORIASIS. NOUVELLE INDICATION : TRAITEMENT D'ASSOCIATION UTILISÉ AVE I) CORTICOSTÉROÏDES TOPIQUES II) CYCLOSPORINE A, ACITRÉTINE III) PHOTOTHÉRAPIE (PUVA THÉRAPIE ET LES RAYONS UVB)","TOPICAL NON-STEROIDAL, ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE TOPIQUE NON STÉROÏDIEN","",""
"1060","03-09-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDREA","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1061","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1062","03-09-02","DUCHESNAY INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY FOAM","TRAITEMENT ANORECTAL","",""
"1063","03-03-24","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1064","00-04-04","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT DES MUSCLES SQUELETTIQUES","",""
"1065","00-03-28","CHX TECHNOLOGIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMICROBIAL","ANTIBACTÉRIEN","",""
"1066","00-03-21","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE - FOR USE DURING CORONARY ARTERY BYPASS GRAFT SURGERY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT - UTILISER LORS DE PONTAGE AORTOCORONARIEN","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"1067","00-03-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT - FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA - ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU - ANTIMANIAQUE","",""
"1068","00-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1069","00-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1070","00-03-07","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1071","00-02-25","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1072","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"1073","00-02-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN","UPJOHN CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1074","00-02-09","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1075","00-02-08","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION (NEW SALT - CISAPRIDE TARTRATE)","NOUVELLE FORMULATION (NOUVEAU SEL - TARTRATE DE CISAPRIDE)","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"1076","00-02-03","PRO-DENTEC CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-GINGIVITIS ORAL RINSE","BAIN DE BOUCHE CONTRE LA GINGIVITE","",""
"1077","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"1078","00-01-17","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1079","00-12-22","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT - ANTIANGINAL AGENT","ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"1080","00-12-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1081","00-12-05","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)","NOUVELLE INDICATION POUR THROMBOCYTOPÉNIE INDUITE PAR L'HÉPARINE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1082","00-11-24","EDWARDS LIFESCIENCES RESEARCH MEDICAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INTERSTITIAL CYSTITIS","TRAITEMENT DE LA CYSTITE INTERSTITIELLE","",""
"1083","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1084","00-11-10","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL STEROID","STÉROÏDE TOPIQUE","",""
"1085","00-10-24","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PITUITARY GONADOTROPIN INHIBITOR","INHIBITEUR DE LA GONADOTROPHINE HYPOPHYSAIRE","",""
"1086","00-10-20","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR (ANTI-HYPERCALCEMIA AGENT)","RÉGULATEUR DE MÉTABOLISME OSSEUX (AGENT ANTIHYPERCALCÉMIQUE)","",""
"1087","00-10-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOESCHT MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"1088","00-10-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC - ANTIBIOTIC","ANTIMITOTIQUE - ANTIBIOTIQUE","",""
"1089","00-09-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT(CARDIZEM, CARDIZEM SR, CARDIZEM CD), ANTIHYPERTENSIVE AGENT (CARDIZEM SR, CARDIZEM CD)","ANTIANGINEUX, ANTIANGINEUX - ANTIHYPERTENSEUR, ANTIANGINEUX - ANTIHYPERTENSEUR","",""
"1090","00-09-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTMIQUE","",""
"1091","00-09-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"1092","00-09-14","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF NOCTURNAL ENURESIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ÉNURÉSIE NOCTURNE","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"1093","00-09-06","BIOVAIL LABORATORIES INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"1094","00-08-31","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-1","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR - TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1095","00-08-24","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW INTEGRATED PRODUCTION FACILITY - NEW CONTINUOUS FLOW CENTRIFUGATION STEP","MODIFICATION À L'EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA MÉTHODE DE FABRICATION","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUE DE LA DIGOXINE","",""
"1096","00-08-23","GILEAD SCIENCES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1097","00-08-17","SKYEPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF ACTINIC KERATOSES","TRAITEMENT DES KÉRATOSES D'ORIGINE ACTINIQUE","",""
"1098","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1099","00-08-15","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN MONOTHERAPY OR IN COMBINATION WITH PLATINUM DERIVATIVES","INDICATION RÉVISÉE : TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER PULMONAIRE NON À PETITES CELLULES (CPNPC) AU STADE LOCAL AVANCÉ OU MÉTASTATIQUE, EN MONOTHÉRAPIE OU ASSOCIÉ À BASE DE PLATINE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1100","00-07-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"1101","00-07-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1102","00-07-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP SPRAY","FERRING INC.","CANADA","CANADA","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"1103","00-07-07","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1104","00-07-05","ATRIX LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMICROBIAL AGENT FOR PERIODONTITIS","ANTIMICROBIEN POUR LA PÉRIODONTITE","",""
"1105","00-06-16","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"1106","00-06-12","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"1107","00-06-06","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATES","MONOGRAPHIES RÉVISÉES","CHOHLINESTERASE INHIBITOR","INHIBITEUR DE CHOLINESTÉRASE","",""
"1108","00-05-29","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZATION","AGENT D'IMMUNISATION ACTIVE","",""
"1109","00-05-29","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROPINE","ALLEGRAN INC.","CANADA","CANADA","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"1110","00-04-25","AGOURON PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1111","00-04-25","UNIMED CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF WEIGHT LOSS ASSOCIATED WITH WASTING SYNDROME","NOUVELLE INDICATION : TRAITEMENT DE LA PERTE DE POIDS ASSOCIÉ À LA CACHEXIE","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"1112","00-04-19","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1113","00-04-13","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPLATELET AGENT","INHIBITEUR DE L'ADHÉSION ET DE L'AGRÉGATION PLAQUETTAIRE","",""
"1114","00-04-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"1115","00-04-04","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTREX","ELI LILLY","CANADA","CANADA","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"1116","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1117","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1118","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1119","00-04-04","BAXTER RESEARCH MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GENITOURINARY DISORDERS","MALADIES GÉNITO-URINAIRES","",""
"1120","00-03-17","DUMEX-ALPHARMA A/S","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"1121","00-03-15","TARO PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","HOECHST CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM: GEL","NOUVELLE PRÉSENTATION : GEL","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1122","00-03-07","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1123","00-03-03","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF PROSTATIC CARCINOMA","THÉRAPIE DU CARCINOME PROSTATIQUE","",""
"1124","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-Depolarizing Skeletal Neuromuscular Blocking Agent","Inhibiteur neuromusculaire squelettique nondépolarisant intraveineux","",""
"1125","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, ALPHA 1 ANTAGONIST","ANTIHYPERTENSEUR, ALPHA 1-BLOQUANT ADRÉNERGIQUE","",""
"1126","00-02-07","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DESFERAL","NOVARTIS","CANADA","CANADA","1","","","IRON AND ALUMINIUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"1127","00-01-13","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DTIC","BAYER INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1128","00-01-04","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISANT ACTIF","",""
"1129","00-01-04","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSANT","",""
"1130","00-12-22","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT TREATMENT OF EARLY STAGE BREAST CANCER FOR PRE- AND PERI-MENOPAUSAL WOMEN","NOUVELLE INDICATION : TRAITEMENT ADJUVANT DU CANCER PRÉCOCE DU SEIN CHEZ LES FEMMES EN PRÉ ET PÉRIMÉNOPAUSE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1131","00-12-22","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT TREATMENT OF EARLY STAGE BREAST CANCER FOR PRE- AND PERI-MENOPAUSAL WOMEN","NOUVELLE INDICATION : TRAITEMENT ADJUVANT DU CANCER PRÉCOCE DU SEIN CHEZ LES FEMMES EN PRÉ- ET PÉRIMÉNOPAUSE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1132","00-12-19","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1133","00-12-19","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1134","00-12-01","IMMUNEX CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"1135","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"1136","00-10-12","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"1137","00-10-05","FOURNIER PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 7.5MG/PAD, 15MG/PAD","NOUVELLES CONCENTRATIONS : 7.5MG/PAD, 15MG/PAD","ESTROGEN","OESTROGÈNE","",""
"1138","00-09-20","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"1139","00-09-11","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"1140","00-08-17","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AROMATASE INACTIVATOR; ANTI-TUMOUR AGENT","INACTIVATEUR DE L'AROMATASE; AGENT ANTINÉOPLASIQUE","",""
"1141","00-08-15","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTICOAGULANT/ANTITHROMBOTIC AGENT (LOW MOLECULAR WEIGHT HEPARIN FRAGMENT)","ANTICOAGULANT/ANTITHROMBOTIQUE (FRAGMENT D'HÉPARINE DE BAS POIDS MOLÉCULAIRE (HBPM))","",""
"1142","00-05-09","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"1143","00-02-29","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"1144","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1145","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1146","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1147","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1148","00-12-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","COMBINATION: HISTAMINE H2-RECEPTOR ANTAGONIST AND ANTACID","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2 ET ANTACIDE","",""
"1149","00-12-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE","INDICATION RÉVISÉE : TRAITEMENT DE L'ASTHME CHEZ LES PATIENTS DE 6 ANS ET PLUS ATTEINTS D'OBSTRUCTION RÉVERSIBLE DES VOIES RESPIRATOIRES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1150","00-11-30","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL-DÉHYDROGÉNASE","",""
"1151","00-11-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1152","00-11-01","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","GONADOTROPHIN","GONADOTROPHINE","",""
"1153","00-09-14","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIDEPRESSANT, ANTIOBESESSIONAL, ANTIBULLMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1154","00-09-14","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1155","00-08-17","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL - ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE AVEC ANTIBACTÉRIEN-ANTIFONGIQUE","",""
"1156","00-08-17","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC CORTICOSTEROID","CORTICOSTÉROÏDE SYNTHÉTIQUE","",""
"1157","00-08-17","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PROUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1158","00-08-17","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1159","00-08-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - PEDIATRIC DOSING FOR CHILDREN 6 YEARS AND OLDER","NOUVELLE INDICATION : POSOLOGIE POUR ENFANTS DE 6 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1160","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"1161","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"1162","00-07-27","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1163","00-06-30","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUANXOL DEPOT INJECTION","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1164","00-06-23","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1165","00-06-13","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW LIQUID FORMULATION AND THREE NEW STRENGTHS","NOUVELLE FORMULATION DE LIQUIDE ET TROIS NOUVELLES CONCENTRATIONS","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"1166","00-06-12","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","COMBINATION: HISTAMINE H2-RECEPTOR ANTAGONIST AND ANTACID","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2, ANTIACIDE","",""
"1167","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1168","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST/SYMPATHOMIMETIC AGENT","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE-SYMPATHOMIMÉTIQUE","",""
"1169","00-06-06","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK SHARP & DOHME","CANADA","CANADA","1","","","HISTAMINE H2 RECETOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"1170","00-05-03","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1171","00-05-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1172","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1173","00-03-30","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODECATE CONCENTRATE","SQUIBB","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1174","00-03-15","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW STRENGTH","NOUVELLE PRÉSENTATION, NOUVELLE CONCENTRATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1175","00-03-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1176","00-03-02","LABORATOIRES FOURNIER S.C.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW FORMULATION","NOUVELLE PRÉSNETATION, NOUVELLE FORMULATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1177","00-02-23","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW INDICATION: USE OF FLONASE NASAL DROPS FOR THE REGULAR TREATMENT OF NASAL POLYPS AND ASSOCIATED SYMPTOMS OF NASAL OBSTRUCTION","NOUVELLE FORME POSOLOGIQUE, NOUVELLE INDICATION : UTILISATION DES GOUTTES NASALES FLONASE POUR LE TRAITEMENT DES POLYPES NASAUX ET DES SYMPTÔMES ASSOCIÉS À L'OBSTRUCTION NASALE","CORTICOSTEROID FOR INTRANASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1178","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1179","00-02-03","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"1180","00-01-13","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1181","00-12-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"1182","00-12-11","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE","",""
"1183","00-11-24","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN METHOD OF MANUFACTURE","MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1184","00-11-24","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM/STRENGTH, REVISED DOSING","NOUVELLE FORME POSOLOGIQUE/CONCENTRATION, POSOLOGIE RÉVISÉE","HYPOGLYCEMIC SULFONYLUREA-ORAL ANTIDIABETIC AGENT","HYPOGLYCÉMIANT SULFONYLURÉE - ANTIDIABÉTIQUE ORAL","",""
"1185","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCULAR RELAXANT","RELAXANT MUSCULAIRE","",""
"1186","00-08-15","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARAMYCIN INJECTABLE","SCHERING","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1187","00-07-18","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"1188","00-06-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT","",""
"1189","00-06-16","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION OF THE DOSAGE FORM","CHANGEMENT DE LA PRÉPARATION DE LA FORME POSOLOGIQUE","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1190","00-06-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1191","00-05-09","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LUTEINIZING HORMONE - RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE LA LH-RH","",""
"1192","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1193","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"1194","00-03-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN THE HORMONAL MANAGEMENT OF ENDOIMETRIOSIS, INCLUDING PAIN RELIEF AND REDUCTION OF ENDOMETRIOTIC LESIONS","NOUVELLE INDICATION : POUR L'HORMONOTHÉRAPIE DE L'ENDOMÉTRIOSE, Y COMPRIS LE SOULAGEMENT DE LA DOULEUR ET LA RÉDUCTION DE LA DIMENSION ET LE NOMBRE DES PLAQUES D'ENDOMÉTRIOSE","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉLINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1195","00-03-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING INTERVAL","INTERVALLE POSOLOGIQUE RÉVISÉE","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉLINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1196","00-02-16","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1197","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1198","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1199","00-02-03","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1200","00-12-19","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1201","00-11-17","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT CREAM & OINTMENT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1202","00-11-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1203","00-11-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUSSIVE, ANTIHISTAMINE","ANTITUSSIF, ANTIHISTAMINIQUE","",""
"1204","00-10-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDREA","SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1205","00-10-10","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY (BUILDING ABIS SUD)","NOUVEL EMPLACEMENT DE FABRICATION (BUILDING ABIS SUD)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1206","00-09-27","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","NAME CHANGE FROM HALOPERIDOL DECANOATE INJECTION","MODIFICATION DU NOM DE HALOPERIDOL DECANOATE INJECTION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1207","00-09-27","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1208","00-08-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: PREVENTION OF HEPATITIS B INFECTION IN PATIENTS WITH CHRONIC LIVER DISEASE, INTRODUCTION OF RAPID IMMUNIZATION SCHEDULE, PRODUCT MONOGRAPH REVISIONS","NOUVELLE INDICATION, NOUVEAU SCHÉMA POSOLOGIQUE, MONOGRAPHIE RÉVISÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1209","00-06-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: INJECTABLE","NOUVELLE FORME POSOLOGIQUE: INJECTABLE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1210","00-06-12","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEPATITIS B VACCINE","VACCIN CONTRE L'HÉPATITE B","",""
"1211","00-04-11","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID/NSAID COMBINATION ANALGESIC","ANALGÉSIQUE AINS/OPIOÏDE","",""
"1212","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1213","00-03-14","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1214","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1215","00-10-27","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1216","00-10-12","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION FOR MIGRAINE PAIN RELIEF","NOUVELLE INDICATION POUR LE SOULAGEMENT DES DOULEURS DUES AUX MIGRAINES","ANALGESIC, ANITPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1217","00-09-29","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1218","00-09-18","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"1219","00-08-17","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE METHOD FOR SYNTHESIS OF LOVERSOL (ASI)","AUTRE MÉTHODE DE SYNTHÈSE L'IOVERSOL","RADIOPAQUE CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE","",""
"1220","00-07-21","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET FORME POSOLOGIQUE","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1221","00-07-14","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1222","00-06-22","D.C. LABS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANTIPYRÉTIQUE","",""
"1223","00-06-13","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW FORMULATION AND TWO NEW FLAVOURED LINE EXTENSIONS","NOUVELLE PRÉPARATION ET EXTENSION DE GAMME : DEUX NOUVELLES SAVEURS","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE, POUR ENFANTS","",""
"1224","00-05-26","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1225","00-05-11","WARNER LAMBERT CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD & SINUS","WHITEHALL-ROBINS INC.","CANADA","CANADA","1","","","ANALGESIC/ANTIPYRETIC/NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT","",""
"1226","00-04-20","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"1227","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC-ANTIHYPERTENSIVE AGENT","DIURÉTIQUE - ANTIHYPERTENSIF","",""
"1228","00-04-19","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW PRODUCT NAME","NOUVEAU NOM DU PRODUIT","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"1229","00-04-19","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW PRODUCT NAME","NOUVEAU NOM DU PRODUIT","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"1230","00-03-07","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1231","00-02-29","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER - DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II - DIURÉTIQUE","",""
"1232","00-02-23","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYME","",""
"1233","00-02-16","BIOGEN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1234","00-02-03","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1235","00-01-04","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - EXTENSION OF HARVEST PHASE","MODIFICATION DE LA FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"1236","00-12-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1237","00-11-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANGALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1238","00-05-29","CIBA VISION CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"1239","00-05-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE - AINS","",""
"1240","00-12-21","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A CHANGE IN FINISHED PRODUCT SPECIFICATION","MODIFICATION DE LA SPÉCIFICATION DU PRODUIT FINI","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1241","00-12-21","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA PRÉPARATION","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"1242","00-11-24","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"1243","00-11-17","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTIVE","CONTRACEPTIF D'URGENCE","",""
"1244","00-11-10","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","TOPICAL ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE TOPIQUE POUR ANALGÉSIE DERMIQUE","",""
"1245","00-11-01","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-PARKINSON AGENT","ANTIPARKINSONIEN","",""
"1246","03-12-23","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1247","00-11-01","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-LOPERAMIDE","CHANGEMENT DU NOM DU PRODUIT DE RHO-LOPERAMIDE","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"1248","00-10-24","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOXAPAC","LEDERLE-CYANAMID","CANADA","CANADA","1","NEW STRENGTH 2.5MG TABLETS","NOUVEAU DOSAGE: COMPRIMÉS DE 2.5MG","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1249","00-10-05","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"1250","00-09-20","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1251","00-09-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARBOLITH","ICN CANADA LTD.","CANADA","CANADA","1","","","ANTIMANIC AGENT","AGENT ANTIMANIAQUE","",""
"1252","00-08-15","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN FOR THE TRIPLE THERAPY","SCHÉMA POSOLOGIQUE RÉVISÉ DE LA TRIPLE THÉRAPIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1253","00-08-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"1254","00-07-06","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH - ADDITION OF NEW INDICATION - FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION","MISE À JOUR DE LA MONOGRAPHIE - AJOUT D'UNE NOUVELLE INDICATION - POUR LE TRAITEMENT DE L'INFARCTUS AIGU DU MYOCARDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1255","00-07-05","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1256","00-06-16","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANDED INDICATION: COMMUNITY ACQUIRED PNEUMONIA DUE TO STREPTOCOCCUS PNEUMONIAE INCLUDING PENICILLIN-RESISTANT STRAINS","INDICATION RÉVISÉE : PNEUMONIE EXTRA-HOSPITALIÈRE DUE À S. PNEUMONIAE INCLUANT LES SOUCHES PÉNICILLORÉSISTANTES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1257","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"1258","00-05-11","GLAXO WELLCOME BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1259","00-05-09","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANESTHETIC","ANESTHÉSIQUE TOPIQUE","",""
"1260","03-12-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1261","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1262","00-03-16","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC AGENT","AGENT ANTIRHUMATISANT","",""
"1263","00-03-09","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1264","00-03-03","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTIVE","CONTRACEPTIF D'URGENCE","",""
"1265","00-02-25","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1266","00-02-21","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"1267","00-02-16","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"1268","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"1269","00-02-09","WOMENS CAPITAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTION","CONTRACEPTIF ORAL","",""
"1270","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1271","00-02-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"1272","03-12-19","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, NASAL DECONGESTANT AND ANTIHISTAMINE","ANALGÉSIQUE, DÉCONGESTIONNANT NASAL, ANTIHISTAMINIQUE","",""
"1273","00-01-13","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1274","00-12-28","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX-OTC","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1275","00-12-22","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SNC","",""
"1276","00-12-11","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR TEH PROPYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC HEPATIC TRANSPLANTS","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA RÉJECTION D'ORGANES CHEZ LES PATIENTS QUIE REÇOIVENT DES GREFFES HÉPATIQUES ALLOGÉNIQUES","IMMUNOSUPPRESSANT AGENT","IMMUNOSUPPRESSEUR","",""
"1277","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE","DIURÉTIQUE - ANTIHYPERTENSEUR","",""
"1278","00-11-24","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1279","00-11-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN SUPPLEMENT","SUPPLÉMENT VITAMINIQUE","",""
"1280","00-11-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","THERAPEUTIC MULTIVITAMIN","MULTIVITAMINE THÉRAPEUTIQUE","",""
"1281","00-11-17","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1282","00-11-17","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1283","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"1284","00-10-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL - ANTIPROTOZOAL","ANTIBACTÉRIEN, ANTIPROTOZOAIRE","",""
"1285","00-10-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM MOBIC","CHANGEMENT DU NOM DU PRODUIT DE MOBIC","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"1286","00-10-24","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA","AGENT ANTIROSACÉE","",""
"1287","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICHOMONACIDE-MONILIACIDE","TRICHOMONACIDE-MONILIACIDE","",""
"1288","00-10-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMAN LA ROCHE","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANAESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"1289","00-10-24","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INOTROPE - VASODILATOR","AGENT INOTROPE - VASODILATATEUR","",""
"1290","03-12-05","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC AND NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT","",""
"1291","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"1292","00-10-19","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1293","00-09-14","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM; REVISED DOSAGE REGIMEN","NOUVELLE FORME POSOLOGIQUE; SHCHÉMA POSOLOGIQUE RÉVISÉ","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1294","00-09-07","LABORATOIRE RIVA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1295","00-09-07","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-METFORMIN","MODIFICATION DU NOM DE RHO-METFORMIN","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1296","00-09-06","ZYMCAN PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1297","00-08-31","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANIT-INFLAMMATORY ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"1298","00-08-15","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1299","00-08-15","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANAESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"1300","03-11-06","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED INDICATION AND DOSING INSTRUCTIONS","INSTRUCTIONS RÉVISÉES EN MATIÈRE D'INDICATIONS ET POSOLOGIE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1301","00-07-27","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"1302","03-10-24","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH: 400 MG CAPSULES","NOUVELLE CONCENTRATION: 400 MG CAPSULES","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1303","00-07-27","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION (500MG) AND NEW STRENGTH (850MG)","NOUVELLE FORMULATION (500MG) ET NOUVELLE CONCENTRATION (850MG)","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1304","00-07-18","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING","POSOLOGIE RÉVISÉE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1305","00-07-12","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"1306","00-07-12","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"1307","00-06-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1308","00-06-19","STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1310","00-06-19","STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1311","00-06-06","SEARLE CANADA - UNIT OF MONSANTO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"1312","00-05-19","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPINS","GONADOTROPHINES","",""
"1313","00-05-09","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","IMMUNOSUPPRESSENT AGENT","IMMUNOSUPPRESSEUR","",""
"1314","00-05-03","FAULDING (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1315","00-05-03","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX POUR LES HOMMES","",""
"1316","00-05-03","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH - 1000MG","NOUVELLE CONCENTRAION - 1000MG","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"1317","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"1318","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"1319","00-04-26","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1320","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1321","00-04-11","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN","PROGESTATIF","",""
"1322","00-04-04","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1323","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1324","00-03-16","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1325","00-03-14","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (HEPATOBILIARY IMAGING)","AGENT RADIODIAGNOSTIC (IMAGE HÉPATOBILIAIRE)","",""
"1326","00-03-07","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1327","00-03-07","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM FLAGYL","MODIFICATION DU NOM DE FLAGYL","ANTIBACTERIAL - ANTIPROTOZOAL","ANTIBACTÉRIEN - ANTIPROTOZOAIRE","",""
"1328","00-02-24","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOPRESSOR","VASOPRESSEUR","",""
"1329","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-Depolarizing Skeletal Neuromuscular Blocking Agent","Inhibiteur neuromusculaire squelettique nondépolarisant","",""
"1330","00-02-09","NYCOMED IMAGING A.S.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE","",""
"1331","00-02-08","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1332","03-10-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC REAGENT","AGENT RADIODIAGNOSTIQUE","",""
"1333","00-02-08","PHARMACIA & UPJOHN COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX POUR HOMMES","",""
"1334","00-12-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHIAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE BRONCHIQUE","",""
"1335","00-11-24","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-NITRAZEPAM","MODIFICATION DU NOM DE RHO-NITRAZEPAM","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"1336","00-11-21","AGOURON PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"1337","00-11-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1338","00-11-09","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1339","00-11-01","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"1340","00-11-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1341","00-10-17","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"1342","00-10-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASODILATOR/PERIPHERAL","VASODILATATEUR, PÉRIPHÉRIQUE","",""
"1343","00-10-02","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"1344","00-08-25","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIALLERGIC","ANTIALLERGIQUE","",""
"1345","00-07-28","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROPROGESTATIVE","",""
"1346","00-07-24","ELAN PHARMACEUTICAL RESEARCH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC DES PROPRIÉTÉS ANALGÉSIQUES ET ANTIPYRÉTIQUES","",""
"1347","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTIANDROGEN","AGENT ANTIANDROGÈNE NON STÉROÏDIEN","",""
"1348","00-05-26","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"1349","00-04-20","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"1350","00-03-30","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIANGINAL/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX - ANTIHYPERTENSEUR","",""
"1351","00-03-21","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"1352","00-03-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN-ESTROGEN","ASSOCIATION OESTRO-PROGESTATIVE","",""
"1353","00-03-10","SANOFI CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW CONDITION OF USE: TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCATION","NOUVELLE CONDITION D'EMPLOI : TRAITEMENT DE L'ANGINE INSTABLE ET INFARCTUS SOUS-ENDOCARDIQUE SANS ONDES","ANTICOAGULANT/ANTITHROMBOTIC","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1354","00-02-24","FC PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1355","00-02-07","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM SERZONE","MODIFICATION DU NOM DE SERZONE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1356","00-01-05","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH 150MG","NOUVELLE CONCENTRATION 150MG","NONSTEROIDAL ANTIANDROGEN","AGENT ANTIANDROGÈNE NON STÉROÏDIEN","",""
"1357","00-01-04","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1358","00-12-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - AGENT ANTISPASMODIQUE","",""
"1359","00-12-01","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLET","NOUVELLE FORME D'ADMINISTRATION : COMPRIMÉS SE DÉSINTÉGRANT ORALEMENT","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1360","00-11-10","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1361","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1362","00-10-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1363","00-10-24","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"1364","00-07-27","DAIICHI PHARMACEUTICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1365","00-07-18","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DITROPAN","MARION MERRELL DOW INC.","CANADA","CANADA","1","","","ANTICHOINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE, AGENT ANTISPASMODIQUE","",""
"1366","00-07-11","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: A MULTIPLE UNIT PELLET SYSTEM (MUPS) TABLETS","NOUVELLE FORME POSOLOGIQUE : MULTIPLE UNIT PELLET SYSTEME (MUPS) TABLETS (ENSEMBLE DE COMPRIMÉS À GRANULES)","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1367","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"1368","00-04-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1369","00-03-16","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DITROPAN","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE - AGENT ANTISPASMODIQUE","",""
"1370","00-02-03","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1371","00-12-28","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"1372","03-09-25","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1373","00-12-22","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"1374","00-12-08","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1375","00-11-24","STIEFEL LABORATORIES (IRELAND) LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC AGENT","AGENT ANTIMITOTIQUE","",""
"1376","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARASITIC AGENT","ANTIPARASITAIRE","",""
"1377","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC - ANTIEMETIC","ANTIPSYCHOTIQUE - ANTIÉMÉTIQUE","",""
"1378","00-11-02","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"1379","00-11-01","DRAXIS HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS EARLY THERAPY IN THE TREATMENT OF PARKINSON'S DISEASE, WITHOUT CONCOMITANT LEVODOPA THERAPY","NOUVELLE INDICATION : THÉRAPIE PRÉCOCE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON SANS TRAITEMENT CONCOMITANT À LA LÉVODOPA","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"1380","00-10-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"1381","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1382","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1383","00-10-24","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1385","00-10-24","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1386","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE - ANTI-INFLAMMATOIRE","",""
"1387","00-10-20","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"1388","00-10-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"1389","04-04-20","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1390","00-09-22","ZIMMER OF CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1391","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTMIQUE","",""
"1392","00-09-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1393","00-09-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"1394","04-04-14","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CLARITIN LIBERATOR","MODIFICATION DU NOM DU PRODUIT DE CLARITIN LIBERATOR","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"1395","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1396","04-04-16","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","NEUROMUSCULAR BLOCKING AGENT","AGENT BLOQUANT NEUROMUSCULAIRE","",""
"1397","04-04-16","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN DOSAGE","CHANGEMENT DANS LA POSOLOGIE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1398","03-08-26","BIOGEN CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","CHANGE TO LABELLING: EXPANSION OF INDICATION","CHANGEMENT DE L'ÉTIQUETAGE: EXPANSION DE L'INDICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1399","00-08-25","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1400","04-04-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY FOR DRUG SUBSTANCE","NOUVLE EMPLACEMENT DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"1401","04-04-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY FOR DRUG SUBSTANCE","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"1402","03-08-11","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1403","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC THYROTROPIN-RELEASING HORMONE","HORMONE RÉGULATRICE DE LA THYRÉOTROPHINE SYNTHÉTIQUE","",""
"1404","00-08-17","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIABETIC AGENT","AGENT ANTI-DIABÉTIQUE","",""
"1405","00-06-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1406","00-06-22","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: NEW INDICATIONS RELATED TO THE PREVENTION OF SECONDARY CARDIOVASCULAR EVENTS","MISE À JOUR DE LA MONOGRAPHIE : NOUVELLE INDICATION ASSOCIÉE À LA PRÉVENTION DES MANIFESTATIONS CARDIOVASCULAIRES SECONDAIRES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1407","00-06-12","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC PHOTOSENSITIZING AGENT","PHOTOSENSIBILISANT ANTINÉOPLASIQUE","",""
"1408","00-06-12","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"1409","00-05-01","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1410","00-04-26","BAKER NORTON PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1411","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANAESTHETIC - SEDATIVE","ANESTHÉSIQUE - SÉDATIF","",""
"1412","00-04-26","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1413","00-04-13","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD COMBINATION THERAPY","NOUVELLE INDICATION : AU COURS DU TRAITEMENT ADJUVANT DU CANCER DU SEIN À NOEUDS POSITIFS, ADMINISTRÉS SÉQUENTIELLEMENT À LA THÉRAPIE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1414","00-04-06","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1415","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1416","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1417","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1418","00-03-16","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1419","00-03-10","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 20MG NEW INDICATION: MAINTENANCE TREATMENT OF PATIENTS WITH REFLUX ESOPHAGITIS","NOUVEAU DOSAGE : 20MG NOUVELLE INDICATION : TRAITEMENT D'ENTRETIEN CHEZ LES PATIENTS ATTEINTS D'OESOPHAGITE PAR REFLUX GASTRO-OESOPHAGIEN","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1420","00-03-10","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH APPROPRIATE ANTIBIOTICS, ERADICATION OF H. PYLORI INFECTION ASSOCIATED WITH AN ACTIVE DUODENAL ULCER","NOUVELLE INDICATION : EN ASSOCIATION AVEC DES ANTIBIOTIQUES APPROPRIÉS, ÉRADICATION D'INFECTION À H. PYLORI ASSOCIÉE À UN ULCÈRE DUODÉNAL ÉVOLUTIF","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1421","00-03-02","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS","NOUVELLE INDICATION : COMME PRÉVENTION SECONDAIRE DES ACCIDENTS CARDIO-VASCULAIRES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1422","00-02-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL POUR INFILTRATION ET BLOCAGE NERVEUX","",""
"1423","00-02-09","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ELECTROLYTE REPLENISHER","RÉAPPROVISIONNEMENT D'ÉLECTROLYTE","",""
"1424","00-02-08","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","ANTIPARKINSONIEN - AGONISTE DOPAMINERGIQUE","",""
"1425","00-01-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA","CANADA","CANADA","1","","","ANESTHETIC/SEDATIVE","ANESTHÉSIQUE/SÉDATIF","",""
"1426","00-01-17","DEY, L.P.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (PORCINE)","SURFACTANT PULMONAIRE (PORCINE)","",""
"1427","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1428","00-08-15","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1429","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1430","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1431","00-07-21","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"1432","03-07-02","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: CHANGE OF PROPELLANT FROM CFC TO HFA","NOUVELLE FORMULATION: CHANGEMENT DU PROPULSEUR DE CFC À HFA","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1433","03-05-28","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1434","03-05-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE FOR PRE-FILLED SYRINGES","NOUVEL EMPLACEMENT DE FABRICATION POUR LES SERINGUES PRÉ-REMPLIES","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1435","00-11-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","1. IN THORACIC EPIDURAL BLOCK FOR ACUTE PAIN MANAGEMENT - 2MG/ML SOLUTION CONTINUOUS INFUSION FOR UP TO 72 HOURS; 2. IN THORACIC EPIDURAL BLOCK FOR SURGICAL ANESTHESIA - 5 AND 7.5 MG/ML SOLUTION; 3. IN MAJOR NERVE BLOCK FOR SURGICAL ANESTHESIA - 7.5MG/ML","1. DANS LE BLOC ÉPIDURAL THORACIQUE, POUR GESTION DE LA DOULEUR AIGUË - ERFUSION CONTINUE JUSQU'À 72 HEURES; 2. DANS LE BLOC ÉPIDURAL THORACIQUE POUR ANESTHÉSIE CHIRURGICALE; 3. DANS LE BLOC NERVEUX MAJEUR POUR ANESTHÉSIE CHIRURGICALE","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1436","03-05-13","WATSON LABORATORIES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH AND THE ADDITIONAL CONDITION OF UNDILUTED ADMINISTRATION","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT ET À LA CONDITION SUPPLÉMENTAIRE D'ADMINISTRATION NON DILUÉE","HEMATINIC","HÉMATINIQUE","",""
"1437","00-10-10","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1438","03-05-12","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1439","00-09-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOUS ANTIBIOTIC","ANTIBIOTIQUE ANTITUBERCULEUX","",""
"1440","00-09-21","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH AND ADDITION OF NEW STRENGTH","MONOGRAPHIE RÉVISÉE ET NOUVELLE CONCENTRATION","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1441","00-09-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1442","00-08-30","AVENTIS PHARMA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGLUTAMATE","ANTIGLUTAMATE","",""
"1443","00-08-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1444","00-07-17","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT AND PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS, NEW STRENGTH","NOUVELLE INIDICATION : TRAITEMENT ET PRÉVENTION DE L'OSTÉOPOROSE POSTMÉNOPAUSIQUE, NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1445","00-05-17","FC PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1446","00-05-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH SULFONYLUREA","NOUVELLE INDICATION : UTILISER EN ASSOCIATION AVEC LES SULFONYLURÉES","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT DE RÉDUCTION POUR LA RÉSISTANCE À L'INSULINE","",""
"1447","00-05-08","CENTOCOR","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FINAL PRODUCT FORMULATION","MODIFICATION À LA FORMULATION","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"1448","03-05-01","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AND LABELS","MONOGRAPHIE DU PRODUIT ET ÉTIQUETTES RÉVISÉES","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1449","00-04-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"1450","00-03-21","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT DE RÉDUCTION POUR LA RÉSISTANCE À L'INSULINE","",""
"1451","03-04-25","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"1452","00-03-17","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNE AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1453","00-03-17","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1454","03-04-23","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DIAGNOSTIQUE OPACIFIANT NON IONIQUE","",""
"1455","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID COMPONENT TO ANAESTHESIA","COMPOSANTE OPIOÏDE POUR L'ANESTHÉSIE","",""
"1456","00-03-02","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOTHERAPEUTIC AGENT (PASSIVE IMMUNIZATION)","AGENT IMMUNOTHÉRAPEUTIQUE (IMMUNISATION PASSIVE)","",""
"1457","00-02-23","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1458","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1459","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1460","00-01-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN","NOUVELLE INDICATION: TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES FEMMES POSTMÉNOPAUSÉES","SELECTIVE ESTROGEN RECEPTOR MODULATOR","MODULATEUR SÉLECTIF DES RÉCEPTEURS OESTROGÉNIQUES","",""
"1461","00-12-28","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT/ANTIOBESITY AGENT","ANOREXIANT/ANTIOBÉSITÉ","",""
"1462","00-12-12","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF TURNER'S SYNDROME","NOUVELLE INDICATION : TRAITEMENT DU SYNDROME DE TURNER","HUMAN GROWTH HORMONE","STIMULANT DE LA CROISSANCE","",""
"1463","00-12-12","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1464","00-12-08","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM SEVORANE","MODIFICATION DU NOM DE SEVORANE","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"1465","00-11-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: DISKUS","NOUVELLE FORME POSOLOGIQUE : DISKUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1466","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1467","00-11-14","SMITH & NEPHEW INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBACTERIAL AGENT","ANTIBACTÉRIEN TOPIQUE","",""
"1468","00-11-10","3M PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF EXERCISE-INDUCED ASTHMA IN PEDIATRIC PATIENTS BETWEEN 6 AND 11 YEARS OLD","NOUVELLE INDICATION : PRÉVENTION DE L'ASTHME D'EFFORT CHEZ LES ENFANTS DE 6 À 11 ANS","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES","",""
"1469","00-11-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1470","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CALCIUM REGULATOR","RÉGULATEUR DE CALCIUM","",""
"1471","00-10-12","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REGULAR TREATMENT OF REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE, INCLUDING ASTHMA, IN CHILDREN 4-11 YEARS","NOUVELLE INDICATION : TRAITEMENT RÉGULIER DE L'OBSTRUCTION RÉVERSIBLE DES VOIES AÉRIENNES, Y COMPRIS L'ASTHME, CHEZ LES ENFANTS DE 4 À 11 ANS","BRONCHODILATOR AND CORTICOSTEROID FOR INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1472","03-04-09","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (FOR RADIOLABELLING AUTOLOGOUS LEUKOCYTES)","AGENT RADIODIAGNOSTIQUE (POUR RADIOMARQUER DES LEUCOCYTES AUTOLOGUES)","",""
"1473","00-10-10","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-SOTALOL","MODIFICATION DU NOM DE RHO-SOTALOL","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1474","00-08-17","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MEDICAL TREATMENT OF OSTOSPONGIOSIS","TRAITEMENT DE L'OTOSPONGIOSE","",""
"1475","00-08-16","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1476","00-07-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1477","00-06-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"1478","00-02-24","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","AGENT D'AGGLUTINATION DU PHOSPHATE","",""
"1479","00-04-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1480","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1481","03-04-09","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW FORMULATION AND FLAVOURED LINE EXTENSIONS","NOUVELLE FORMULATION ET EXTENSIONS DE LA LIGNE AROMATISÉE","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE - POUR ENFANTS","",""
"1482","00-03-30","ZIMMER OF CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"1483","00-03-16","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1484","00-03-14","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1485","00-03-10","LEVER PONDS, A DIVISION OF U L CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTICARIES TOOTHPASTE","DENTIFRICE ANTICARIES","",""
"1486","00-01-19","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1487","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1488","00-01-17","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME","CANADA","CANADA","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES","",""
"1489","03-02-25","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"1490","00-01-12","RIVA LABORATORY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1491","00-12-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA","CANADA","CANADA","1","","","ANTI-COAGULANT","ANTICOAGULANT","",""
"1492","00-10-05","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1493","03-02-18","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"1494","00-08-09","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1495","03-02-04","D.C. LABS LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1496","00-11-17","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - ORALLY DISPERSIBLE TABLETS","NOUVELLE FORME POSOLOGIQUE -  COMPRIMÉS SE DISSOLVANT ORALEMENT","5-HT RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT, ANTIMIGRAINEUX","",""
"1497","00-10-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1498","00-08-21","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1499","00-07-05","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1500","03-01-22","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","IONIC, LOW OSMOLALITY, WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVENOUS USE","PRODUIT DE CONTRASTE RADIO-OPAQUE HYDROSOLUBLE, IONIQUE, À FAIBLE OSMOLALITÉ POUR USAGE INTRAVEINEUX","",""
"1501","00-05-11","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1502","00-02-03","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR DES LEUCOTRIÈNES","",""
"1503","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MIGRAINE THERAPY","TRAITEMENT DES MIGRAINES","",""
"1504","00-09-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILIEPTIC","ANTIÉPILEPTIQUE","",""
"1505","00-08-23","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: EXTENDED-RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS À ACTION PROLONGÉE","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1507","00-07-04","ANTHRA PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYTOTOXIC ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE CYTOTOXIQUE","",""
"1508","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIZORAL CREAM","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"1509","00-05-31","QLT INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION","PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE ASSOCIÉE À L'ÂGE","",""
"1510","00-03-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"1511","03-04-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE TOPIQUE","",""
"1512","00-03-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOCIN","ELI LILLY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1513","00-03-07","SWISS SERUM & VACCINE INSTITUTE BERNE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1514","03-11-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1515","00-01-28","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"1516","00-12-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROLOPRIM","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"1517","00-12-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1518","03-11-12","CARTER-HORNER CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"1519","00-12-13","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL FOR MYOCARDIAL INFARCTION","AGENT RADIODIAGNOSTIQUE DE L'INFARCTUS MYOCARDIQUE","",""
"1520","00-12-07","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL FOR BREAST IMAGING","AGENT RADIODIAGNOSTIQUE","",""
"1521","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"1522","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1523","00-11-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1524","00-11-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","CORTICOSTÉROÏDE POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"1525","00-11-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TESTOSTERONE REPLACEMENT THERAPY","THÉRAPIE DESTINÉE À REMPLACER LE TESTOSTÉRONE","",""
"1526","00-10-02","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TESTOSTERONE REPLACEMENT THERAPY","THÉRAPHIE DESTINÉE À REMPLACER LE TESTOSTÉRONE","",""
"1527","00-11-16","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1528","00-11-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1529","00-11-16","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1530","03-11-07","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉ À ACTION CONTRÔLÉE","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"1531","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPRURITIC-ANTIHISTAMINIC","ANTIPRURIGINEUX, ANTIHISTAMINIQUE","",""
"1532","00-11-10","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1533","00-10-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"1534","03-11-06","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ANALOG","ANALOGUE DE LA LHRH","",""
"1535","00-10-05","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRANQUILLIZER - ANTIPSYCHOTIC","TRANQUILLISANT - ANTIPSYCHOTIQUE","",""
"1536","00-09-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1537","00-08-17","LIFEHEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MONOAMINE DEPLETING AGENT","AGENT DE DÉPLÉTION DE MONOAMINES","",""
"1538","00-06-13","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: GEL FORMING SOLUTION","NOUVELLE FORME POSOLOGIQUE : SOLUTION GÉLIFIANTE","ELEVATE INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"1539","00-06-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1540","00-05-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1541","00-05-09","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1542","00-05-01","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW REFILL PACKAGE","NOUVEL EMBALLAGE DE RECHARGE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1543","00-05-01","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1544","00-05-01","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1545","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"1546","00-04-20","MEDIMMUNE ONCOLOGY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPROTOZOAL AGENT","AGENT ANTIPROTOZOAIRE","",""
"1547","00-03-16","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1548","00-03-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1549","00-02-29","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1550","00-02-29","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1551","00-02-16","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"1552","00-02-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"1553","00-01-24","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW RAW MATERIAL SUPPLIER, ALTERNATE FORMULATION (UNCOATED TABLETS) AND AN ADDITIONAL MANUFACTURING SITE","NOUVELLE MATIÈRE PREMIÈRE, AUTRE FORME PHARMACEUTIQUE (COMPRIMÉS NON ENROBÉS) ET UN LIEU DE FABRICATION SUPPLÉMENTAIRE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1554","03-10-24","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: CHANGES TO DOSAGE & ADMINISTRATION AND WARNINGS SECTIONS WITH REGARDS TO RHABDOMYOLYSIS","MONOGRAPHIE RÉVISÉE DU PRODUIT: CHANGEMENTS AUX RUBRIQUES POSOLOGIE ET MISES EN GARDE RELATIVEMENT À LA RHABDOMYOLISE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1555","99-12-10","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR USE IN PAEDIATRIC PATIENTS WITH PARAOXYSMAL SUPERAVENTRICULAR TACHYCARDIA (PSVT)","POUR L'UTILISATION CHEZ LES ENFANTS ATTEINTS DE TACHYCARDIE PAROXYSTIQUE SUPRAVENTRICULAIRE","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"1556","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2ALPHA ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"1557","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1558","99-11-17","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"1559","03-09-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"1560","99-11-08","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTRO-INTESTINALES INFÉRIEURES","",""
"1561","99-11-08","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1562","99-11-08","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1563","99-10-29","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"1564","99-10-18","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1565","99-10-01","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"1566","99-10-01","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT AND MANUFACTURER'S NAME","MODIFICATION DU NOM DU PRODUIT ET DU FABRICANT","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE - INHIBITEUR DE B-LACTAMASES","",""
"1567","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1568","99-09-28","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC RELIEF OF ANXIETY IN PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD)","NOUVELLE INDICATION : SOULAGEMENT SYMPTOMATIQUE DE L'ANXIÉTÉ CHEZ LES PATIENTS SOUFFRANT DU TROUBLE D'ANXIÉTÉ GÉNÉRALISÉE","ANTIDEPRESSANT/ANXIOLYTIC","ANTIDÉPRESSEUR/ANXIOLYTIQUE","",""
"1569","99-09-21","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT FOR THE PREPARATION OF TECHNETIUM TC 99M ALBUMIN AGGREGATED","TROUSSE DIAGNOSTIQUE POUR LA PRÉPARATION DE TECHNÉTIUM 99M TC ALBUMINE AGRÉGÉ","",""
"1570","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2ALPHA ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA ET INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"1571","99-09-02","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXYDASE","",""
"1572","03-09-05","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH CHRONIC ANGLE-CLOSURE GLAUCOMA WHO UNDERWENT PERIPHERAL IRIDOTOMY OR LASER IRIDOPLASTY","NOUVELLE INDICATION - RÉDUCTION DE LA PRESSION INTRA-OCULAIRE CHEZ LES PATIENTS QUI SOUFFRENT DE GLAUCOME PAR FERMETURE DE L'ANGLE ET QUI ONT SUBI UNE IRIDOTOMIE PÉRIPHÉRIQUE OU UNE IRIDOPLASTIE AU LASER","PROSTAGLANDIN F2ALPHA ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"1573","99-09-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL ANTIBIOTIC","ANTIBACTÉRIEN ANTIBIOTIQUE","",""
"1574","99-08-18","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR USE IN COMBINATION WITH METFORMIN OR INSULIN IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS","POUR L'UTILISATION EN ASSOCIATION AVEC METFORMIN OU INSULIN POUR LE TRAITEMENT DES PATIENTS ATTEINTS DE DIABÈTE SUCRÉ DE TYPE 2","ORAL ANTIDIABETIC AGENT, ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL, INHIBITEUR DES ALPHA-GLUCOSIDASES","",""
"1575","99-08-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1576","99-07-02","IMMUNOMEDICS,INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","SCALE-UP IN MANUFACTURING PROCESS AND NEW MANUFACTURING SITE","CHANGEMENT DE FABRICATION ET NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSITQUE","",""
"1577","03-08-26","GLAXOSMITHKLINE SHIRE BIOCHEM","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND NEW 300 MG ONCE DAILY DOSING REGIMEN","NOUVELLE CONCENTRATION ET NOUVELLE POSOLOGIE DE 300 MG UNE FOIS PAR JOUR","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1578","99-06-16","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE","",""
"1579","99-06-16","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","VITAMIN D ANALOGUE","MÉTABOLITE DE LA VITAMINE D3","",""
"1580","99-03-26","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARON","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1581","99-06-11","LIGAND PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"1582","99-06-04","GLAXO WELLCOME INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1583","99-05-20","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","HAEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"1584","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1585","99-03-04","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","BURROUGHS WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1586","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","AGENT ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"1587","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","AGENT ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"1588","99-03-04","FC PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"1589","99-05-05","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1590","99-04-15","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW DOSAGE FORM","FOURNIS POUR UNE NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1591","99-03-04","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN CELL BANKS AND USE OF DIFFERENT CELL GROWTH MEDIUM","NOUVELLES BANQUES CELLULAIRES ET UN NOUVEAU MILIEU DE CROISSANCE","IMMUNOMODULATOR","AGENT D'IMMUNOMODULATION","",""
"1592","99-02-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HISMANAL TABLETS","JANSSEN PHARMACEUTICA INC.","CANADA","CANADA","1","","","HISTAMINE H1-ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE - ANTAGONISTE","",""
"1593","99-02-16","HOFFMANN-LA ROCHE LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION FOR MANAGEMENT OF ACUTE ISCHEMIC STROKE","NOUVELLE INDICATION : POUR LA GESTION DES ATTAQUES D'APOPLEXIE AIGUS ET ISCHÉMIQUES","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"1594","99-02-12","FC PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"1595","99-02-02","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","MILIEU DE CONTRASTE INTRAVEINEUX POUR ULTRASON","",""
"1596","99-01-14","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","VITAMIN D ANALOGUE","VITAMINE D ANALOGUE","",""
"1597","99-01-12","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: AS AN ADJUNCT TO DIET FOR THE REDUCTION OF ELEVATED TOTAL CHOLESTEROL IN DYSBETALIPOPROTEINEMIA (TYPE III), HYPERTRIGLYCERIDEMIA (TYPE IV), AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","NOUVELLE INDICATION : ADJUVANT À LA DIÈTE POUR LA RÉDUCTION DU TAUX DE CHOLESTÉROL DANS LA DYSBÊTALIPOPROTÉINÉMIE, L'HYPERTRIGLYCÉRIDÉMIE ET L'HYPERCHOLESTÉROLÉMIE FAMILIALE HOMOZYGOTE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1598","99-12-22","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1599","99-11-18","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RHINOCORT AQUA","ASTRA PHARMA","CANADA","CANADA","1","","","CORTICOSTEROID","CORITCOSTÉROÏDE","",""
"1600","99-11-08","CRYSTAAL CORPORATION, A DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","B-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"1601","99-10-15","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RHINOCORT AQ NASAL SPRAY","ASTRA PHARMA","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1602","99-09-02","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1603","99-08-27","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MAINTENANCE DOSING: TREATMENT WITH ZYBAN FOR UP TO 1 YEAR TO PREVENT RELAPSE","DOSE D'ENTRETIEN : TRAITEMENT AVEC ZYBAN JUSQU'À 1 AN AFIN DE PRÉVENIR UNE RECHUTE","SMOKING CESSATION AID","AIDE POUR ARRÊTER DE FUMER","",""
"1604","99-08-25","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1605","99-08-06","SOLVAY PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"1606","99-08-06","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR CHANGES TO THE PRODUCT MONOGRAPH AND LABELLING","PRODUIT POUR LES MODIFICATIONS À LA MONOGRAPHIE ET À L'ÉTIQUETAGE","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"1607","99-08-06","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMCEUTICALS","CANADA","CANADA","1","","","BENZYDAMINE MOUTHWASH, BP","BENZYDAMINE (BAIN DE BOUCHE), BP","",""
"1608","99-07-22","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1609","99-07-07","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF EQUINUS FOOT DEFORMITY DUE TO SPASTICITY IN PEDIATRIC CEREBRAL PALSY PATIENTS","NOUVELLE INDICATION : TRAITEMENT DE LA DÉFORMATION EN PIED ÉQUIN SECONDAIRE À LA SPASTICITE CHEZ LES ENFANTS ATTEINTS DE PARALYSIE CÉRÉBRALE","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"1610","99-06-21","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT - SEDATIVE - ANAESTHETIC AGENT","PRÉMÉDICATION - SÉDATIF - ANESTHÉSIQUE","",""
"1611","99-06-16","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BEZALIP","BOEHRINGER MANNHEIM CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1612","99-05-14","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW FACILITY, UPGRADES TO PRODUCTION PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION - NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA MÉTHODE DE FABRICATION","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"1613","99-05-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETOPTIC OPHTHALMIC SOLUTION","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIGLAUCOMA AGENT (OPHTHALMIC)","AGENT POUR LE TRAITEMENT DU GLAUCOME (OPHTHALMIQUE)","",""
"1614","99-05-05","MEDICAN TECHNOLOGIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SCABICIDE","SCABICIDE","",""
"1615","99-01-28","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTHS - 0.75%; NEW INDICATION - SENSORCAINE 0.75% WITH/WITHOUT EPINEPHRINE FOR RETROBULBAR BLOCK","NOUVELLES CONCENTRATIONS 0.75%, NOUVELLE INDICATION - SENSORCAINE 0.75% AVEC/SANS ÉPINÉPHRINE POUR BLOC RÉTROBULBAIRE","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1616","99-01-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"1617","99-12-22","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1618","99-11-17","SKYEPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1619","99-10-18","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC","HÉMOSTATIQUE","",""
"1620","04-04-13","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","WITHDRAWAL OF INDICATION: TREATMENT OF LOCALIZED PROSTATE CANCER; AND WITHDRAWAL OF STRENGTH: 150MG","RETRAIT DE L'INDICATION : POUR LE TRAITEMENT DU CANCER LOCALISÉ DE LA PROSTATE; ET RETRAIT DE LA CONCENTRATION DE 150MG","NON-STEROIDAL ANTI-ANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"1621","04-04-14","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"1622","99-10-07","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"1623","04-04-14","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-INDAPAMIDE","MODIFICATION DU NOM DU PRODUIT DE RIVA-INDAPAMIDE","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"1624","99-09-28","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1625","04-04-14","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1626","99-09-21","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1627","04-04-14","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-SOTALOL","MODIFICATION DU NOM DU PRODUIT DE RIVA-SOTALOL","ANTIARRHYTHMIC","ANTIAHYTHMIQUE","",""
"1628","99-08-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"1629","04-04-14","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM TERAZOSIN","MODIFICATION DU NOM DU PRODUIT DE TERAZOSIN","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1630","04-04-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1631","04-04-15","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION: FOR UNCOMPLICATED CYSTITIS AND COMPLICATED URINARY TRACT INFECTIONS","RETRAIT DE L'INDICATION : POUR LE TRAITEMENT DE LA CYSTITE NON COMPLIQUÉE ET DES INFECTIONS URINAIRES COMPLIQUÉES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1632","04-04-16","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"1633","04-04-19","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"1634","99-08-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURICEF","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1635","04-04-20","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH AS REQUESTED IN TPD LETTER REGARDING WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","MODIFICATION À LA MONOGRAPHIE DU PRODUIT COMME DEMANDÉ DANS LA LETTRE DE LA DPT RELATIVEMENT AU WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","PROGESTIN","PROGESTATIF","",""
"1636","04-04-23","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AS REQUESTED IN TPD LETTER REGARDING WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","MODIFICATION À LA MONOGRAPHIE DU PRODUIT COMME DEMANDÉ DANS LA LETTRE DE LA DPT RELATIVEMENT AU WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","PROGESTAGEN, PROGESTATIONAL STEROID","PROGESTOGÈNE, HORMONE STÉROÏDE PROGESTATIVE","",""
"1637","99-07-30","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"1638","99-07-26","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURICEF","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1639","04-04-20","NABI BIOPHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","AGGLOMÉRANT PHOSPHATE","",""
"1640","99-07-13","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIDEX","PROCTER & GAMBLE INC.","CANADA","CANADA","1","","","ANTIGINGIVITIS ORAL RINSE","ANTIGINGIVITE","",""
"1641","04-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1642","99-07-13","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1643","04-04-20","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1644","99-07-07","GERMIPHENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","BAIN DE BOUCHE CONTRE LA GINGIVITE","",""
"1645","04-04-21","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","PROGESTIN","PROGESTATIF","",""
"1646","99-06-29","A.R. MEDICOM CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","BAIN DE BOUCHE CONTRE LA GINGIVITE","",""
"1647","99-06-09","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC/CORTICOSTEROID","ANTIBIOTIQUE/CORTICOSTÉROÏDE","",""
"1648","99-06-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1649","99-06-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1650","04-04-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH WITH NEW CLINICAL TRIAL INFORMATION","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR INCLURE DE NOUVEAUX RENSEIGNEMENTS SUR LES ESSAIS CLINIQUES","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1651","99-05-28","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1652","04-04-26","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OCUFLOX","ALLERGAN INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1653","04-04-26","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1654","04-04-28","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"1655","99-05-10","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"1656","04-04-30","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1657","99-05-06","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL/CORTICOSTEROID","ANTIBACTÉRIEN/CORTICOSTÉROÏDE","",""
"1658","04-04-30","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP & DOHME","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1659","99-04-14","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"1660","04-04-30","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRIENT SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"1661","99-04-12","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1662","04-04-30","GMD DISTRIBUTING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTALITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"1663","99-02-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1664","04-04-30","GMD DISTRIBUTING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"1665","99-02-05","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1666","99-02-05","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1667","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"1668","99-01-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"1669","99-12-31","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"1670","99-11-22","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1671","99-11-17","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","GEIGY (CANADA)","CANADA","CANADA","1","","","ANTI-INFLAMMATORY -ANALGESIC","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1672","99-11-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1673","99-11-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","5-HT1 RECEPTOR AGONIST","AGONISTE SUR LE RÉCEPTEUR 5-HT1","",""
"1674","99-10-07","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1675","99-10-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1676","99-08-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","CIBA GEIGY CANADA LTD., GEIGY PHARMACEUTICALS","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1677","99-08-25","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1678","99-07-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","AGENT ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1679","01-05-08","MEDIMMUNE ONCOLOGY, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO REDUCE THE INCIDENCE AND SEVERITY OF RADIATION-INDUCED XEROSTOMIA, IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","NOUVELLE INDICATION : POUR RÉDUIRE L'INCIDENCE ET LA SÉVÉRITÉ DE LA XÉROSTOMIE RADIO-INDUITE CHEZ LES PATIENTS ATTEINTS DE CANCER ÉPIDERMOÏDE DE LA TÊTE ET DU COU","CYTOPROTECTRIVE AGENT","AGENT CYTOPROTECTEUR","",""
"1680","01-04-30","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"1681","01-04-30","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"1682","01-04-26","CHIRON CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGIC RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"1683","01-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DE PLAQUETTES","",""
"1684","01-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DE PLAQUETTE","",""
"1685","01-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DE PLAQUETTES","",""
"1686","01-04-09","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN THE TREATMENT OF OSTEOPOROSIS IN MEN","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES HOMMES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1687","01-04-09","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"1688","01-04-06","THE LIPOSOME COMPANY INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WHO ARE REFRACTORY TO OR INTOLERANT OF CONVENTIONAL AMPHOTERICIN B THERAPY","INDICATION RÉVISÉE : POUR LE TRAITEMENT D'INFECTIONS FONGIQUES ENVAHISSANTES CHEZ LES PATIENTS QUI SOUFFRENT D'INTOLÉRANCE OU QUI SONT RÉFRACTAIRES À LA THÉRAPIE À AMPHOTÉRICINE B","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1689","01-03-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"1690","01-03-01","GLAXO WELLCOME INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1691","01-02-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"1692","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","FUJISAWA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1693","01-02-15","MGI PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"1694","01-02-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"1695","01-01-31","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1696","01-01-25","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"1697","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1698","01-01-18","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1699","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1700","01-01-09","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"1701","01-11-30","ACTELION PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"1702","01-11-21","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"1703","01-11-13","BIOVAIL PHARMACEUTICALS, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"1704","01-10-30","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT FOR BLADDER INSTILLATION","ANTINÉOPLASIQUE","",""
"1705","01-10-24","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: MANAGEMENT OF FOCAL SPASTICITY, INCLUDING THE TREATMENT OF UPPER LIMB SPASTICITY ASSOCIATED WITH STROKE IN ADULTS","NOUVELLE INDICATION : TRAITEMENT DE LA SPASTICITÉ FOCALE INCLUANT LA SPASTICITÉ DES MEMBRES SUPÉRIEURS CAUSÉE PAR UN ACCIDENT VASCULAIRE CÉRÉBRAL CHEZ L'ADULTE","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"1706","01-10-12","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT UTILISÉ DANS LA MALADIE DE PARKINSON","",""
"1707","01-10-12","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASMODIQUE","",""
"1708","99-07-16","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1709","03-08-13","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTILEUKEMIC AGENT","AGENT ANTI-LEUCÉMIQUE","",""
"1710","03-08-01","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1712","03-05-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINEMET","MERCK SHARP & DOHME FOR DUPONT PHARMA","CANADA","CANADA","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"1713","03-05-14","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: REVISIONS TO THE CLINICAL PHARMACOLOGY SECTION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT: RÉVISIONS À LA RUBRIQUE PHARMACOLOGIE CLINIQUE","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"1714","03-04-30","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1715","03-04-25","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR FIRST LINE THERAPY","POURVOIR AU TRAITEMENT DE PREMIÈRE LIGNE","PROSTAGLANDIN F2ALPHA ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"1716","03-04-07","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1717","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1718","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"1719","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"1720","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1721","01-09-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STADOL NS","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"1722","01-09-21","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION OF THE 100MG TABLET","MODIFICATION DE LA PRÉPARATION DES COMPRIMÉS DE 100MG","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1723","01-08-31","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF HYPERHIDROSIS OF THE AXILLA","NOUVELLE INDICATION : TRAITEMENT DE L'HYPERHIDROSE DES AISSELLES","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"1724","01-08-24","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMACEUTICALS","CANADA","CANADA","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"1725","01-08-22","SCHERING-PLOUGH HEALTHCARE PRODUCTS CANADA, A DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1726","03-03-14","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: RENAL PROTECTION IN TYPE 2 DIABETES WITH PROTEINURIA","NOUVELLE INDICATION: PROTECTION RÉNALE POUR LE DIABÈTE DE TYPE 2 AVEC PROTÉINURIE","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"1727","01-07-19","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"1728","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1729","03-03-06","UCB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1730","01-07-18","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BCG MANUFACTURING FACILITY","NOUVELLE INSTALLATION DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1731","03-02-26","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP AND DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1732","01-07-18","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1733","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC, ANTIPARKINSON AGENT","AGENT ANTICHOLINERGIQUE, ANTIPARKINSONIEN","",""
"1734","01-05-22","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"1735","01-04-04","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: FOR THE TREATMENT OF GLABELLAR LINES ASSOCIATED WITH CORRUGATOR AND/OR PROCERUS MUSCLE ACTIVITY","NOUVELLE INDICATION - POUR LE TRAITEMENT DES RIDES GLABELLAIRES RELIÉES À L'ACTIVITÉ DU MUSCLE CORRUGATOR ET/OU DU PROCERUS","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"1736","03-02-20","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE TO CLINICAL STUDIES AND ADVERSE REACTIONS SECTIONS","MISE À JOUR AUX RUBRIQUES ÉTUDES CLINIQUES ET RÉACTIONS INDÉSIRABLES DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOR AGENT","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; ANTINÉOPLASIQUE","",""
"1737","01-02-16","N.V. ORGANON","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1738","03-02-18","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"1739","99-06-16","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION FOR A PRIMARY VACCINE SERIES (2, 4 AND 6 MONTHS)","NOUVELLE INIDICATION IMMUNISATION (2,4 et 6 MOIS)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1740","01-12-28","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: XELODA IN COMBINATION WITH DOCETAXEL FOR HTE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING CHEMOTHERAPY","NOUVELLE INDICATION : XELODA COMBINÉ AU DOCETAXEL POUR LE TRAITEMENT DU CANCER DU SEIN MÉTASTATIQUE RÉSISTANT À UN TRAITEMENT PRÉALABLE À L'ANTHRACYCLINE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1741","03-02-17","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1742","01-12-21","TOBA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1743","03-02-06","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1744","01-11-21","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1745","99-05-10","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"1746","01-11-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"1747","03-01-22","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1748","01-11-19","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1749","01-11-13","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGGRÉGATION PLAQUETTAIRE","",""
"1750","03-01-14","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA LTD.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","ADJUVANT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"1751","99-05-06","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INIDICATION: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CARCINOMA AFTER FAILURE OF A PREVIOUS CHEMOTHERAPY REGIMEN","INDICATION RÉVISÉE : TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER MÉTASTATIQUE DU SEIN OU LOCALEMENT AVANCÉ QUI N'ONT PAS RÉPONDU AU SCHÉMA CHIMIOTHÉRAPIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1752","99-05-06","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: OVARIAN CANCER","NOUVELLE INDICATION : CANCER OVARIEN","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1753","99-05-05","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","BENZODIAZÉPINE ANTICONVULSIVANT","",""
"1754","99-05-05","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1755","99-03-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1756","99-01-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","GEIGY PHARMACEUTICALS, CIBA GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1757","99-12-10","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"1758","99-11-10","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1759","99-10-07","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTOR AND GAMBLE PHARMACEUTICALS","CANADA","CANADA","1","","","NON-STEROIDAL, ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"1760","99-08-25","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIONTENSINE II","",""
"1761","99-08-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ERYTHROPORISE","",""
"1762","99-08-18","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF SECONDARY PULMONARY HYPERTENSION DUE TO SCLERODERMA DUE TO SCLERODERMA SPECTRUM OF DISEASES (SSD)","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE SECONDAIRE DUE À DES MALADIES DE TYPE SCLÉRODERMIQUE","VASODILATOR","VASODILATATEUR","",""
"1763","99-07-07","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR AT1 DE L'ANGIOTENSIVE II","",""
"1764","99-06-11","COR THERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"1765","99-05-28","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1766","99-03-19","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1768","99-01-25","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"1769","99-01-12","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","AGENT NON STÉROÏDIEN ANTI-INFLAMMOATOIRE - ANALGÉSIQUE","",""
"1770","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITCOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1771","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE POUR INHALATION","",""
"1772","99-03-09","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉE","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"1773","03-12-19","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLET","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉ SE DÉSINTÉGRANT PAR VOIE ORALE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1774","99-12-22","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","UPDATING PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1775","99-12-09","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE EN AÉROSOL","",""
"1776","99-12-08","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1777","99-12-07","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"1778","03-12-17","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MUSCLE RELAXANT, ANALGESIC","RELAXANT MUSCULAIRE, ANALGÉSIQUE","",""
"1779","99-11-25","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: RELIEF OF SYMPTOMS ASSOCIATED WITH PERENNIAL ALLERGIC RHINITIS","NOUVELLE INDICATION : SOULAGEMENT DES SYMPTÔMES ASSOCIÉS AVEC LA RHINITE ALLERGIQUE NON-SAISONNIÈRE","HISTAMINE H1 RECEPTOR ANTAGONIST","ANAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1780","99-11-22","RIVA LABORATORY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1781","99-11-22","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1782","99-11-18","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATE LABELLING - TO REDUCE AND CONTROL STOMACH ACID IN THE NIGHT","MISE À JOUR DE L'ÉTIQUETAGE - POUR RÉDUIRE ET CONTRÔLER L'ACIDE GASTRIQUE DURANT LA NUIT","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"1783","99-11-17","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE","PRÉSENTATION RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1784","03-12-12","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1785","99-11-08","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MODIFICATION OF PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT, ANTIOBSESSIVE, ANTIBULIMIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1786","99-11-08","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1787","03-12-05","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-ROSACEA AGENT","AGENT ANTI-ROSACÉE","",""
"1788","99-10-21","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITCOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE EN AÉROSOL","",""
"1789","03-12-05","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE AND ANTIRHEUMATIC","ANTIMÉTABOLITE ET ANTIRHUMATISMAL","",""
"1790","03-12-02","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1791","99-10-07","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1792","99-09-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1793","99-08-13","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF RECURRENT EPISODES OF MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-INFECTED PATIENTS","NOUVELLE INDICATION : TRAITEMENT D'ÉPISODES RÉCURRENTS D'INFECTIONS MUCOCUTANÉES À HERPES SIMPLEX CHEZ LES PATIENTS ATTEINTS D'UNE INFECTION AU VIH","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1794","99-08-06","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: PROVIDES LONG-TERM USE IN PATIENTS SUFFERING FROM DEPRESSSION. PRODUCT MONOGRAPH REVISIONS","INDICATION RÉVISÉE : FOURNIT POUR L'UTILISATION À LONG TERME DES PATIENTS SOUFFRANT DE DÉPRESSION. MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1795","99-07-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"1796","99-07-13","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1797","99-07-06","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FENTANYL CITRATE INJECTION","ABBOTT LABORATORIES","CANADA","CANADA","1","","","OPIOID ANALGESIC - ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE OPIOÏDE - MÉDICAMENT D'APPOINT À L'ANESTHÉSIE","",""
"1798","99-06-29","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE POUR INHALATION","",""
"1799","03-12-02","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1800","99-06-29","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1801","03-11-06","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1802","99-06-21","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1803","99-06-16","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1804","03-11-06","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"1805","99-06-09","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1806","99-06-09","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1807","99-04-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1808","99-04-12","ZAMBON CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1809","03-10-28","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT, ALPHA-GUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL, INHIBITEUR DES ALPHA-GLUCOSIDASES","",""
"1810","99-03-26","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1-RECEPTOR ANTAGONIST/SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE/AMINE SYMPATHOMIMÉTIQUE","",""
"1811","99-03-16","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1812","99-02-12","OMEGA LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1813","03-10-24","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELOCOM 0.1% OINTMENT","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1814","99-01-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"1815","99-05-26","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1816","03-10-24","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE PRODUCT MONOGRAPH RE: DISCONTINUATION SYMPTOMS AND THE MANAGEMENT OF THESE SYMPTOMS","CHANGEMENTS À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'INTERRUPTION DES SYMPTÔMES ET À LA GESTION DE CES DERNIERS","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1817","99-03-17","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING SCHEDULE","PROGRAMME DE POSOLOGIE RÉVISÉE","ANTI-INFLAMMATORY STEROID","ANTI-INFLAMMATOIRE STÉROÏDE","",""
"1818","99-03-26","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER S.C.A.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1819","99-04-15","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"1820","99-08-25","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR - AGENT ANTIOBSESSIONNEL","",""
"1821","99-09-13","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"1822","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"1823","99-12-17","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL","",""
"1824","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID, ANTIBIOTIC","GLUCOCORTICOÏDE, ANTIBIOTIQUE","",""
"1825","99-12-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH FRACTIONATED ABDOMINAL IRRADIATION OR TOTAL BODY IRRADIATION","POUR LA PRÉVENTION DES NAUSÉES ET VOMISSEMENTS ASSOCIÉS À L'IRRADIATION ABDOMINALE FRACTIONNÉE OU L'IRRADIATION CORPORELLE TOTALE","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"1826","99-11-30","PHARMACYCLICS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"1827","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"1828","03-10-17","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA REPOUSSE DES CHEVEUX POUR HOMMES","",""
"1829","99-11-08","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"1830","99-08-25","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1831","99-08-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMIBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","NOUVELLE INDICATION : EN ASSOCIATION AVEC CISPLATIN POUR LE TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER PULMONAIRE NON À PETITES CELLULES (CPNPC) AU STADE LOCAL AVANCÉ OU MÉTASTATIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1832","99-08-18","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH A NON-STEROIDAL ANTIANDROGEN FOR THE MANAGEMENT OF LOCALLY ADVANCED, BULKY STAGE T2B, T2C, T3 AND T4 CARCINOMA OF THE PROSTATE","NOUVELLE INDICATION : POUR L'UTILISATION EN ASSOCIATION À UN ANTIANDROGÈNE NON STÉROÏDIEN POUR LE TRAITEMENT DE VOLUMINEUX CANCERS LOCALISÉS DE LA PROSTATE AU STADE T2B, T2C, T3 ET T4","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"1833","99-08-18","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE AS ADJUVANT HORMONE THERAPY TO EXTERNAL BEAM IRRADIATION FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER (STAGE T3-T4)","NOUVELLE INDICATION : POUR L'UTILISATION COMME HORMONOTHÉRAPIE ADJUVANTE À LA RADIOTHÉRAPIE EXTERNE CHEZ LES PATIENTS ATTEINTS D'UN CANCER LOCALISÉ AVANCÉ DE LA PROSTATE (STADE T3-T4)","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"1834","99-07-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, REVISED SPECIFICATIONS, ALTERNATE MANUFACTURING SITE, MANUFACTURING CHANGES, PRODUCT MONOGRAPH REVISIONS","NOUVELLE CONCENTRATION, SPÉCIFICATIONS RÉVISÉES, AUTRE EMPLACEMENT DE FABRICATION, MODIFICATION DE LA MÉTHODE DE FABRICATION, MONOGRAPHIE RÉVISÉE","ANTIVIRAL AGENT","ANTIVIRAL","",""
"1835","99-06-29","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN","SCHÉMA POSOLOGIQUE RÉVISÉ","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1836","99-04-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET PRÉSENTATION","ANTIHYPERLIPIDEMIC AGENT","HYPLIPIDÉMIANT","",""
"1837","99-04-06","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1838","99-03-16","TEVA PHARMACEUTICALS USA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1839","99-02-25","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"1840","99-11-17","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN DOSAGE - ALTERNATE TWO-DOSE REGIMEN IN ADOLESCENTS","NOUVEAU SCHÉMA POSOLOGIQUE - ALTERNATION POUR LES ADOLESCENTS DE LA POSOLOGIE À DEUX DOSES","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1841","99-08-30","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPANDED MANUFACTURING FACILITIES","MODIFICATION DE L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"1842","99-07-12","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1843","99-04-06","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"1844","99-04-06","SWISS SERUM & VACCINE INSTITUTE BERNE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGETN D'IMMUNISATION ACTIF","",""
"1845","99-02-12","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1846","99-12-20","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"1847","99-12-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOVUE","BRACCO DIAGNOSTIC","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"1848","99-12-09","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1849","99-12-08","HALOCARBON LABORATORIES, A DIVISION OF HALOCARBON PRODUCTS CORP.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"1850","99-11-01","MEDICAN PHARMA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGE PRESENTATION","NOUVELLE PRÉSENTATION D'EMBALLAGE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1851","99-11-01","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1852","99-10-07","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HYPERTENSIVE/DIURETIC","ANTIHYPERTENSEUR/DIURÉTIQUE","",""
"1853","99-10-05","COOK IMAGING CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONIONIC CONTRAST AGENT","AGENT DE CONTRASTE NON IONIQUE","",""
"1854","99-09-17","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PERITONEAL DIALYSIS SOLUTION","SOLUTION DE DIALYSE PÉRITONÉALE","",""
"1855","99-09-02","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE; NEW DOSAGE REGIMEN: 'ONCE-EVERY-THREE-WEEK' DOSAGE SCHEDULE","MONOGRAPHIE RÉVISÉE; NOUVEAU SCHÉMA POSOLOGIQUE : UNE FOIS TOUTES LES TROIS SEMAINES","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1856","99-08-13","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","THREE NEW STRENGTHS FOR SOLUTION IN MULTI-DOSE PEN - ALBUMIN (HUMAN) FREE","TROIS NOUVELLES CONCENTRATIONS DANS STYLO MULTI-DOSE - SANS ALBUMINE (HUMAIN)","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"1857","99-07-16","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE - POUR ENFANTS","",""
"1858","99-06-30","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS","NOUVELLE INDICATION : TRAITEMENT DES PATEINTS ATTEINTS DE SCLÉROSE EN PLAQUES SECONDAIRE PROGRESSIVE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1859","99-06-29","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE POUR L'ADMINISTRATION NASALE","",""
"1860","03-10-14","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"1861","99-06-29","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE POUR L'ADMINISTRATION NASALE","",""
"1862","99-06-03","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FORMULATION CHANGE","NOUVELLE FORMULATION","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"1863","99-05-10","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCNETRATION","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE - ANTIHYPERTENSEUR","",""
"1864","03-10-10","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID WITH LOCAL ANAESTHETIC","GLUCOCORTICOÏDE AVEC ANESTHÉSIQUE LOCAL","",""
"1865","03-10-03","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1866","99-05-05","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","BRONCHODILATATEUR","",""
"1867","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"1868","99-04-20","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW MASTER CELL BANK - NEW MANUFACTURING FACILITY","MODIFICATION DE LA MÉTHODE DE FABRICATION : NOUVELLE BANQUE DE CELLULES PRIMAIRES, NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"1869","99-04-06","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE/ANTIHYPERTENSIF","",""
"1870","99-03-16","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A REVISED INDICATION","FOURNIS POUR UNE INDICATION RÉVISÉE","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"1871","99-03-09","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"1872","99-02-12","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIO-DIAGNOSTIQUE","",""
"1873","99-02-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE/ANTIHYPERTENSEUR","",""
"1874","99-02-12","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE POUR ADMINISTRATION NASALE","",""
"1875","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1876","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1877","99-01-25","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE IMMUNITAIRE","",""
"1878","99-10-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II - DIURÉTIQUE","",""
"1879","99-10-13","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1880","99-10-01","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"1881","99-09-28","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1882","99-08-25","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"1883","99-08-13","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: GASTROESOPHAGEAL REFLUX DISEASE (GERD), TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD","NOUVELLE INDICATION : REFLUX GASTRO-OESOPHAGIEN, TRAITEMENT DES BRÛLURES D'ESTOMAC ET AUTRES SYMPTÔMES ASSOCIÉS AU REFLUX GASTRO-OESOPHAGIEN","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1884","99-07-26","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATED PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","CHOLESTEROL LOWERING AGENT","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1885","99-07-22","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1886","99-07-07","ROBERTS PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRACEPTIVE AGENT","CONTRACEPTIF ORAL","",""
"1887","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID ACNE COMPOUND","CORTICOSTÉROÏDE TOPIQUE POUR LE TRAITEMENT DE L'ACNÉ","",""
"1888","99-07-02","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"1889","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"1890","99-07-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: UNCOMPLICATED URINARY TRACT INFECTIONS (MILD TO MODERATE) DUE TO ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE OR STAPHYLOCOCCUS SAPROPHYTICUS.","NOUVELLE INDICATION : INFECTIONS DES VOIES URINAIRES SIMPLES (DOUCES ET MODÉRÉES) DUES À ESCHERICHIA COLI, PNEUMONIE KLEBSIELLA OU STAPHYLOCOQUE SAPROPHYTE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1891","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"1892","99-06-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUPRON","TAP PHARMACEUTICALS","CANADA","CANADA","1","","","GONADOTROPIN RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1893","99-06-18","WESTCAN PHARMACEUTICALS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"1894","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-MANIC AGENT","ANTIMANIAQUE","",""
"1895","99-06-07","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, CHANGE IN TABLET SIZE","MODIFICATION DE LA PRÉPARATION ET DE LA TAILLE DES COMPRIMÉS","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1897","99-05-28","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION AND REVISED DOSAGE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE","INDICATION ET PRÉSENTATION RÉVISÉES POUR LE TRAITEMENT DE LA DÉFAILLANCE CARDIAQUE CONGESTIVE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1898","99-05-18","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: CHEWABLE/DISPERSIBLE TABLET","NOUVELLE FORMULATION: COMPRIMÉ À MÂCHER/DISPERSER","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1899","99-05-18","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS ADJUNCTIVE THERAPY FOR THE MANAGEMENT OF THE SEIZURE ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN ADULTS AND CHILDREN","NOUVELLE INDICATION : ADJUVANT POUR LE TRAITEMENT DES CRISES ASSOCIÉES AU SYNDROME DE LENNOX-GASTAUT CHEZ LES ADULTES ET LES ENFANTS","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1900","99-04-20","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1901","99-04-20","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1902","99-04-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1903","99-03-26","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH; PRODUCT MONOGRAPH REVISION","NOUVELLE CONCENTRATION, MONOGRAPHIE RÉVISÉE","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1904","99-03-26","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1905","99-03-16","GYNETICS LTD/LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTIVE","CONTRACEPTIF D'URGENCE","",""
"1906","99-02-16","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOUR AGENT","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; AGENT ANTI-TUMEUR","",""
"1907","99-01-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"1908","99-11-04","CORIXA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOSTIMULATING AGENT","AGENT IMMUNOSTIMULANT","",""
"1909","99-02-25","METHAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","DIAGNOSTIC CHOLINERGIQUE (ASTHME BRONCHIQUE)","",""
"1910","99-12-17","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"1911","99-11-22","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMIDE","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1912","99-10-14","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CHOLINERGIC, DIAGNOSTIC AID","CHOLINERGIQUE, AUXILIAIRE DIAGNOSTIQUE","",""
"1913","99-09-28","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EDITORIAL CHANGES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","MODIFICATION À LA SECTION POSOLOGIE DE LA MONOGRAPHIE DU PRODUIT","PROGERSTOGEN, ANTINEOPLASTIC, ANTIANOREXIC, ANTICACHECTIC/ANTIANOREXIC, ANTICACHECTIC","PROGESTATIF, ANTINÉOPLASIQUE, ANTIANOREXIQUE, ANTICACHECTIQUE/ANTIANOREXIQUE, ANTICACHECTIQUE","",""
"1914","99-09-28","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1915","99-09-21","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT FOR THE PREPARATION OF TECHNETIUM TC 99M MEDRONATE","TROUSSE DIAGNOSTIQUE POUR LA PRÉPARATION DE TECHNÉTIUM 99M TC","",""
"1916","99-08-27","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1917","99-08-25","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1918","99-08-23","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PEDIATRIC INDICATION: FOR USE IN CHILDREN BETWEEN THE AGES OF 3 AND 11 YEARS TO TREAT THE SYMPTOMS OF SEASONAL OR PERENNIAL ALLERGIC RHINITIS","NOUVELLE INDICATION PÉDIATRIQUE : POUR L'UTILISATION CHEZ LES ENFANTS DE 3 À 11 ANS POUR TRAITER LES SYMPTÔMES DE RHINITE ALLERGIQUE SAISONNIÈRE ET NON SAISONNIÈRE","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1919","99-08-19","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"1920","99-07-12","CONNAUGHT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1921","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"1922","99-07-12","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1923","99-06-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","IMMUNOSUPPRESSANT AGENT","IMMUNOSUPPRESSEUR","",""
"1924","03-09-22","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1925","99-05-13","CONNAUGHT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1926","99-05-10","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1927","99-04-12","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION LIPIDIQUE POUR ALIMENTATION PAR VOIE INTRAVEINEUSE","",""
"1928","99-03-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PONSTAN","PARKE-DAVIS","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"1929","99-03-12","FOURNIER PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"1930","99-03-09","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"1931","99-03-09","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1932","99-03-08","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"1933","99-02-26","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CNS STIMULANT","STIMULANT DU SNC","",""
"1934","99-02-23","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTRO-INTESTINALES","",""
"1935","99-02-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1936","99-02-16","PROCTER & GAMBLE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASE DU TUBE DIGESTIF","",""
"1937","99-02-05","MCNEIL CONSUMER PRODUCTS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1938","99-02-03","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PATIENT PACKAGE INSERT","RÉVISIONS DU PAQUET D'INSERTION DU PATIENT","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTROINTESTINALES INFÉRIEURES","",""
"1939","99-01-14","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW SUPPLIER OF ALBUMIN (HUMAN)","CHANGEMENT DANS LE PROCESSUS DE FABRICATION - UTILISATION D'UN NOUVEAU FOURNISSEUR D'ALBUMINE (HUMAINE)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1940","99-01-14","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW SUPPLIER OF ALBUMIN (HUMAN)","CHANGEMENT DANS LE PROCESSUS DE FABRICATION - UTILISATION D'UN NOUVEAU FOURNISSEUR D'ALBUMINE (HUMAINE)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1941","99-01-12","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT - ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL - INHIBITEUR DES ALPHA GLUCOSIDASES","",""
"1942","99-12-17","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","ANTIALLERGIC","ANTIALLERGIQUE","",""
"1943","99-12-03","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1945","99-10-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E 500MG TABLETS","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTI-PYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"1946","99-09-28","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM (CANADA) INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"1947","99-09-07","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVENTYL","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1948","99-09-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1949","99-08-27","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME ONLY","MODIFICATION DU NOM DU PRODUIT SEULEMENT","ANTI-INFLAMMATORY AGENT, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1950","99-08-27","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE ET ANTIPYRÉTIQUE","",""
"1951","99-08-18","ICN CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE - ANTICONVULSIVANT","",""
"1952","99-08-11","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1953","99-07-23","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXID","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTATGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1954","99-07-22","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","PROPRIÉTÉS ANTI-INFLAMMATOIRE, ANALGÉSIQUE ET ANTIPYRÉTIQUE","",""
"1955","99-06-09","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1956","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1957","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1958","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1959","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1960","99-06-04","SANOFI CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND NEW DOSAGE REGIMEN","NOUVELLE CONCENTRATION ET NOUVEAU SCHÉMA POSOLOGIQUE","ANTICOAGULANT/ANTITHROMBOTIC","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1961","99-05-28","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1962","99-05-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCNETRATION ET PRÉSENTATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"1963","99-05-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉES","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"1964","99-04-06","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1965","99-02-23","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"1966","99-02-12","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1967","99-02-12","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1968","99-01-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"1969","99-01-25","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"1970","99-01-25","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"1971","99-12-23","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1972","99-12-02","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF DYSPEPSIA","NOUVELLE INDICATION: TRAITEMENT DE DYSPEPSIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1973","99-06-04","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO PRODUCT MONOGRAPH","MONOGRAHIE RÉVISÉE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1974","99-11-22","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"1975","99-08-26","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STORAGE CONDITIONS; PRODUCT NAME CHANGE; COMPANY NAME CHANGE","NOUVELLE CONDITIONS DE STOCKAGE, CHANGEMENTS DANS LE NOM DU FABRICANT ET DU PRODUIT","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1976","99-08-06","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTICHOLINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE - AGENT ANTISPASMODIQUE","",""
"1977","99-06-03","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-OBESITY AGENT/GASTROINTESTINAL LIPASE INHIBITOR","AGENT ANTI-OBÉSITÉ/INHIBITEUR DE LIPASE GASTRO-INTESTINAL","",""
"1978","99-05-18","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1979","99-04-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: TREATMENT OF SYMPTOMS ASSOCIATED WITH CARCINOID TUMORS AND VASOACTIVE INTESTINAL PEPTIDE TUMORS (VIPOMAS)","NOUVELLSE INDICATIONS : TRAITEMENT DES SYMPTÔMES ASSOCIÉS AVEC : LES TUMEURS CARCINOÏDES ET LES TUMEURS PEPTIDES INTESTINALES VASOACTIVES (VIPOMAS)","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDES SYNTHÉTIQUES ANALOGUE DE LA SOMATOSTATINE","",""
"1980","99-04-06","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1981","99-12-10","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1982","99-09-28","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1983","99-10-21","COLUMBIA LABORATORIES (UK) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"1984","99-10-05","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN METHOD OF MANUFACTURE","MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, THÉRAPIE (TROUBLES D'ANXIÉTÉ SOCIAL) DE PHOBIE SOCIALE","",""
"1985","99-09-07","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED FORMULATION TO ALLOW EMBOSSING OF THE TABLETS","PRÉPARATION RÉVISÉE POUR PERMETTRE LE BOSSELAGE DES COMPRIMÉS","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1986","99-08-25","PASTEUR MERIEUX SERUM & VACCIN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1987","99-08-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES OSSEUX","",""
"1988","99-08-03","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIETARY FIBRE SUPPLEMENT, BULK FORMING LAXATIVE, CHOLESTEROL LOWERING AGENT","SUPPLÉMENT DE FIBRE ALIMENTAIRE, LAXATIF, BAISSE DU CHOLESTÉROL","",""
"1989","99-07-26","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DRUG IDENTIFICATION NUMBER FOR 5 DOSE VIAL","NOUVELLE IDENTIFICATION NUMÉRIQUE DE DROGUE POUR FIOLE DE 5 DOSE","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1990","99-07-16","QLT PHOTOTHERAPEUTICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO ALLOW FOR THE USE OF PHOTODYNAMIC THERAPY WITH PHOTOFIRN IN THE REDUCTION OF OBSTRUCTION AND PALLATIVE TREATMENT OF PATIENTS WITH OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER AND IN THE TREATMENT OF SUPERFICIAL ENDOBRONCHIAL NSCLC IN PATIENTS WHO ARE NOT ELIGIBLE FOR SURGERY OR RADIOTHERAPY","NOUVELLE INDICATION : THÉRAPIE PHOTODYNAMIQUE AVEC PHOTOPHRIN POUR DIMINUER L'OBSTRUCTION ET TRAITEMENT PALLIATIF DES PATIENTS ATTEINTS D'UN CANCER ENDOBRONCHIQUE OBSTRUCTIF À NON-PETITES CELLULES (NSCLC) ET TRAITEMENT D'UN CANCER PULMONAIRE SUPERFICIEL À NON-PETITES CELLULES (NSCLC)","ANTINEOPLASTIC PHOTOSENSITIZING AGENT","PHOTOSENSIBILISANT ANTINÉOPLASIQUE","",""
"1991","99-07-13","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAHIE RÉVISÉE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1992","99-07-12","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1993","99-06-16","V.I. TECHNOLOGIES INC. (VITEX)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","POOLED BLODD COMPONENT/DERIVATIVE","COMPOSANTS DU SANG/PRODUITS DÉRIVÉS DU SANG","",""
"1994","99-05-12","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED FORMULATION","FORMULATION RÉVISÉE","INTRAVENOUS EMULSION - ANAESTHETIC - SEDATIVE","ÉMULSION I.V. - ANESTHÉSIQUE - SÉDATIF","",""
"1995","99-04-15","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE TREATMENT OF SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA","NOUVELLE INDICATION : TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE)","ANTIDEPRESSANT - ANTIOBSESSIONAL - ANTIPANIC AGENT- SOCIAL PHOBIA","ANTIDÉPRESSEUR, ANTIOBESSIONNEL, ANTIPANIQUE, THÉRAPIE (TROUBLES D'ANXIÉTÉ SOCIAL) DE PHOBIE SOCIALE","",""
"1996","99-04-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1997","99-03-26","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1998","99-03-17","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMTOIRE - ANALGÉSIQUE","",""
"1999","99-03-16","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ORAP","MCNEIL PHARMACEUTICALS CANADA LTD.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"2000","99-03-02","CRYSTAAL CORPORATION, A DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"2001","99-02-17","BYK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2002","99-02-02","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2003","99-01-25","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2004","99-01-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2005","99-12-17","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2006","99-12-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2007","99-10-29","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2008","99-09-01","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"2009","99-06-16","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2010","99-06-07","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2011","99-05-05","RHODIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2012","99-03-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2013","99-03-08","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2014","99-03-08","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN","SEARLE CANADA","CANADA","CANADA","1","","","ANTIANGINAL/ANTIARRHYTHMIC/ANTIHYPERTENSIVE AGENT","AGENT ANTIANGINEUX/ANTIARYTHMIQUE/ANTIHYPERTENSEUR","",""
"2015","99-01-15","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2016","99-05-21","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTICOAGULANT","ANTICOAGULANT","",""
"2017","99-11-02","GLAXO WELLCOME INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2018","99-09-01","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"2019","99-08-03","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"2020","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2021","99-12-23","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"2022","99-12-17","STANLEY PHARMACEUTICALS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC 75","GLAXO WELLCOME","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2023","99-11-17","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGE FORMAT INCORPORATING REBETRON MULTI-DOSE PEN","NOUVEL EMBALLAGE CONTENANT LE STYLO MULTI-DOSE REBETRON","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODIFIER","ANTIVIRAL/MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2024","99-11-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC 75","GLAXO WELLCOME INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2025","99-10-25","MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2026","99-08-25","PASTEUR MERIEUX SERUM & VACCIN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2027","99-08-18","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2028","99-07-29","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: TABLETS (0.25MG & 0.5MG); NEW INDICATION: FOR USE IN SEVERE DEMENTIA FOR THE SHORT-TERM SYMPTOMATIC MANAGEMENT OF INAPPROPRIATE BEHAVIOUR DUE TO AGRESSSION AND/OR PSYCHOSIS","NOUVELLES CONCENTRATIONS : TAB (0.25MG & 0.5MG); NOUVELLE INDICATION : L'UTILISATION POUR LA DÉMENCE GRAVE DANS LA GESTION SYMPTOMATIQUE À COURT TERME DU COMPORTEMENT INAPPROPRIÉ RÉSULTANT DE L'AGRESSION ET/OU LA PSYCHOSE","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"2029","99-07-28","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","ANTIPARKINSONIEN/AGONISTE DOPAMINERGIQUE","",""
"2030","99-07-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS 5-HT1","",""
"2031","99-04-22","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY","TRAITEMENT DE L'HÉPATITE C CHRONIQUE CHEZ LES PATIENTS ANTÉRIEUREMENT NON TRAITÉS À LA THÉRAPIE DE L'INTERFÉRON ALPHA","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODIFIER","AGENT ANTIVIRAL ET MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2032","99-04-06","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"2033","99-02-26","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODULATOR","AGENT ANTIVIRAL ET MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2034","99-02-12","WARNER LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTIHISTAMINIQUE SPÉCIFIQUE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2035","99-02-12","NOVO NORDISK CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"2036","99-12-14","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 4 YEARS OF AGE AND OLDER","NOUVELLE INDICATION : TRAITEMENT D'ENTRETIEN DE L'ASTHME CHEZ LES PATIENTS DE 4 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2037","99-10-25","3M PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","BRONCHODILATOR","BRONCHODILATEUR","",""
"2038","99-09-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2039","99-08-12","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT AGENT","ANTIDÉPRESSEUR","",""
"2040","99-02-25","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO PROVIDE FOR ADDITIONAL WORDING UNDER CLINICAL TRIALS-OBSESSIVE COMPULSIVE DISORDER SECTION OF THE PM TO INCLUDE PEDIATRIC AND ADOLESCENT EXPERIENCE","POUR L'ADDITION, À LA SECTION TROUBLE OBSESSIONNEL COMPULSIF DE LA MONOGRPHIE, D'INFORMATION SUPPLÉMENTAIRE CONCERNANT LES ÉTUDES CLINIQUES CHEZ LES ENFANTS ET LES ADOLESCENTS","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","AGENT ANTIDÉPRESSEUR, ANTIPANIQUE ET ANTIOBSESSIONNEL","",""
"2041","99-09-02","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATIONS: 1. REDUCE THE RISK OF FATAL PLUS NON-FATAL CEREBROVASCULAR EVENTS (STROKE AND TRANSIENT ISCHEMIC ATTACKS); 2. REDUCE THE RISK OF MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLEMIC PATIENTS WITH DIABETES MELLITUS","INDICATIONS RÉVISÉES : RÉDUIT LE RISQUE DES INCIDENTS CÉRÉBROVASCULAIRE MORTEL ET NON-MORTEL (ATTAQUE ET CRISE ISCHÉMIQUE TRANSITOIRE); RÉDUIT LE RISQUE DES INCIDENTS CORONAIRES MAJEURS SUR LES PATIENTS ATTEINTS DE HYPERCHOLESTÉROLÉMIE AYANT LE DIABÈTE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2042","99-09-03","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR AND CORTICOSTEROID FOR INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"2043","99-09-21","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PYROPHOSPHATE","TROUSSE DIAGNOSTIQUE POUR LA PRÉPARATION DE TECHNÉTIUM 99M TC PYROPHOSPHATE","",""
"2044","99-09-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS IN FEMALES GREATER THAN FIVE YEARS POSTMENOPAUSE WITH LOW BONE MASS (FOR PATIENTS WHO REFUSE OR CANNOT TOLERATE TREATMENT WITH ESTROGENS OR IN WHOM ESTROGENS ARE CONTRAINDICATED)","POUR LE TRAITEMENT DE L'OESTÉOPOROSES POST-MÉNOPAUSALE POUR LES FEMMES AYANT PLUS DE CINQ ANS DE POST-MÉNOPAUSE AVEC UNE FAIBLE MASSE OSSEUSE (POUR LES PATIENTES QUI REFUSENT OU QUI NE PEUVENT TOLÉRER LE TRAITEMENT AVEC DES OESTROGÈNES OU CELLES OÙ LES OESTROGÈNES LEUR SONT CONTREINDIQUÉES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2045","99-08-19","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE TO PRODUCT NAME; RX TO OTC SWITCH","CHANGEMENT DE NOM DE PRODUIT, RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2046","99-07-12","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"2047","99-06-29","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2048","99-06-29","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2049","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2050","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2051","99-06-21","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH; REVISED INDICATION: TO INCLUDE THE REDUCTION OF ELEVATED LEVELS OF APOLIPOPROTEIN B AND TRIGLYCERIDES; REVISED DOSAGE","NOUVELLE CONCENTRATION; INDICATION REVISÉE : POUR INCLURE LA RÉDUCTION DES NIVEAUX ÉLEVÉS D'APOLOPROTÉINE B ET DES TRIGLYCÉRIDES; PRÉSENTATION REVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2052","99-05-18","FRESENIUS KABI AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FAT EMULSIONS FOR INTRAVENOUS NUTRITION","ÉMULSION DE GRAS, ALIMENTATION I.V.","",""
"2053","99-04-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRODUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"2054","99-03-08","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","GMPC-INHIBITEUR SPÉCIFIQUE DE LA PHOSPHODIESTÉRASE DE TYPE 5","",""
"2055","99-03-04","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN SOURCE OF BULK DRUG SUBSTANCE AND FINISHED DRUG PRODUCT","NOUVELLE SOURCE DE SUBSTANCE BIOLOGIQUE ET PRODUIT FINAL","GROWTH STIMULANT","STIMULANT DE CROISSANCE","",""
"2056","99-02-22","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OPTICROM","FISONS CORPORATION LTD.","CANADA","CANADA","1","","","ANTIALLERGIC AGENT","AGENT ANTIALLERGIQUE","",""
"2057","99-01-14","BAUSCH & LOMB SURGICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2058","99-01-12","TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE - NEW STRENGTHS","MONOGRAPHIE RÉVISÉE - NOUVELLES CONCENTRATIONS","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BÊTA2-ADRÉNERGIQUES","",""
"2059","99-12-17","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF CLOTTING IN INDWELLING INTRAVENOUS LINES DURING HAEMODIALYSIS AND EXTRACORPOREAL CIRCULATION","NOUVELLE INDICATION : POUR PRÉVENIR LA COAGULATION DANS LES LIGNES DE PERFUSION I.V. À DEMEURE DURANT L'HÉMODIALYSE ET LA CIRCULATION EXTRACORPORELLE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"2060","99-12-01","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2061","99-06-16","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN RECOMMENDED DOSAGE FOR LIVER TRANSPLANTATION","MODIFICATION DE LA POSOLOGIE RECOMMANDÉE POUR LA GREFFE DU FOIE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2062","99-11-18","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2063","99-11-10","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2064","99-10-25","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2065","99-10-07","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"2066","99-10-01","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TWO NEW STRENGTHS","DEUX NOUVELLES CONCENTRATIONS","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2067","99-09-02","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE","DIURÉTIQUE/ANTIHYPERTENSEUR","",""
"2068","99-08-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2069","99-08-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2070","99-08-26","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"2071","99-08-19","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"2072","99-08-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2073","99-07-28","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW MANUFACTURING FACILITY, CHANGE IN MANUFACTURING PROCESS, NEW STRENGTH, NEW INDICATION-USE IN SPECT IMAGING","NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA FABRICATION, NOUVELLE CONCENTRATION, NOUVELLE INDICATION-UTILISATION DANS L'IMAGE SPECT","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2074","99-06-29","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASTIC AGENT","AGENT ANTISPASTIQUE","",""
"2075","99-06-16","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","POLYTRIM OPHTHALMIC SOLUTION","ALLERGAN INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2076","99-06-16","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PHARMACEUTICAL FORM AND NEW STRENGTH","NOUVELLE PRÉSENTATION PHARMACEUTIQUE ET NOUVELLE CONCENTRATION","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"2077","99-05-28","HEXAL PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"2078","99-05-20","CONNAUGHT LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2079","99-05-20","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - SPRINKLE CAPSULE FORMULATION","NOUVELLE PRÉSENTATION - FORMULATION D'UNE CAPSULE À SAUPOUDRER","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2080","99-05-20","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PEDIATRIC USE IN PARTIAL ONSET SEIZURES","NOUVELLE INDICATION : POUR L'USAGE EN PÉDIATRIE À L'APPROCHE D'ATTAQUES PARTIELLES","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2081","99-05-06","DEBIO RECHERCHE PHARMACEUTIQUE S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (LH-RH)","",""
"2082","99-03-19","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM (GEL)","NOUVELLE PRÉSENTATION (GEL)","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2083","99-03-15","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF RECURRENT SMALL CELL LUNG CANCER","NOUVELLE INDICATION : POUR LE TRAITEMENT DE FRÉQUENTE PETITE CELLULE DU CANCER DU POUMON","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2084","99-03-04","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2085","99-02-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TESTOSTERONE REPLACEMENT THERAPY","THÉRAPIE DESTINÉE À REMPLACER LE TESTOSTÉRONE","",""
"2086","99-02-16","PATHOGENISIS CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RESPIRATORY ANTIBIOTIC","RESPIRATOIRE ANTIBIOTIQUE","",""
"2087","99-02-02","ORTHO DERMATOLOGICAL, DIVISION OF JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"2088","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2089","99-01-25","ATHENA NEUROSCIENCES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASTIC AGENT","AGENT ANTISPASTIQUE","",""
"2090","99-01-12","CROWNPHARMA CANADA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK SHARP & DOHME","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE ÉLEVÉE DE LA PRESSION INTRAOCULAIRE","",""
"2091","99-08-19","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"2092","01-11-02","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2093","01-11-02","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"2094","01-10-26","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2095","01-10-31","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW EXTENDED RELEASE FORMULATION","NOUVELLE FORMULATION À ACTION PROLONGÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2096","01-10-24","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTIVONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"2097","01-10-24","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX","FACTEUR IX ANTIHÉMORRAGIQUE DE COAGULATION SANGUINE","",""
"2098","01-10-24","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AND CORTICOSTEROID AGENT","ANTIFONGIQUE - CORTICOSTÉROÏDE TOPIQUE","",""
"2099","01-10-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"2100","01-09-21","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION OF THE 125MG/5ML CLARITHROMYCIN FOR ORAL SUSPENSION","REFORMULATION DU CLARITHROMYCIN","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2101","01-09-21","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2102","01-09-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINEMET","MERCK SHARP & DOHME","CANADA","CANADA","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"2103","01-08-31","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC LUNG SURFACTANT","SURFACTANT PULMONAIRE SYNTHÉTIQUE","",""
"2104","01-08-31","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2105","01-08-28","TARO PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CHEWTABS","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE FORME POSOLOGIQUE ET CONCENTRATION","ANTICONVULSANT, FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"2106","01-08-27","CHX TECHNOLOGIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CHLORZOIN","MODIFICATION DU NOM DU PRODUIT DE CHLORZOIN","ANTIMICROBIAL AGENT","ANTIBACTÉRIEN","",""
"2107","01-08-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE ORAL","",""
"2108","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2109","01-08-24","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2110","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2111","01-08-17","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2112","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2113","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2114","01-08-24","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"2115","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2116","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2117","01-08-07","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2118","01-08-07","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2119","01-08-07","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2120","01-07-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"2121","01-07-11","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIPSORIATIC AGENT, VITAMIN D ANALOGUE, CORTICOSTEROID","AGENT ANTIPSORIASIQUE TOPIQUE, ANALOGUE DE LA VITAMINE D, CORTICOSTÉROÏDE TOPIQUE","",""
"2122","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2123","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2124","01-06-18","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER + DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"2125","01-06-07","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2126","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2127","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VAGINAL ANTIBACTERIAL PREPARATION","AGENT ANTIBACTÉRIEN POUR ADMINISTRATION VAGINALE","",""
"2128","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2129","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2130","01-05-08","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"2131","01-05-08","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE TO PRODUCT MONOGRAPH","MODIFICATION DE LA MONOGRAPHIE DU PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2132","01-05-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","INTAL NEBULIZER SOLUTION","FISONS CORP. LTD.","CANADA","CANADA","1","","","ASTHMA PROPHYLAXIS","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2133","01-04-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"2134","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2135","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2136","01-04-17","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ION EXCHANGE RESIN","RÉSINE ÉCHANGEUSE D'IONS","",""
"2137","01-04-06","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2138","01-04-04","AVENTIS BEHRING LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BLOOD COAGULATION PRODUCT","PRODUIT DE COAGULATION DE SANG","",""
"2139","01-03-29","GLADES, DIVISION OF STIEFEL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN T","UPJOHN COMPANY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2140","01-03-07","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DU RÉCEPTEUR DOPAMINERGIQUE","",""
"2141","01-02-15","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT, ANTIMANIC, SYMPTOMATIC RELIEF OF TRIGERMINAL NEURALGIA","ANTICONVULSIVANT, ANTIMANIAQUE, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRAGE DU TRIJUMEAU","",""
"2142","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2143","01-02-08","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE - BIAXIN TO BIAXIN BID","MODIFICATION DU NOM DU PRODUIT - BIAXIN À BIAXIN BID","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2144","01-02-01","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL - ANTIPARASITIC","ANTIPALUDÉEN - PARASITICIDE","",""
"2145","01-01-31","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2146","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2147","01-01-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2148","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2149","01-01-11","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES/PROGESTIN","HORMONE OESTROGÈNES, PROGESTATIF","",""
"2150","01-01-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAGAMET","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2151","01-01-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2152","01-01-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2153","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2154","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2155","01-08-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2156","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"2157","01-08-15","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR/ANTI-PAGETIC AGENT/ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTIPAGÉTIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"2158","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUES DE LA DIGOXINE","",""
"2159","01-08-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2160","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2161","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2162","01-07-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2163","01-07-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2164","01-06-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2165","01-06-04","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"2166","01-05-29","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2167","01-04-30","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMIN D","",""
"2168","01-04-17","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"2169","01-03-29","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"2170","01-03-02","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CARCINOMA","NOUVELLE INDICATION: TRAITEMENT DES PATIENTS SOUFFRANT DU CANCER DU SEIN AVANCÉ LOCALISÉ OU MÉTASTATIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2171","01-02-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTRAN RAPIDE","CIBA-GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2172","01-02-16","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2173","01-02-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT, ANTITHROMBIC AGENT","ANTICOAGULANT, ANTITHROMGBOTIQUE","",""
"2174","01-02-15","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIHYPERTENSIVE - ANTIANGINAL AGENT","ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"2175","01-02-13","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"2176","01-02-13","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"2177","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT WITH A PROTECTIVE MUCOSAL AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2178","01-02-06","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2179","04-05-05","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC AGENT","SYMPATHOMIMÉTIQUE","",""
"2180","04-05-03","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION: THE ADDITION OF 3 NEW EXCIPIENTS TO IMPROVE THE TASTE","CHANGEMENT DANS LA COMPOSITION : AJOUT DE 3 NOUVEAUX EXCIPIENTS POUR AMÉLIORER LE GOÛT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2181","04-05-03","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA INC.","CANADA","CANADA","1","","","NON DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"2182","04-05-03","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2183","04-05-03","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2184","04-05-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2185","04-05-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2186","01-02-06","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2187","04-05-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2188","01-01-24","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2189","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"2190","01-01-22","DEPARTMENT OF NATIONAL DEFENCE, CANADIAN FORCES MEDICAL GROUP HEADQUARTERS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"2191","01-01-18","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIMSO-50 USP","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","INTRAVESICAL INSTILLATION FOR THE TREATMENT OF INTERSTITIAL CYSTITIS","MALADIES GÉNITO-URINAIRES","",""
"2192","01-01-18","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANIHYPERTENSIVE AGENT; SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR; TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2193","01-12-21","THE LIPOSOME COMPANY INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2194","01-12-21","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF CHRONIC IDIOPATHIC URTICARIA","NOUVELLE INDICATION: POUR LE TRAITEMENT DE L'URTICAIRE CHRONIQUE IDIOPATHIQUE","HISTAMINE H1-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2195","01-12-05","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"2196","01-11-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM CANADA INC.","CANADA","CANADA","1","","","CORONARY VASODILATOR AND INHIBITOR OF PLATELET ADHESION AND AGGREGATION","VASODILATATEUR CORONARIEN ET INHIBITEUR DE L'ADHÉSION ET L'AGRÉGATION PLAQUETTAIRES","",""
"2197","01-11-21","BIOVAIL PHARMACEUTICALS, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"2198","01-11-13","BIOVAIL PHARMACEUTICALS, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPETENSEUR, ANTIANGINEUX","",""
"2199","01-11-13","XCEL PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","BENZODIAZÉPINE, ANTICONVULSIVANT","",""
"2200","01-10-16","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NIGTHTIME SLEEP-AID","ADIE-SOMMEIL","",""
"2201","01-10-12","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM INJECTABLE","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2202","01-10-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"2203","01-10-09","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM","CANADA","CANADA","1","","","CORONARY VASODILATOR","VASODILATATEUR CORANARIEN","",""
"2204","01-10-09","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","CORTICOSTÉROÏDE TOPIQUE","",""
"2205","01-10-04","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO GAIN APPROVAL FOR A NEW ENCAPSULATED ENTERIC-COATED BEADLET FORMULATION AS WELL AS A ONCE-DAILY DOSAGE ADMINISTRATION","PERMETTRE L'AJOUT D'UNE PRÉSENTATION À ENROBAGE ENTÉROSOLUBLE ET L'ADMINISTRATION D'UNE DOSE PAR JOUR","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2206","01-09-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-4","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE","",""
"2207","01-12-28","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2208","01-12-05","BRISTOL-MYERS SQUIBB PHARMA. GROUP, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"2209","01-10-30","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"2210","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK SHARP & DOHME","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2211","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2212","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL MYERS SQUIBB CANADA","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2213","04-05-05","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"2214","04-05-03","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2215","04-05-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI SYNTHELABO CANADA INC.","CANADA","CANADA","1","","","Inotrope, Vasodilator","Inotrope, Vasodilatateur","",""
"2216","04-05-06","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"2217","04-05-06","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISION TO PRODUCT MONOGRAPH","RÉVISION À LA MONOGRAPHIE DU PRODUIT","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2218","04-05-06","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGES TO MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2219","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2220","01-08-17","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"2221","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"2222","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2223","01-06-06","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE OF VASOTEC IN HYPETENSIVE PEDIATRIC PATIENTS","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2224","01-06-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2225","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2226","01-05-24","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR (AT1) DE L'ANGIOTENSINE II","",""
"2227","01-05-10","WESTWOOD-SQUIBB COLTON HOLDINGS PARTNERSHIP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH INHIBITOR","INHIBITEUR DE LA POUSSE DE POILS","",""
"2228","01-05-08","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT TO LEVODOPA AND DDC INHIBITOR/COMT-INHIBITOR","TRAITEMENT D'APPOINT À LA LÉVODOPA ET INHIBITEUR DE LA DDC/COMT","",""
"2229","01-05-08","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTICOAGULANT/ANTITHROMBOTIC AGENT (LOW MOLECULAR WEIGHT HEPARIN FRAGMENT)","ANTICOAGULANT/ANTITHROMBOTIQUE (FRAGMENT D'HÉPARINE DE BAS POIDS MOLÉCULAIRE)","",""
"2230","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AROMATASE INACTIVATOR; ANTI-TUMOR AGENT","INACTIVATEUR DE L'AROMATASE, AGENT ANTINÉOPLASIQUE","",""
"2231","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2232","01-04-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2233","01-04-04","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2234","01-04-04","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"2235","01-03-20","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) IN MEDICAL PATIENTS BEDRIDDEN DUE TO ACUTE CARDIAC INSUFFICIENCY, ACUTE RESPIRATORY FAILURE AND ACUTE RESPIRATORY INFECTIONS (EXCLUDING SEPTIC SHOCK)","INDICATION RÉVISÉE: PRÉVENTION DES THROMBOSES VEINEUSES PROFONDES (TVP) CHEZ LES PATIENTS ALITÉS EN RAISON D'UNE INSUFFISANCE CARDIAQUE AIGÜE, D'UNE INSUFFISACE RESPIRATOIRE AIGÜE ET D'INFECTIONS RESPIRATOIRES AIGÜES (EXCLUANT LE CHOC SEPTIQUE)","ANTICOAGULANT/ANTITHROMBOTIC AGENT (LOW MOLECULAR WEIGHT HEPARIN FRAGMENT)","ANTICOAGULANT/ANTITHROMBOTIQUE (FRAGMENT D'HÉPARINE DE BAS POIDS MOLÉCULAIRE)","",""
"2236","01-02-23","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN-ESTROGEN","ASSOCIATION OESTRO-PROGESTATIVE","",""
"2237","01-01-25","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2238","01-02-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN PREVENTION OF OSTEOPOROSIS","NOUVLLE INDICATION:  USAGE DANS LA PRÉVENTION DE L'OSTÉOPOROSE","ESTROGEN","OESTROGÈNE","",""
"2239","01-02-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ESTROGEN","OESTROGÈNE","",""
"2240","01-01-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2241","01-12-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2242","01-12-13","DR REDDYS LABORATORIES INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","MANUFACTURER NAME CHANGE","MODIFICATION DU NOM DU FABRICANT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2243","01-12-10","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2244","01-12-10","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2245","01-12-10","PREMPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2246","01-12-04","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK FROSST CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH SAFETY UPDATE","MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2247","01-12-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINNIQUES H2","",""
"2248","01-11-30","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINNIQUES H2","",""
"2249","01-11-30","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISAMINIQUES H2","",""
"2250","01-11-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF SINUS PAIN AND PRESSURE ASSOCIATED WITH ALLERGIC RHINITIS","NOUVELLE INDICATION: GESTION DE LA DOULEUR ET PRESSION SINUSALES RELIÉS À LA RHINITE ALLERGIQUE","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"2251","01-11-16","REDDY-CHEMINOR, INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2252","01-11-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IDARAC","SANOFI WINTHROP","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2253","01-11-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTI-SPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"2254","01-11-05","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2255","01-11-05","ORPHAN MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AN ANTIDOTE FOR METHANOL POISONING","NOUVELLE INDICATION: UN ANTIDOTE À L'EMPOISONNEMENT AU MÉTHANOL","SYNTHETIC ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL DÉSHYDROGÉNASE","",""
"2256","01-10-30","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN THE TREATMENT OF LOW-GRADE NON-HODGKIN'S LYMPHOMA (LG-NHL) IN PATIENTS WHO HAVE FAILED OTHER CONVENTIONAL TREATMENT","NOUVELLE INDICATION : COMME TRAITEMENT DU LYMPHOME PEU AVANCÉ NON-HODGKINIEN CHEZ LES PATIENTS RÉFRACTAIRES AUX TRAITEMENTS CONVENTIONNELS","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2257","01-10-12","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR VOIE NASALE","",""
"2258","01-10-09","DR REDDYS LABORATORIES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2259","01-10-09","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","GONADOTROPHIN","GONADOTROPHINE","",""
"2260","01-10-04","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF A NEW CLAIM","AJOUT D'UNE NOUVELLE INDICATION","GONADOTROPHIN","GONADOTROPHINE","",""
"2261","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE","",""
"2262","01-07-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODECATE","SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"2263","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2264","01-07-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANSION OF THE INDICATION FROM MANAGEMENT OF CHRONIC CANCER PAIN TO CHRONIC PAIN","ÉLARGISSEMENT DE L'INDICATION DE GESTION DE LA DOULEUR CHRONIQUE RELIÉE AU CANCER À LA DOULEUR CHRONIQUE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2265","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"2266","01-07-18","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2267","01-07-06","REDDY-CHEMINOR, INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"2268","01-06-22","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC-ANABOLIC STEROID","ANDROGÈNE, STÉROÏDE ANABOLISANT","",""
"2269","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2270","01-05-24","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL OPHTHALMIC ANTIBIOTIC","ANTIBIOTIQUE","",""
"2271","01-05-11","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MULTIPLE DOSE PRESENTATION","NOUVELLE PRESENTATION À DOSE MULTIPLE","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"2272","01-04-26","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2273","01-04-17","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MILD TO MODERATE ACTUTE EXACERBATIONS OF ASTHMA IN CHILDREN 4-16 YEARS OF AGE. NEW DOSAGE FORM: NEBULES","NOUVELLE INDICATION : POUR LE TRAITEMENT DES EXACERBATIONS LÉGÈRES AIGUES DE L'ASTHME CHEZ LES ENFANTS DE 4 À 16 ANS. NOUVELLE FORME POSOLOGIQUE : NÉBULES","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE","",""
"2274","01-04-17","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIHYPERLIPIDEMIC AGENT","AGENT ANTIHYPOLIPIDÉMIANT","",""
"2275","01-04-02","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2276","01-03-29","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: PREVENTION OF NOCTURNAL SYMPTOMS ASSOCIATED WITH THE EVENING MEAL AND EXPECTED TO CAUSE SLEEP DISTURBANCE","NOUVELLE INDICATION: PRÉVENTION DES SYMPTÔMES NOCTURNES ASSOCIÉS AU REPAS DU SOIR ET DE NATURE À CAUSER DES TROUBLES DU SOMMEIL","H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2277","01-03-29","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","FOURNIER PHARMA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2278","01-02-22","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"2279","01-01-31","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIDEX OINTMENT, TOPSYN GEL","SYNTEX CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2280","01-01-31","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2281","01-01-25","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2282","01-01-24","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ALLEGRA","MODIFICATION DU NOM DU PRODUIT DE ALLEGRA","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2283","01-01-18","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2284","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2285","01-01-12","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN: ON-DEMAND (PRN) DOSIND IN PATIENTS 12 YEARS OF AGE AND OLDER","NOUVEAU SCHÉMA POSOLOGIQUE: ADMINISTRATION SUR DEMANDE (PRN) CHEZ LES PATIENTS DE 12 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2286","01-01-11","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TREATMENT AND PREVENTION OF SYMPTOMS OF REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE INLCUDING ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER. NEW INDICATION: TREATMENT AND PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 6 YEARS OF AGE AND OLDER.","INDICATION RÉVISÉE : TRAITEMENT ET PRÉVENTION DE MALADIE OBSTRUCTIVE RÉVERSIBLE DES VOIES RESPIRATOIRES COMPRENANT L'ASTHME CHEZ LES PATIENTS DE 6 ANS ET PLUS.  NOUVELLE INDICATION : TRAITEMENT ET PRÉVENTION DE LA BRONCHOCONSTRICTION DÉCLENCHÉE PAR L'EXERCICE CHEZ LES PATIENTS DE 6 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2287","01-01-11","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER S.C.A.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2288","01-01-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: LONG-TERM TREATMENT OF ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","NOUVELLE INDICATION : SOINS À LONG TERME DES ADULTES ATTEINTS DE BRONCHO-PNEUMONIE CHRONIQUE OBSTRUCTIVE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2289","01-09-21","TEVA PHARMACEUTICALS USA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO PROVIDE FOR ADDITIONAL WORDING UNDER CLINICAL STUDIES TO INCLUDE RESULTS FROM A MRI-MONITORED STUDY","FOURNIR L'AJOUT, SOUS ÉTUDES CLINIQUES, DES RÉSULTATS D'UNE ÉTUDE MESURÉE PAR IRM","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2290","01-09-21","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2291","01-08-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2292","01-07-31","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"2293","01-04-30","BIOMET ORTHOPEDICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2294","01-04-04","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN HEAD AND NECK","NOUVELLE INDICATION: POUR REHAUSSER LE CONTRASTE DANS LES EXAMENS IRM CHEZ L'ADULTE ET POUR AMÉLIORER LA DÉTECTION DES LÉSIONS DE LA TÊTE ET DU COU","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","PRODUIT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"2295","01-04-04","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2296","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2297","01-02-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"2298","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2299","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"2300","01-01-11","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","HYPERGLYCEMIC AGENT","AGENT HYPERGLYCÉMIANT","",""
"2301","01-01-09","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2302","01-12-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","INJECTABLE VACCINE","VACCIN INJECTABLE","",""
"2303","01-11-06","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2304","01-10-16","PRECISION PHARMA SERVICES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","POOLED BLOOD COMPONENT/DERIVATIVE","COMPSANTS DU SANG/PRODUITS DÉRIVÉE DU SANG","",""
"2305","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY CORTICOSTEROID FOAM","ANTI-INFLAMMATOIRE RECTAL","",""
"2306","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY FOAM","TRAITEMENT ANORECTAL","",""
"2307","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2308","01-07-19","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2309","01-07-19","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"2310","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTION BY HEPATITIS A VIRUS","AGETN D'IMMUNISATION ACTIVE CONTRE L'INFECTION PAR LE VIRUS DE L'HÉPATITE A","",""
"2311","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2312","01-06-14","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2313","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID/NSAID COMBINATION ANALGESIC","OPIOÏDES, ANALGÉSIQUE AINS","",""
"2314","01-04-06","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 80 ANTIGEN UNIT FORMULATION FOR PEDIATRIC USE","NOUVELLE FORMULATION DE 80 UNITÉS D'ANTIGÈNE POUR USAGE PÉDIATRIQUE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2315","01-03-29","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2316","01-03-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION (PRESERVATIVE-FREE)","NOUVELLE FORMULATION (SANS AGENTS DE CONSERVATION)","VACCINE FOR IMMUNIZATION","VACCIN","",""
"2317","01-02-01","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING PROCESS","MODIFICATION DU PROCESSUS DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2318","01-01-25","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY/ANTIMALARIAL","ANTI-INFLAMMATOIRE - ANTIPALUDÉEN","",""
"2319","01-01-24","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT CREAM","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2320","01-01-24","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT OINTMENT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2321","01-12-27","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","AUTRE SITE DE FABRICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"2322","01-12-21","BIOGEN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SUPPLIER FOR HSA AS EXCIPIENT","FOURNISSEUR ALTERNATIF DE ASH","IMMUNODULATOR","IMMUNODULATEUR","",""
"2323","01-12-17","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FACILITY CHANGES","MODIFICATION À L'EMPLACEMENT DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2324","01-12-17","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DELIVERY DEVICE","NOUVEAU SYSTÈME D'ADMINISTRATION","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"2325","01-11-23","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCEDURE","MODIFICATION DES PROCÉDURES DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2326","01-11-23","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCEDURE","MODIFICATION DES PROCÉDURES DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2327","01-11-14","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SUPPLIER FOR HSA USED AS EXCIPIENT IN MANUFACTURE OF BETASERON","FOURNISSEUR ADDITIONEL DE L'ASH UTILISÉE COMME EXCIPIENT DANS LA FABRICATION DE BETASERON","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2328","01-10-12","INTERMUNE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"2329","01-09-27","CENTOCOR INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER (ADDITIONAL INDICATION: RHEUMATOID ARTHRITIS)","MODULATEUR DES RÉACTIONS BIOLOGIQUES (INDICATION ADDITIONNELLE: RHUMATISME ARTICULAIRE)","",""
"2330","01-08-28","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA PHARMA INC.","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2331","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2332","01-09-20","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"2333","01-07-25","WATSON LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATINIC","HÉMATINIQUE","",""
"2334","01-07-18","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"2335","01-06-18","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANALGESI/ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2336","01-06-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT UDV","BOEHRINGER INGELHEIM INC.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2337","01-06-06","CENTOCOR INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"2338","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2339","01-05-29","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT UDV","BOEHRINGER INGELHEIM","CANADA","CANADA","1","NEW STRENGTH","NOUVEAU DOSAGE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2340","01-05-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2341","01-04-20","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRNCHODILATATEUR","",""
"2342","01-04-17","LUITPOLD PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATINIC","HÉMATINIQUE","",""
"2343","01-04-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ACCUTANE","MODIFICATION DU NOM DU PRODUIT DE ACCUTANE","NODULAR/INFLAMMATORY AND CONGLOBATE ACNE THERAPY","TRAITEMENT DE L'ACNÉ NODULAIRE/INFLAMMATOIRE ET DE L'ACNE CONGLOBATA","",""
"2344","01-02-28","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM INDICATION: FOR THE TREATMENT OF THE FOLLOWING SYSTEMIC FUNGAL INFECTIONS IN IMMUNOCOMPROMISED AND NON-IMMUNOCOMPROMISED PATIENTS: 1.BLASTOMYCOSIS 2.CHRONIC PULMONARY HISTOPLASMOSIS 3.INVASIVE AND NON-INVASIVE PULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY","NOUVELLE FORME POSOLOGIQUE INDICATION : POUR LE TRAITEMENT DES INFECTIONS FONGIQUES SYSTÉMIQUES SUIVANTES CHEZ LES INDIVIDUS IMMUNODÉPRIMÉS OU NON : 1. BLASTOMYCOSE 2. HISTOPLASMOSE PULMONAIRE CHRONIQUE 3. ASPERGILLOSE PULMONAIRE ENVAHISSANTE ET NON-ENVAHISSANTE CHEZ LES PERSONNES QUI PRÉSENTENT UNE INTOLÉRANCE OU QUI SONT RÉFRACTAIRES À UN TRAITEMENT À L'AMPHOTÉRICINE B","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2345","01-02-28","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVORIN AS FIRST-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER","NOUVELLE INDICATION:  POUR UTILISATION EN COMBINAISON AVEC 5-FLUOROURACILE ET LEUCOVORINE COMME THÉRAPIE DE PREMIÈRE LIGNE POUR LES PATIENTS SOUFFRANT D'UN CANCER MÉTASTATIQUE DU CÔLON OU DU RECTUM","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2346","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2347","01-02-08","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: CHEWABLE TABLET","NOUVELLE FORME POSOLGIQUE","ANALGESIC/ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2348","01-02-02","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"2349","01-01-30","R & D LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATINIC","HÉMATIQUE","",""
"2350","01-01-18","LABORATOIRE CHAUVIN S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"2351","01-01-18","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"2352","01-11-30","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL IM","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2353","01-06-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORM POSOLOGIQUE","NSAID ANALAGESIC AGENT","ANALGÉSIQUE AINS","",""
"2354","01-03-20","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2355","01-02-16","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"2356","01-01-24","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2357","01-01-24","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"2358","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PARENTERAL GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL PARENTÉRAL","",""
"2359","01-12-21","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2360","01-12-21","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2361","01-12-21","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2362","01-12-18","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET NOUVELLE FORME POSOLOGIQUE","HISTAMINE H1 RECEPTOR ANTAGONIST/SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"2363","01-12-06","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: HEALING OF NSAID-ASSOCIATED GASTRIC ULCER AND REDUCTION OF RISK OF NSAID-ASSOCIATED GASTRIC ULCER","NOUVELLES INDICATIONS : CICATRISATION DE L'ULCÈRE GASTRIQUE RELIÉ À L'USAGE DES AINS ET RÉDUCTION DU RISQUE D'ULCÈRE GASTRIQUE RELIÉ À L'USAGE DES AINS","K+, H+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2364","01-11-19","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTION IN FEBRIL, NEUTROPENIC PATIENTS, AND TREATMENT OF CRYPTOCOCCAL MENINGITIS IN IMMUNOCOMPROMISED PATIENTS","NOUVELLE INDICATION : TRAITEMENT EMPIRIQUE DES PATIENTS EN ÉTAT DE NEUTROPÉNIE ET DE FÉBRILITÉ ET TRAITEMENT DE LA MÉNINGITE À CRYPTOCOQUE CHEZ LES PATIENTS QUI PRÉSENTENT UN DÉFICIT IMMUNITAIRE","ANTIFUNGAL","ANTIFONGIQUE","",""
"2365","01-11-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRANDATE","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2366","01-10-12","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2367","01-10-12","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2368","01-10-12","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLES CONCENTRATION ET FORME POSOLOGIQUE","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE","",""
"2369","01-08-31","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TWO ALTERNATIVE DOSING SCHEDULES AND A SEROLOGIC CORRELATE OF PROTECTION","DEUX NOUVEAUX PLANS POSOLOGIQUES ET UNE CORRÉLATION SÉROLOGIQUE PROTECTRICE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2370","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2371","01-07-20","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2372","01-07-18","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2373","01-07-06","D.C. LABS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"2374","01-06-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2375","01-06-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2376","01-05-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FIRST-LINE THERAPY IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER","NOUVELLE INDICATION: THÉRAPIE DE PREMIÈRE LIGNE CHEZ LA FEMME ATTEINTE DE CANCER AVANCÉ DU SEIN ET EN ÉTAT POSTMÉNOPAUSIQUE","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOUR AGENT","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; ANTINÉOPLASIQUE","",""
"2377","01-04-30","SIGMA-TAU PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS","NOUVELLE INDICATION: POUR LA PRÉVENTION ET LE TRAITEMENT DU DÉFICIT EN CARNITINE CHEZ LES PATIENTS EN INSUFFISANCE RÉNALE TERMINALE QUI REÇOIVENT DES TRAITEMENTS DE DIALYSE","REPLENISHER (CARNITINE)","AGENT DE RECHARGE EN CARNITINE","",""
"2378","01-04-04","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA PRÉPARATION","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"2379","01-04-02","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2380","01-03-09","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Human Immunodeficiency Virus (HIV) Protease Inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"2381","01-03-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRANDATE","ROBERTS PHARMACEUTICAL INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2382","01-02-23","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED LABELLING: REMOVAL OF DUAL THERAPY IN THE TREATMENT OF H. PYLORI INFECTION","ÉTIQUETTE RÉVISÉE: RETRAIT DE LA BITHÉRAPIE DANS LE TRAITEMENT DE L'INFECTION À H.PYLORI","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2383","01-02-22","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2384","01-02-15","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW METHOD OF ADMINISTRATION: INGESTION OF INTACT GRANULES","NOUVELLE MÉTHODE D'ADMINISTRATION: INGESTION DE GRANULES ENTIERS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2385","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2 ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2","",""
"2386","01-02-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2387","01-01-25","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATIVAN","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"2388","01-01-24","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2389","01-01-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2390","01-05-07","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: CHEWABLE/DISPERSIBLE TABLET","NOUVEAU DOSAGE; COMPRIMÉ À MÂCHER/DISPERSABLE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2391","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2392","01-12-31","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"2393","01-12-21","BAXTER CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"2394","01-12-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL VIRAL BULK MANUFACTURING FACILITY","NOUVEL ÉTABLISSEMENT DE FABRICATION EN VRAC DU VIRUS","PROPHYLACTIC VACCINE","VACCIN PROPHYLACTIQUE","",""
"2395","01-12-18","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2396","01-12-06","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","UROMITEXAN","BRISTO-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","UROPROTECTOR","AGENT UROPROTECTEUR","",""
"2397","01-12-05","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2398","01-12-05","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2399","01-11-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE/VASODILATOR","AGENT INOTROPE, VASODILATATEUR","",""
"2400","01-11-13","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE FREDERICK","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2401","01-11-06","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE/VASODILATOR","AGENT INOTROPE, VASODILATATEUR","",""
"2402","01-11-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","PROGESTIN","PROGESTATIF","",""
"2403","01-10-24","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN SUPPLEMENT FOR TOTAL PARENTERAL NUTRITION","SUPPLÉMENT VITAMINIQUE POUR NUTRITION PARENTÉRALE TOTALE","",""
"2404","01-10-24","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF HSA","SOURCE D'ALBUMINE (HUMAINE) ALTERNATIVE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2405","01-10-24","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"2406","01-10-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","B-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"2407","01-10-16","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"2408","01-10-12","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTION BY MEASLES, MUMPS AND RUBELLA","AGENT D'IMMUNISATION ACTIVE","",""
"2409","01-10-09","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE/VASODILATOR","AGENT INOTROPE/VASODILATATEUR","",""
"2410","01-10-01","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH-AYERST","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2411","01-09-21","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AND ANTIPROTOZOAL AGENT","ANTIBACTÉRIEN ET ANTIPROTOZOAIRE","",""
"2412","01-09-19","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST MENINGOCOCCAL MENINGITIS CAUSED BY GROUPS A AND C","AGENT D'IMMUNISATION ACTIVE CONTRE LA MÉNINGITE À MÉNINGOCOQUE CAUSÉE PAR LES GROUPES A ET C","",""
"2413","01-08-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LARIAM","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIMALARIAL","ANTIPALUDIQUE","",""
"2414","01-08-28","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC (ALKYLATING) AGENT","ANTINÉOPLASIQUE","",""
"2415","01-08-27","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2416","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"2417","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"2418","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"2419","01-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2420","01-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2421","01-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2422","01-07-30","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF OPIOID DEPENDENCE","TRAITEMENT DE LA DÉPENDANCE AUX OPIACÉS","",""
"2423","01-07-30","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF THE INDICATION TREATMENT OF OPIOID DEPENDENCE","RETRAIT DE L'INDICATION TRAITEMENT DE LA DÉPENDENCE AUX OPIACÉS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2424","01-07-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"2425","01-07-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHYROID AGENT","ANTITHYROÏDIEN","",""
"2426","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2427","01-07-18","WHITEHALL-ROBINS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"2428","01-07-11","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2429","01-06-26","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"2430","01-06-22","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE, AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"2431","01-06-22","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID - ANTIBIOTIC","GLUCOCORTICOÏDE, ANTIBIOTIQUE","",""
"2432","01-06-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2433","01-06-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2434","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID ACNE COMPOUND","TRAITEMENT DE L'ACNÉ","",""
"2435","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"2436","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"2437","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID WITH LOCAL ANAESTHETIC","GLUCOCORTICOÏDE AVEC ANESTHÉSIQUE LOCAL","",""
"2438","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"2439","01-05-18","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2440","01-04-24","CHIRON S.P.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2441","01-04-20","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT - VACCINE FOR IMMUNIZATION AGAINST MEASLES, MUMPS AND RUBELLA","AGENT D'IMMUNISATION ACTIF - VACCIN POUR L'IMMUNISATION CONTRE LA ROUGEOLE, LES OREILLONS ET LA RUBÉOLE","",""
"2442","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUTICORTICOID","GLUCOCORTICOÏDE","",""
"2443","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2444","01-04-09","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","VACCINE FOR IMMUNIZATION AGAINTS MUMPS","PROPHYLAXIE CONTRE LES OREILLONS","",""
"2445","01-03-20","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REGLAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIEMETIC, MODIFIER OF UPPER GASTROINTESTINAL TRACT MOTILITY","ANTIÉMÉTIQUE, MODIFICATEUR DE LA MOTILITÉ DE VOIES DIGESTIVES SUPÉRIEURES","",""
"2446","01-03-09","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH AND NEW INDICATION: FOR USE IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR THE PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA","NOUVEAU DOSAGE INDICATION RÉVISÉE: CHEZ LES ADULTES ET LES ENFANTS DE 2 ANS ET PLUS POUR LA PRÉVENTION ET LE TRAITEMENT À LONG TERME DE L'ASTHME","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"2447","01-03-02","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"2448","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"2449","01-02-01","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2450","01-01-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","Premedicant, Sedative, Anesthetic Agent","Prémédication, Sédatif, Anesthésique","",""
"2451","01-01-24","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHYROID AGENT","ANTITHYROÏDIEN","",""
"2452","01-01-24","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","ROCHE CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2453","01-01-23","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","URINARY ANTIBACTERIAL","ANTI-INFECTIEUX DES VOIES URINAIRES","",""
"2454","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"2455","01-01-17","WESTWOOD-SQUIBB, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF SOLAR LENTIGINES AND RELATED HYPERPIGMENTATED LESIONS","AGENT POUR LE TRAITEMENT DES LENTIGINES SOLAIRES ET LÉSIONS CONNEXES DE PIGMENTATION EXCESSIVE","",""
"2456","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2457","01-01-09","LABORATOIRE RIVA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","RX TO OTC","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2458","01-01-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2459","01-01-05","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","ROCHE CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2460","01-12-28","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN RELEASING HORMONE (GNRH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (GNRH)","",""
"2461","01-12-04","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2462","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE DES OPIOÏDES","",""
"2463","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANTAGONIST","ANTAGONISTE DES NARCOTIQUES","",""
"2464","01-11-22","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"2465","01-11-22","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"2466","01-10-26","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"2467","01-10-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2468","01-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2469","01-08-27","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2470","01-08-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2471","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"2472","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2473","01-07-19","METRO PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"2474","01-06-04","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"2475","01-05-08","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"2476","01-04-30","BIOENHANCE MEDICINES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2477","01-04-26","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2478","01-04-20","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"2479","01-03-13","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2480","01-03-09","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NITROLINGUAL SPRAY","RHÔNE-POULENC RORER INC.","CANADA","CANADA","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"2481","01-03-09","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTI-INFLAMMATORY, ANALGESIC, ANTI-PYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2482","01-02-23","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ENTERIC COATED TABLET","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉ GASTRO-RÉSISTANT","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2483","01-02-13","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL - ANTIHYPERTENSIVE AGENT","ANTIANGINEUX - ANTIHYPERTENSEUR","",""
"2484","01-02-06","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT - ANTITHROMBOTIC","ANTICOAGULANT - ANTITHROMBOTIQUE","",""
"2485","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2486","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROPROGESTATIVE","",""
"2487","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2488","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTATIONAL AGENT","AGENT PROGESTATIF","",""
"2489","01-01-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2490","01-10-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2491","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT3 RECEPTOR ANTAGONIST","ANTIÉMÉTIQUE","",""
"2492","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"2493","01-05-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DAYPRO","SEARLE CANADA","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2494","01-05-24","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOXIN","ORTHO-MCNEIL INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2495","01-05-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DAYPRO","SEARLE CANADA","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2496","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"2497","01-01-30","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2498","01-01-30","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR-EXPECTORANT","BRONCHODILATATEUR-EXPECTORANT","",""
"2499","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2500","01-03-02","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: DYSPEPSIA","NOUVELLE INDICATION: DYSPEPSIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2501","01-12-17","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCEDURE","MODIFICATION DANS LA MÉTHODE DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2502","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","EXPANSEUR DU VOLUME PLASMATIQUE","",""
"2503","01-11-21","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASMODIC AGENT","ANTIPARKINSONIEN","",""
"2504","01-11-14","PRECISION PHARMA SERVICES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING METHOD","MODIFICATION DE LA MÉTHODE DE FABRICATION","PLASMA COMPONENT/DERIVATIVE","COMPOSANTS DU SANG/PRODUITS DÉRIVÉS DU SANG","",""
"2505","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL PEDICULICIDE AND OVICIDE","AGENT PÉDICULICIDE ET OVICIDE TOPIQUE","",""
"2506","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL SCABICIDE","SCABICIDE TOPIQUE","",""
"2507","01-10-12","CHIESI FARMACEUTICI, S.P.A","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (PORCINE)","SURFACTANT PULMONAIRE (PROCINE)","",""
"2508","01-10-02","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA INC.","CANADA","CANADA","1","","","INTRAVENOUS EMULSION - ANAESTHETIC - SEDATIVE","ÉMULSION I.V. - ANESTHÉSIQUE - SÉDATIF","",""
"2509","01-10-01","BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2510","01-08-31","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)","NOUVELLE INDICATION : TRAITEMENT D'UN TROUBLE D'ANXIÉTÉ GÉNÉRALISÉ","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT SOCIAL PHOBI (SOCIAL ANXIETY DISORDER) THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIAL","",""
"2511","01-08-31","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLSIME OSSEUX","",""
"2512","01-08-27","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2513","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2514","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL SCABICIDE","SCABICIDE TOPIQUE","",""
"2515","01-08-22","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"2516","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL","ANTIMALARIQUE","",""
"2517","01-08-01","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN MILD TO MODERATE CONGESTIVE HEART FAILURE","NOUVELLE INDICATION: UTILISATION DANS LE CAS DE DÉFAILLANCE CARDIAQUE CONGESTIVE LÉGÈRE À MODÉRÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2518","01-07-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINOMIMETIC AGENT","AGENT CHOLINOMIMÉTIQUE","",""
"2519","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, TRAITEMENT DE LA PHOBIE SOCIALE","",""
"2520","01-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2521","01-06-07","BIOVAIL LABORATORIES INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRENTAL","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"2522","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"2523","01-05-07","BYK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2524","01-04-30","BIOENHANCE MEDICINES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2525","01-04-20","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2526","01-04-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"2527","01-04-02","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL","ANTIPALUDÉEN","",""
"2528","01-03-09","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2529","01-03-02","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SYMPTOMATIC GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), SUCH AS, ACID REGURGITATION AND HEARTBURN","NOUVELLE INDICATION: TRAITEMENT DES SYMPTÔMES ASSOCIÉS AU REFLUX GASTRO-OESOPHAGIEN TELS QUE RÉGURGITATION ACIDE ET PYROSIS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2530","01-02-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2531","01-02-08","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2532","01-02-01","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2533","01-02-01","IPSEN BIOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILIQUE","",""
"2534","01-02-01","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PEDICULICIDE - OVICIDE","AGENT PÉDICULICIDE - OVICIDE","",""
"2535","01-01-26","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2536","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2537","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2538","01-01-18","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2539","01-01-18","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ADVANCED OVARIAN CANCER FOLLOWING FAILURE OF STANDARD FIRST-LINE THERAPY","NOUVELLE INDICATION: TRAITEMENT DU CANCER OVARIEN AVANCÉ SUITE À L'ÉCHEC DU TRAITEMENT NORMAL DE PREMIÈRE LIGNE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2540","01-06-20","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"2541","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"2542","01-01-09","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"2543","01-10-19","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT AND PREVENTION OF GULCOCORTICOID-INDUCED OSTEOPOROSIS","NOUVELLE INDICATION: LE TRAITEMENT ET LA PRÉVENTION DE L'OSTÉOPOROSE PROVOQUÉE PAR L'USAGE DES GLUCOCORTICOÏDES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2544","01-10-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2545","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2546","01-07-25","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO PRODUCT MONOGRAPH","MODIFICATIONS DE LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2547","01-07-19","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DE RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2548","01-07-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS","NOUVELLE INDICATION : GESTION DES PATIENTS À RISQUE ÉLEVÉ D'ACCIDENTS CARDIOVASCULAIRES","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2549","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT; INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT INSULINOSENSIBILISATEUR","",""
"2550","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT, DOPAMINE AGONIST","ANTIPARKINSONIEN, AGONISTE DOPAMINERGIQUE","",""
"2551","01-06-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","ANTIPARKINSONIEN, AGONISTE DOPAMINERGIQUE","",""
"2552","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT - ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"2553","01-05-29","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, MODIFIED MANUFACTURING PROCESS, AND REVISION TO DRUG PRODUCT SPECIFICATIONS AND METHODS","MODIFICATION APPORTÉE À LA FORMULATION, PROCESSUS DE FABRICATION MODIFIÉ ET RÉVISION DES SPÉCIFICATIONS ET MÉTHODES DU PRODUIT MÉDICAMENTEUX","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"2554","01-05-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2555","01-04-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"2556","01-03-06","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM PEPTIC RELIEF","MODIFICATION DU NOM DU PRODUIT DE PEPTIC RELIEF","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2557","01-02-15","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2558","01-02-13","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS","NOUVELLE INDICATION: GESTION DES PATIENTS À RISQUE ACCRÛ D'INCIDENTS CARDIOVASCULAIRES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEURS DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2559","01-01-31","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2560","01-01-17","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2561","01-01-11","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2562","01-01-08","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2563","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST: MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 ANTI-MIGRAINEUX","",""
"2564","01-08-27","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2565","01-08-28","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2566","01-12-21","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: INHALATION AEROSOL","NOUVELLE FORME POSOLOGIQUE","BRONCHOLDILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"2567","01-12-21","TOBA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2568","01-11-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION: FOR USE OF ADJUNCTIVE BORNCHODILATOR TREATMENT FOR  PATIENTS WHO HAVE INADEQUATE RELIEF OF SYMPTOMS WITH SHORT-ACTING BRONCHODILATORS; PRODUCT MONOGRAPH REVISIONS","RETRAIT DE L'INDICATION: COMME TRAITEMENT BORNCHODILATATEUR D'APPOINT CHEZ LE PATIENTS QUI N'OBTIENNENT PAS UN SOULAGEMENT ADÉQUAT DE LEURS SYMPTÔMES AVEC LES BRONCHODILATATEURS À COURTE DURÉE D'ACTION; RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (RÉCEPTEURS BETA2-ADRÉNERGIQUES)","",""
"2569","01-10-26","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES B2-ADRÉNERGIQUES)","",""
"2570","01-08-31","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE FORME POSOLOGIQUE ET CONCENTRATIONS","PHOSPHATE BINDER","AGENT D'AGGLUTINATION DU PHOSPHATE","",""
"2571","01-08-27","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2572","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES)","",""
"2573","01-08-22","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST WITH A DIURETIC","ANTAGONISTE DE L'ALDOSTÉRONE, DIURÉTIQUE","",""
"2574","01-08-17","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST","ANTAGONISTE DE L'ALDOSTÉRONE","",""
"2575","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2576","01-07-27","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"2577","01-07-26","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUFENTA","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC/ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE OPIOÏDE, ADJUVANT ANESTHÉSIQUE","",""
"2578","01-07-20","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2579","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2580","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR AND CORTICOSTEROID FOR INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"2581","01-06-22","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS; NEW ROUTE; NEW INDICATION - THERAPEUTIC USE OF NEW STRENGTHS AND ROUTE FOR TREATMENT OF IDIOPATHIC GROWTH HORMONE DEFICIENCY IN CHILDREN WITH GROWTH FAILURE","NOUVELLES CONCENTRATIONS; NOUVELLE VOIE D'ADMINISTRATION; NOUVELLE INDICATION - USAGE THÉRAPEUTIQUE DE NOUVELLES FORCES CONCENTRATIONS ET VOIE D'ADMINISTRATION POUR LE TRAITEMENT DE L'INSUFFISANCE IDIOPATHIQUE DE L'HORMONE DE CROISSANCE CHEZ LES ENFANTS QUI PRÉSENTENT DES TROUBLES DE CROISSANCE","GROWTH HORMONE RELEASING HORMONE - THERAPEUTIC AGENT","HORMONE LIBÉRATRICE D'HORMONE DE CROISSANCE, AGENT THÉRAPEUTIQUE","",""
"2582","01-06-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"2583","01-06-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA INC.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2584","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT/ANTIOBESITY AGENT","ANOREXIANT, ANTIOBÉSITÉ","",""
"2585","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBACTERIAL AGENT","ANTIBACTÉRIEN TOPIQUE","",""
"2586","01-05-11","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVEAU DOSAGE","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2587","01-05-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME","CANADA","CANADA","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2588","01-04-20","BIOENHANCE MEDICINES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2589","01-04-04","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: GROWTH FAILURE IN CHILDREN DUE TO CHRONIC RENAL FAILURE","NOUVELLE INDICATION : LE TRAITEMENT DU RETARD DE CROISSANCE CHEZ LES ENFANTS ATTRIBUABLE À UNE INSUFFISANCE RÉNALE CHRONIQUE","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"2590","01-03-29","COLGATE-PALMOLIVE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM COLGATE SENSATION FRESH/COOL MINT TOOTHPASTE","MODIFICATION DU NOM DU PRODUIT DE COLGATE SENSATION FRESH/COOL MINT TOOTHPASTE","ANTICARIES TOOTHPASTE","DENTIFRICE ANTICARIES","",""
"2591","01-02-13","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM FORTOVASE","MODIFICATION DU NOM DU PRODUIT DE FORTOVASE","ANTIRETROVIRAL - HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH - ANTIRÉTROVIRAL","",""
"2592","01-01-30","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2593","01-01-25","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION","INDICATION RÉVISÉE: POUR ADMINISTRATION CONCOMITANTE À D'AUTRES AGENTS ANTIRÉTROVIRAUX POUR LE TRAITEMENT DE L'INFECTION AU VIH-1","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2594","01-01-24","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CATION-EXCHANGE RESIN","RÉSINE POUR ÉCHANGE CATONIQUE","",""
"2595","01-01-18","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2596","01-01-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"2597","01-01-05","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","AGENT IMMUNODÉPRESSEUR","",""
"2598","01-01-30","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION FOR GALLSTONE DISSOLUTION","RETRAIT DE L'INDICATION POUR LA DISSOLUTION DU CALCUL BILIAIRE","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"2599","01-12-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT MERCK PHARMA","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"2600","01-12-04","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"2601","01-12-20","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","HYPNOTIC","HYPNOTIQUE","",""
"2602","01-11-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO UPDATE THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","5-HT1 RECEPTOR AGONIST MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 ANTIMIGRAINEUX","",""
"2603","01-08-14","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2604","01-02-15","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER","CANADA","CANADA","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC","HYPNOTIQUE","",""
"2605","01-11-19","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"2606","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA INC.","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEURO-MUSCULAIRE NON DÉPOLARISANT","",""
"2607","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2608","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"2609","01-07-25","QLT INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENSION OF THE INDICATION: TO INCLUDE THE TREATMENT OF PATHOLOGIC MYOPIA IN PATIENTS WITH PREDOMINANTLY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION (CNV)","ÉLARGISSEMENT DE L'INDICATION : POUR INCLURE LE TRAITEMENT DE LA MYOPIE PATHOLOGIQUE CHEZ LES PATIENTS QUI PRÉSENTENT UNE NÉOVASCULARISATION CHOROÏDIENNE SUBFOVÉALE","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION AND PATHOLOGIC MYOPIA","AGENT PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGEET POUR LA MYOPIE PATHOLOGIQUE","",""
"2610","01-06-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"2611","01-06-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL/ANTIARRHYTHMIC/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIARYTHMIQUE, ANTIHYPERTENSEUR","",""
"2612","01-05-18","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2613","01-04-17","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED FORMULATION","FORMULATION RÉVISÉE","ANTIANGINAL/ANTIHYPERTENSIVE/ANTIARRHYTHMIC AGENT","ANTIANGINEUX/ANTIHYPERTENSEUR/ANTIARHYTHMIQUE","",""
"2614","01-03-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPGRADES TO THE PRODUCTION PROCESS","MISE À JOUR AU PROCESSUS DE PRODUCTION","ACTIVE IMMUNIZING AGENT AGAINST VARICELLA","AGENT D'IMMUNISATION ACTIVE","",""
"2615","01-02-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR - ANTIGANGINEUX","",""
"2616","01-02-06","ANTHRA PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FORM VALSTAR","MODIFICATION DU NOM DU PRODUIT DE VALSTAR","CYTOTOXIC ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE CYTOTOXIQUE","",""
"2617","01-01-18","CANGENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2618","01-12-28","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2619","01-11-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","SYNTEX INC. (HOFFMANN-LA ROCHE LTD.)","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION PLAQUETTAIRE","",""
"2620","01-11-09","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY - PROSTAGLANDIN F2 ANALOGUE","TRAITEMENT DE LA PRESSION INTRAOCULAIRE ÉLEVÉE - PROSTAGLANDINE F2 ANALOGUE","",""
"2621","01-10-23","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","ANTICHOLINERGIC  - ANTISPASMODIC AGENT","ANTICHOINERGIQUE - ANTISPASMODIQUE","",""
"2622","01-10-17","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"2623","01-10-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2624","01-09-06","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"2625","01-08-31","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2626","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2627","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE BETA-LACTAMASES","",""
"2629","01-08-17","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","TETANUS VACCINE","VACCIN CONTRE LE TÉTANOS","",""
"2630","01-08-15","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER/DIURETIC","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II, DIURÉTIQUE","",""
"2631","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"2632","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2633","01-08-07","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC ACID","AGENT ANTIFIBRINOLYTIQUE","",""
"2634","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2635","01-07-31","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","COMPATIBILITY OF AGGRASTAT WITH INTRAVENOUS MEDICATION WHICH MAY OR MAY NOT BE CO-ADMINISTERED","COMPATIBILITÉ D'AGGRASTAT AVEC UNE MÉDICATION INTRAVEINEUSE QUI PEUT OU NE PEUT ÊTRE ADMINISTRÉ CONJOINTEMENT","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"2636","01-06-25","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL IMMUNOMODULATOR","IMMUNOSUPPRESSEUR","",""
"2637","01-07-11","ORTHO DERMATOLOGICAL, DIVISION OF JOHNSON & JOHNSON INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"2638","01-06-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2639","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2640","01-05-30","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-PSORIASIS AGENT","ANTIPSORIASIQUE","",""
"2641","01-05-24","DEBIO RECHERCHE PHARMACEUTIQUE SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LUTEINIZING HORMONE RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LA LUTÉINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"2642","01-03-29","DEBIO RECHERCHE PHARMACEUTIQUE SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MANAGEMENT AND RELIEF OF CHRONIC PAIN ASSOCIATED WITH ENDOMETRIOSIS","NOUVELLE INDICATION: POUR LA GESTION ET LE SOULAGEMENT DE LA DOULEUR CHRONIGUQ RELIÉE À L'ENDOMÉTRIOSE","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE  DE LA LUTÉINOSTIMULINE (ANALOGUEDE LA LH-RH)","",""
"2643","01-05-11","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2644","01-05-07","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","ROCHE CANADA INC.","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2645","01-04-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT/BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR/TRAITEMENT SYMPTOMATIQUE DEL'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2646","01-04-06","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT AND FOLIC ACID DERIVATIVE","ANTINÉOPLASIQUE ET DÉRIVÉ D'ACIDE FOLIQUE","",""
"2647","01-04-04","CHIRON CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RESPIRATORY ANTIBIOTIC","ANTIBIOTIQUE RESPIRATOIRE","",""
"2648","01-03-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC AGENT","HYPNOTIQUE","",""
"2649","01-03-19","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","ROCHE CANADA LIMITED","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2650","01-03-09","THERAMED CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIVIRAL AGENT","ANTIVIRAL TOPIQUE","",""
"2651","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT/BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR - TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2652","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","ROCHE CANADA INC.","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2653","01-02-16","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON INC.","CANADA","CANADA","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2654","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"2655","01-01-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE","",""
"2656","01-01-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE","",""
"2657","01-01-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COTICOSTEROID","CORTICOSTÉROÏDE","",""
"2658","01-01-08","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATIONS","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2659","98-12-04","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2660","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2661","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2662","98-11-12","B. BRAUN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","3% AMINO ACID AND 3% GLYCERIN INJECTION WITH ELECTROLYTES","3% ACIDES AMINÉS ET 3% INJECTION DE GLYCÉRINE AVEC ÉLECTROLYTES","",""
"2663","98-11-09","B. BRAUN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"2664","98-11-06","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN BATCH SIZE AND CHANGES IN PRODUCT TESTING","MODIFICATION À LA GRANDEUR DE LÔT ET AUX MÉTHODES D'ANALYSE POUR LE PRODUIT","IMMUNOMODULATING AGENT","AGENT D'IMMUNOMODULATEUR","",""
"2665","98-11-01","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN","NOUVELLE INDICATION :  TRAITEMENT ET PRÉCAUTIONS DE L'ENDUIT DE GLUCOCORTICOÏDE OSTÉOPOROSE POUR HOMMES ET FEMMES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2666","98-11-01","B. BRAUN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"2667","98-10-28","CENTOCOR","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION: ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION AND STABILIZATION OF UNSTABLE ANGINA PATIENTS","NOUVELLE INDICATION : AGENT ADJOINT À L'INTERVENTION CORONAIRE PERCUTANÉE ET POUR LA STABILISATION DES PATIENTS AVEC L'ANGINE INSTABLE","ANTIPLATELET ANTIBODY","ANTICORPS ANTIPLAQUETTE","",""
"2668","98-10-28","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTRO-INTESTINALES INFÉRIEURES","",""
"2669","98-10-13","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN, NEW STRENGTH","NOUVEAU SCHÉMA POSOLOGIQUE, NOUVELLES CONCENTRATIONS","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE - INHIBITEUR DE BETA-LACTAMASES","",""
"2670","98-10-07","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"2671","98-08-13","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2672","98-08-06","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"2673","98-08-06","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF RELAPSE OF CROHN'S DISEASE IN PATIENTS FOLLOWING BOWEL RESECTION","NOUVELLE INDICATION : POUR LA PRÉVENTION DES RECHUTES DE LA MALADIE DE CROHN CHEZ LES PERSONNES AYANT SUBI UNE RÉSECTION INTESTINALE","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO INTESTINAL INFÉRIEUR","",""
"2674","98-08-06","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"2675","98-07-30","TAP PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC H+, K+-ATPASE","ANTIBIOTIQUE H+, K+-ATPASE","",""
"2676","98-07-30","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2677","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR/ANTIANGINEUX","",""
"2678","98-07-14","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2679","98-07-13","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2680","98-07-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL, ANTIPARKINSONIAN","ANTIVIRAL, ANTIPARKINSONIEN","",""
"2681","98-07-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTIANGINAL","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2682","98-06-22","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL AGENT","ANTIMALARIAL","",""
"2683","98-06-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2684","98-06-01","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2685","98-06-01","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"2686","98-05-27","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2687","98-05-11","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"2690","98-04-15","OSTERREICHISCHES INSTITUT","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"2691","98-04-06","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2692","98-03-25","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","CHANGE IN PRODUCT NAME AND IN MANUFACTURING","MODIFICATION DU NOM ET DE LA MÉTHODE DE FABRICATION","ANTICOAGULANT","ANTICOAGULANT","",""
"2693","98-03-24","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE TO DOSAGE REGIMEN","MODIFICATION DU SCHÉMA POSOLOGIQUE","ORAL ANTIDIABETIC AGENT","ANTIDIABÉTIQUE ORAL","",""
"2694","98-03-23","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"2695","98-03-04","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2696","98-03-04","FUJISAWA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2697","98-03-04","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2698","98-02-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"2699","98-02-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"2700","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"2701","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2702","98-01-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2703","98-12-30","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","WOUND HEALING GROWTH FACTOR","AGENT CURATIF POUR LES BLESSURES","",""
"2704","98-12-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO WELLCOME","CANADA","CANADA","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR L'USAGE NASAL","",""
"2705","98-12-04","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2706","98-11-16","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE-ANTISPASMODIQUE","",""
"2707","98-11-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMACEUTICALS","CANADA","CANADA","1","","","ORAL RINSE AND GARGLE","RINSE BOUCHE ET GARGARISME","",""
"2708","98-11-03","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2710","98-10-23","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRA-OCULAIRE","",""
"2711","98-10-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO-WELLCOME","CANADA","CANADA","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASALE","",""
"2712","98-10-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID AND ANTIBIOTIC","CORTICOSTÉROÏDE - ANTIBIOTIQUE TOPIQUE","",""
"2713","98-10-06","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID AND ANTIBIOTIC","CORTICOSTÉROÏDE - ANTIBIOTIQUE TOPIQUE","",""
"2714","98-09-25","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMACEUTICALS","CANADA","CANADA","1","","","LOCALLY ACTING ANALGESIC AGENT","ANALGÉSIQUE À ACTION LOCALE","",""
"2715","98-08-21","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR - GROWTH HORMONE SUPPRESSANT IN ACROMEGALY - ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"2716","98-08-13","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO WELLCOME","CANADA","CANADA","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"2717","98-08-13","PENTAPHARM LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2718","98-07-30","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HOMOCYSTEINE AGENT","AGENT ANTIHOMOCYSTIQUE","",""
"2719","98-07-30","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGLAUCOMA AGENT","AGENT POUR LE TRAITEMENT DU GLAUCOME","",""
"2720","98-07-30","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"2721","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT ANTISPASTIC AGENT","RELAXANT MUSCULAIRE ET AGENT ANTISPASTIQUE","",""
"2722","98-07-27","FTP PHARMACAL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYER SQUIBB LTD.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2723","98-06-19","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR - GROWTH HORMONE SUPPRESSANT IN ACROMEGALY - ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT UTILISÉ DANS LA MALADIE DE PARKINSON","",""
"2724","98-06-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2725","98-04-30","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA LTD.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2726","98-04-28","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2727","98-03-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"2728","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"2729","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2731","03-08-07","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2732","03-07-21","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOPRESSOR","VASOPRESSEUR","",""
"2733","03-07-15","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"2734","98-02-11","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"2735","98-02-11","B.D.H. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2736","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2737","98-01-16","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA MÉTHODE DE FABRICATION","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"2738","98-12-14","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"2739","98-12-04","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2740","98-11-27","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APR-CLONIDINE","APOTEX","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2741","98-11-20","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN 11 AT1 RECEPTOR BLOCKER","BLOQUEUR DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"2742","98-11-20","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2743","98-11-20","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - ORAL SUSPENSION","NOUVELLE PRÉSENTATION - SUSPENSION ORALE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2744","98-11-06","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2745","98-11-01","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2746","98-10-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"2747","98-10-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2748","98-10-07","SANOFI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGGRÉGATION PLAQUETTAIRE","",""
"2749","98-09-30","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT ADJUNCTIVE THERAPY","ANTICONVULSIVANT POUR THÉRAPIE ADJUNCTIF","",""
"2750","98-09-09","BALLARD MEDICAL PRODUCTS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2751","98-09-09","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"2752","98-08-31","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2753","98-08-21","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR SYMPTOMATIC RELIEF OF TRIGERMINAL NEURALGIA - ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU - ANTIMANIAQUE","",""
"2754","98-08-21","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"2755","98-08-12","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: PEDIATRIC USAGE IN UTI, SKIN AND SKIN STRUCTURE INFECTIONS, LRTI (NOSOCOMIAL AND COMMUNITY ACQUIRED PNEUMONIA) AND FEBRILE NEUTROPENIA","NOUVELLES INDICATIONS : USAGE PÉDIATRIQUE DANS LES CAS D'INFECTION DES VOIES URINAIRES, DE LA PEAU ET DES STRUCTURES DERMIQUES, INFECTIONS NOSOCOMIALES ET ACQUISES DANS LA COMMUNAUTÉ, ET NEUTROPÉNIE FÉBRILE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2756","98-08-06","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2757","98-07-30","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2758","03-07-11","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 1MG, 5MG, 10MG, 25MG TABLETS","NOUVELLE FORME POSOLOGIQUE: 1MG, 5MG, 10MG, 25MG COMPRIMÉS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2759","98-07-30","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2760","98-07-30","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2761","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"2762","98-07-27","FTP PHARMACAL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2763","98-07-22","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"2764","98-07-22","NU-PHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2765","98-07-14","LABORATOIRES PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFACLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2766","98-07-14","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","COMPETITIVE HISTAMINE H2 - RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2767","98-07-14","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2768","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2769","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2770","98-07-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST-ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2771","98-06-19","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR SYMPTMATIC RELIEF OF TRIGEMINAL NEURALGIA/ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU / ANTIMANIAQUE","",""
"2772","98-06-18","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2773","98-06-18","TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2774","98-06-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2775","98-06-15","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH - LABELLING ONLY","RX À OTC","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2776","98-06-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2777","98-06-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2778","98-06-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2779","98-06-05","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR PEDIATRIC USE","NOUVELLE INDICATION POUR USAGE PÉDIATRIQUE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2780","98-06-05","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATING PM FROM RX TO OTC","MONOGRAPHIE RÉVISÉE - RX À OTC","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2781","98-05-27","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TOPICAL TREATMENT OF MILD TO MODERATE PSORIASIS IN CHILDREN AGED 2 YEARS AND OLDER","NOUVELLE INDICATION : TRAITEMENT TOPIQUE DU PSORIASIS BÉNIN À MODÉRÉ POUR LES ENFANTS ÂGÉS DE DEUX ANS ET PLUS","TOPICAL NON-STEROIDAL ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE TOPIQUE NON STÉROÏDIEN","",""
"2782","98-05-22","ALPHA THERAPEUTIC CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"2783","98-05-11","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR TRIPLE THERAPY (CLARITHROMYCIN/OMEPRAZOLE/AMOXICILLIN) REGIMEN FOR THE ERADICATION OF H.PYLORI","NOUVELLE INDICATION : TRI-THÉRAPIE (CLARITHROMYCINE/OMÉPRAZOLE/AMOXICILLINE) RÉGIME D'ÉRADICATION DE H.PYLORI","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2784","98-05-06","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","CIBA GEIGY CANADA","CANADA","CANADA","1","","","ANTICONVULSANT, FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIQUE","",""
"2785","98-05-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VAGINAL ANTIBACTERIAL PREPARATION","ANTIBACTÉRIEN","",""
"2786","98-04-23","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2787","98-04-06","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY AND COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2788","98-03-30","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2789","98-03-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2790","98-03-23","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2791","98-03-23","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN AIDS PATIENTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA PNEUMNIE À PNEUMOCYSTIS CARINII CHEZ LES PERSONNES ATTEINTES DU SIDA","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2792","98-03-13","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DOSAGE FORM","AUTRE MÉTHODE DE PRÉSENTATION","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"2793","98-03-06","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE PRÉSENTATION ET CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2794","98-03-06","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2795","98-03-06","MEDICAN PHARMA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2796","98-03-06","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2797","98-03-05","ZILA PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","RINCE-BOUCHE ANTIGINGIVITE","",""
"2798","98-02-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2799","01-11-30","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARASONE","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID - ANTIBIOTIC","CORTICOSTÉROÏDE TOPIQUE - ANTIBIOTIQUE","",""
"2800","98-02-18","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW NONPRESCRIPTION STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2801","98-02-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2802","98-02-11","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2803","98-02-11","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2804","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN LA ROCHE","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2805","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST","CANADA","CANADA","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"2806","98-02-11","B.D.H. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA","CANADA","CANADA","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"2807","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA","CANADA","CANADA","1","","","ANTIANDROGEN","ANTIANDROGEN","",""
"2808","98-02-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2809","98-01-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2810","98-01-28","FUJISAWA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2811","98-01-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2812","98-01-19","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2813","98-12-16","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE REVISÉE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"2814","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2815","98-11-16","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","HOECHST CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2816","98-10-23","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATED PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR - TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2817","98-09-24","ATHENA NEUROSCIENCES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","ANTICONVULSIVANT - BENZODIAZÉPINES","",""
"2818","98-08-24","BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF CHRONIC STABLE ANGINA PECTORIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ANGINE STABLE CHRONIQUE","ANTI-HYPERTENSIVE, ANTI-ANGINAL","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2819","98-08-17","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"2820","98-08-07","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN UNSTABLE CORONARY ARTERY DISEASE","NOUVELLE INDICATION : USAGE DANS LA MALADIE CORONARIENNE NON-STABLE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"2821","98-08-06","RATIOPHARM CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2822","98-08-04","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN OPHTHA","CIBA VISION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTI-INFLAMMATORY/ANALGESIC AGENT","ANTI-INFLAMMATOIRE/ANALGÉSIQUE","",""
"2823","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFIE LA MOTILITÉ GASTRO-INTESTINALE","",""
"2824","98-07-22","PHARMACIA & UPJOHN INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2825","98-07-20","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2826","98-07-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE MOTILITÉ GASTROINTESTINAL","",""
"2827","98-07-13","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE MOTILITÉ GASTROINTESTINAL","",""
"2828","98-06-10","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2829","98-05-06","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHEMORRHAGIC","ANTIHÉMORRAGIQUE","",""
"2830","98-05-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY AGENT","TRAITEMENT DU GLAUCOME","",""
"2831","98-04-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"2832","98-04-09","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","CIBA-GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY AND ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUES","",""
"2833","03-07-11","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 1MG, 5MG, 10MG, 25MG TABLETS","NOUVELLE FORME POSOLOGIQUE: 1MG, 5MG, 10MG, 25MG COMPRIMÉS","TREATMENT OF OPIOID DEPENDENCE","TRAITEMENT DE LA DÉPENDANCE AUX OPIACÉS","",""
"2834","98-02-13","MEDICAN PHARMA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIHYPERTENSIVE AGENT, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2835","98-02-11","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"2836","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2837","98-11-12","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: 1. PREVENTION OF BONE LOSS IN POSTMENOPAUSAL WOMEN WHO ARE AT RISK OF DEVELOPING OSTEOPOROSIS; 2. PREVENTION OF CORTICOSTEROID INDUCED OSTEOPOROSIS","NOUVELLES INDICATIONS: 1. EMPÊCHEMENT DE LA PERTE DES OS POUR LES FEMMES POSTMÉNOPAUSÉES QUI SONT À RISQUES DE DÉVELOPPER L'OSTÉOPOROSE. 2. EMPÊCHEMENT DU CORTICOSTÉROÏDE INDUIT D'OSTÉOPOROSE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2838","03-07-11","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"2839","03-07-09","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"2840","03-07-02","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2841","03-07-02","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPINS FOR INFERTILITY","GONADOTROPHINES POUR L'INFERTILITÉ","",""
"2842","99-05-18","FRESENIUS KABI AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE AND ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","SUPPLÉMENT NUTRITIF ET ÉLECTROLYTIQUES POUR PERFUSION I.V.","",""
"2843","03-06-26","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 1MG/ML SOLUTION","NOUVELLE CONCENTRATION: 1 MG/ML SOLUTION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2844","03-06-26","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CNS STIMULANT","STIMULANT DU SNC","",""
"2846","99-11-18","NOVARTIS CONSUMER HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"2847","03-06-20","MAYNE PHARMA (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM METHOTREXATE SODIUM INJECTION USP","MODIFICATION DU NOM DE METHOTREXATE SODIUM INJECTION USP","ANTIMETABOLITE, ANTIRHEUMATIC","ANTIMÉTABOLITE, ANTIRHUMASTISMAL","",""
"2848","03-06-18","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: LIQUID FOR INTRAVENOUS ADMINISTRATION FOR COMMUNITY ACQUIRED PNEUMONIA IN HOSPITALIZED PATIENTS","NOUVELLE FORME POSOLOGIQUE: LIQUIDE POUR ADMINISTRATION INTRAVEINEUSE POUR LA PNEUMONIE COMMUNAUTAIRE CHEZ LES PERSONNES HOSPITALISÉES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2849","03-06-09","CHIRON S.P.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2850","03-05-12","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"2851","99-04-15","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL","HOFFMANN LAROCHE LIMITED","CANADA","CANADA","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"2852","03-04-02","WHITEHALL-ROBINS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MUSCLE RELAXANT / ANALGESIC","RELAXANT MUSCULAIRE / ANALGÉSIQUE","",""
"2853","98-09-15","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2854","98-09-04","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR D'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2855","98-07-30","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS AND NEW DOSAGE FORM: PREFILLED SYRINGES","NOUVELLES INIDCATIONS ET NOUVELLE CONCENTRATION : SERINGUES PRÉREMPLIES","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT ET ANTITHROMBOTIQUE","",""
"2856","98-07-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW ALBUMIN (HUMAN)-FREE FORMULATION FOR PRE-FILLED SYRINGES","NOUVELLE FORMULE SANS ALBUMINE (HUMAINE) POUR SERINGUES PRÉREMPLIES","ERYTHROPOIESIS REGULATING HOMRONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"2857","03-04-07","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"2858","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2859","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN - PROGESTATIONAL STEROID","STÉROÏDE PROGESTAGÈNE - PROGESTATIONAL","",""
"2860","98-11-12","PROCTER & GAMBLE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: 1. PREVENTION  OF BONE LOSS IN POSTMENOPAUSAL WOMEN WHO ARE AT RISK OF DEVELOPING OSTEOPOROSIS; 2. PREVENTION OF CORTICOSTEROID INDUCED OSTEOPOROSIS","NOUVELLES INDICATIONS: 1) EMPÊCHEMENT DE LA PERTE DES OS POUR LES FEMMES POSTMÉNOPAUSÉES QUI SONT À RISQUES DE DÉVELOPPER L'OSTÉOPOROSE. 2) EMPÊCHEMENT DU CORTICOSTÉROÏDE INDUIT D'OSTÉOPOROSE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES OSSEUX","",""
"2861","03-03-31","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM CRITILIP 20%","MODIFICATION DU NOM DE CRITILIP 20%","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION LIPIDIQUE POUR ALIMENTATION PAR VOIE INTRAVEINEUSE","",""
"2862","03-03-11","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"2863","98-05-04","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2864","04-05-10","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL, CORTICOSTEROID (OTIC)","ANTIBACTÉRIEN, CORTICOSTÉROÏDE (OTIQUE)","",""
"2865","98-05-04","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2866","03-03-04","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2867","98-05-04","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2868","04-05-14","DENTSPLY CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CITANEST DENTAL (WITH EPINEPHRINE 1:200,000)","MODIFICATION DU NOM DU PRODUIT DE CITANEST DENTAL (WITH EPINEPHRINE 1:200,000)","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2869","98-04-28","FOURNIER PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2870","04-05-14","DENTSPLY CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CITANEST DENTAL","MODIFICATION DU NOM DU RPRODUIT DE CITANEST DENTAL","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2871","98-04-15","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ETHRANE","ZENECA","CANADA","CANADA","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2872","04-05-13","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2873","04-05-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM IMITREX","MODIFICATION DU NOM DU PRODUIT DE IMITREX","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"2874","04-05-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","PROGESTIN","PROGESTATIF","",""
"2875","98-04-15","IPSEN LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","CYTOSTATIC","AGENT CYTOSTATIQUE","",""
"2876","98-03-25","PHARMACHEMIE B.V.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2877","98-02-16","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"2878","04-05-13","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2879","98-02-16","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","ESTROGÈNE","",""
"2880","04-05-11","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRACEPTIVE VAGINAL RING","ANNEAU VAGINAL CONTRACEPTIF","",""
"2881","04-05-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"2882","98-12-30","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EUFLEX","SCHERING CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2883","04-05-13","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRA[HIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2884","98-12-21","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2885","04-05-13","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE DE LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2886","04-05-11","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"2887","98-12-16","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - PAEDIATRIC ONCOLOGY PATIENTS","NOUVELLE INDICATION: POUR LE TRAITEMENT DES PATIENTS PÉDIATRIQUES CANCÉREUX","HAEMATOPOIETIC AGENT","AGENT HÉMATOPÉTIQUE","",""
"2888","04-05-14","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","CHANGEMENT AU PROCESSUS DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2889","98-11-20","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EUFLEX","SCHERING CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2890","98-11-09","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2891","03-03-03","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC GROWTH FACTOR","FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE","",""
"2892","98-11-12","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION","INDICATION RÉVISÉE","TYPE 11 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE","",""
"2893","98-10-27","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2894","98-10-09","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2895","98-10-07","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2896","98-10-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EUFLEX","SCHERING CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2897","98-09-24","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN DOSING INSTRUCTIONS","NOUVEAU SCHÉMA POSOLOGIQUE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2898","03-03-03","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGE","CHANGEMENT DE FABRICATION","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"2899","98-09-09","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH CHANGES","MONOGRAPHIE RÉVISÉE","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"2900","03-02-28","SHIRE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","VASOPRESSOR","VASOPRESSEUR","",""
"2901","98-08-13","LEO LABORATORIES CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC/CORTICOSTEROID","ANTIBIOTIQUE, CORTICOSTÉROÏDES TOPIQUES","",""
"2902","03-02-25","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2903","04-05-14","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","CHANGEMENT AU PROCESSUS DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2904","03-02-13","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2905","98-08-06","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITCOSTEROID","CORTICOSTÉROÏDE","",""
"2906","98-07-30","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTISPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"2907","98-07-27","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SUPPRESSION GENITAL HERPES IN IMMUNIOCOMPETENT ADULTS","NOUVELLE INDICATION : SUPPRESSION DE L'HERPÈS GÉNITAL CHEZ L'ADULTE IMMUNOCOMPÉTENT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2908","98-07-22","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2909","98-07-15","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: ACUTE MYELOID LEUKEMIA","NOUVELLE INDICATION","HAEMATOPOIETIC AGENT","HÉMATOPOÏÉTIQUE","",""
"2910","98-06-26","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR 5-ALPHA RÉDUCATASE DU TYPE II","",""
"2911","98-06-17","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2912","98-06-17","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2913","98-05-15","CARTER-HORNER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2914","98-05-11","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2915","98-05-11","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2916","98-05-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2917","98-05-04","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FROBEN SR","ORGANON CANADA LTD.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2918","98-04-23","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2919","98-03-30","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"2920","98-03-25","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING, NEW SITE FOR FORMULATION AND FILLING","MODIFICATION DE LA MÉTHODE DE FABRICATION, NOUVEL EMPLACEMENT DE FABRICATION","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILIQUE","",""
"2921","98-03-23","J.C.P. LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"2922","98-03-06","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH COROANRY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS.","NOUVELLE INDICATION POUR RALENTIR LA PROGRESSION DE L'ATHÉROSCLÉROSE CORONARIENNE CHEZ LES PATIENTS PRÉSENTANT UNE INSUFFISANCE CORONAIRE DANS UNE STRATÉGIE DE TRAITEMENT POUR RÉDUIRE LES NIVEAUX CIBLES DE CHOLESTÉROL TOTAL ET LIPOPROTÉINE DE FAIBLE DENSITÉ (LDL)","LIPID METABOLISM REGULATOR","RÉULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2923","98-03-01","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2924","98-02-23","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"2925","98-02-18","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2926","98-02-11","J.C.P. LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 À L'HISTAMINE","",""
"2927","98-02-11","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","CORTICOSTEROID FOR INAHALATION","CORTICOSTÉROÏDE PAR VOIE NASALE","",""
"2928","98-02-05","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2929","98-01-28","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2930","98-01-23","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUBLIMAZE INJ.","JANSSEN PHARMA INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC ADJUNCT FTO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE - ADJUVANT ANESTHÉSIQUE","",""
"2931","98-01-22","STANLEY PHARMACEUTICALS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"2932","98-01-19","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW TABLET SIZE","NOUVELLE TAILLE DE COMPRIMÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"2933","98-01-16","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"2934","98-12-04","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - FOR DIAGNOSTIC USE","AGENT RADIOPHARMACEUTIQUE - POUR USAGE DIAGNOSTIQUE","",""
"2935","98-08-26","OMNI LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2936","98-06-17","NYCOMED IMAGING A.S.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR APPROVAL FOR THE USE OF OMNISCAN FOR BODY IMAGING","APPROBATION DE L'UTILISATION D'OMNISCAN DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"2937","98-06-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON","SERVIER CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORALE","",""
"2938","98-04-09","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"2939","98-04-09","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2940","98-04-08","PHARMACYCLICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","PRÉPARATION DE CONTRASTE DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"2941","98-04-08","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PALLATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN WHOSE TUMOR CONTAINS ESTROGEN AND/OR PROGESTERONE RECEPTORS","NOUVELLE INDICATION : POUR LE TRAITEMENT PALLIATIF DU CANCER AVANCÉ DU SEIN CHEZ LA FEMME EN PÉRIODE DE PRÉ OU PÉRI-MÉNOPAUSE DONT LES TUMEURS CONTIENNENT DE L'ESTROGÈNE ET OU DES RÉCEPTEURS DE PROGESTÉRONE","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"2942","98-02-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN THE TREATMENT OF PANCREATIC CANCER","NOUVELLE INDICATION : TRAITEMENT DU CANCER PANCRÉATIQUE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2943","04-05-18","WYETH CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ADVIL ALLERGY SINUS CAPLETS TO ADVIL COLD AND SINUS PLUS","MODIFICATION DU NOM DU PRODUIT DE ADVIL ALLERGY SINUS CAPLETS À ADVIL COLD AND SINUS PLUS","ANALGESIC, NASAL DECONGESTANT, ANTIHISTAMINE","ANALGÉSIQUE, DÉCONGESTIONNANT NASAL, ANTIHISTAMINIQUE","",""
"2944","04-05-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"2945","04-05-21","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2946","04-05-20","PFIZER CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","","","ANTI-INFLAMMATORY ANALGESIC AGENT, FAMILIAL ADENOMATOUS POLYPOSIS","ANTI-INFLAMMATOIRE ANALGÉSIQUE, POLYPOSE ADÉNOMATEUSE FAMILIALE","",""
"2947","04-05-18","AMPHASTAR PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADRENOCORTICAL INSUFFICIENCY DIAGNOSTIC AGENT","HORMONE ADRÉNOCORTICOTROPE","",""
"2948","04-05-17","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: ADDITION OF A PHOSPHATE BUFFER","NOUVELLE COMPOSITION : AJOUT D'UN TAMPON DE PHOSPHATE","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"2949","04-05-20","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"2950","04-05-18","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2951","04-05-18","GMD DISTRIBUTING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"2952","04-05-21","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI-WINTHROP CANADA INC.","CANADA","CANADA","1","","","ANTI-RHEUMATIC, ANTIMALARIAL","ANTIRHUMATISMAL, ANTIPALUDÉEN","",""
"2953","04-05-17","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2954","04-05-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"2955","04-05-18","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2956","04-05-21","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"2957","04-05-20","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2958","98-02-18","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ULTRASOUND CONTRAST AGENT","AGENT DE CONTRASTE POUR ULTRASON","",""
"2959","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOPID","PARKE-DAVIS (CANADA) INC.","CANADA","CANADA","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPOLIPIDÉMIANT","",""
"2960","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"2961","98-12-04","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"2962","98-11-27","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDRALAZINE","APOTEX","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2963","98-11-12","MERCK, SHARP AND DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - SCALE UP AND NEW BUILDING","NOUVEL IMMEUBLE ET AUGMENTATION PROPORTIONNELLEMENT AU PROCESSUS DE FABRICATION","VACCINE","VACCIN","",""
"2966","98-08-06","RATIOPHARM CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"2967","98-07-14","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2968","98-04-08","CONNAUGHT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"2969","98-03-06","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH AND NEW DOSAGE REGIMEN FOR INFANTS, CHILDREN AND ADOLESCENTS 1 THROUGH 18 YEARS OF AGE","NOUVELLE CONCENTRATION ET NOUVEAU SCHÉMA POSOLOGIQUE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2970","98-12-04","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE ANALGÉSIQUE NON STÉROÏDIEN","",""
"2971","98-12-04","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE ANALGÉSIQUE NON STÉROÏDIEN","",""
"2972","98-12-04","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW MULTIDOSE SOLUTION","FOURNIS POUR UNE NOUVELLE SOLUTION MULTIDOSE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2973","98-11-20","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","AGENT ANTIANGINEUX","",""
"2974","98-11-16","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2975","98-11-13","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE FILTRATION STEP","ÉTAPE DE FILTRAGE ALTERNATIF","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2976","98-11-12","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2977","98-09-21","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - ALTERNATE FILTRATION SEPARATION STEP","MODIFICATION DE LA MÉTHODE DE FABRICATION","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPHIE PASSIVE","",""
"2978","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUVANT THERAPY IN GASTROINTESTINAL DISORDERS","TRAITEMENT D'APPOINT DE TROUBLES GASTO-INTESTINAUX","",""
"2979","98-09-08","MCNEIL CONSUMER PRODUCTS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE - POUR LES ENFANTS","",""
"2980","98-08-20","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TWO NEW STRENGTHS FOR READY-TO-USE SOLUTION - ALBUMIN (HUMAN) FREE","NOUVELLE CONCENTRATIONS D'UNE NOUVELLE FORMULATION SANS ALBUMINE (HUMAINE)","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2981","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC-ANTIPYRETIC","ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"2982","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANALGÉSIQUE ET ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"2983","98-07-27","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN TEST SPECIFICATION","SPÉCIFICATION RÉVISÉE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2984","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"2985","98-06-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2986","98-06-08","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - CHRONIC HEPATITIS C INFECTION PLUS ADDITIONAL REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION - INFECTION CHRONIQUE DE L'HÉPATITE C, MONOGRAPHIE RÉVISÉE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"2987","98-06-01","SANOFI WINTHROP CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE II","",""
"2988","98-04-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-INFLAMMTORY/ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2989","98-04-15","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA PHARMA","CANADA","CANADA","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2990","98-04-06","BIOGEN CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATION","",""
"2991","98-03-30","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2992","98-03-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN TEST SPECIFICATIONS","SPÉCIFICATIONS RÉVISÉES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2993","98-03-05","UNITED STATES SURGICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIAGNOSTIC AGENT FOR THE DELINEATION OF LYMPHATIC VESSELS","AGENT DIAGNOSTIQUE POUR LA DÉLINÉATION DES VAISSEAUX LYMPHATIQUES","",""
"2994","98-02-11","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRACCO DIAGNOSTICS","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE","",""
"2995","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"2996","98-02-05","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2997","98-01-28","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT INHALATION SOLUTION","BEORHINGER INGELHEIM","CANADA","CANADA","1","NEW DOSAGE FORM: STERULES","NOUVELLE PRÉSENTATION : STÉRULES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2998","98-01-27","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2999","98-01-21","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVELLE EMPLACEMENT DE FABRICATION","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"3000","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"3001","98-11-16","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW INDICATION FOR USE IN PEDIATRIC PATIENTS","NOUVELLE INDICATION - POUR L'UTILISATION AVEC LES PATIENTS PÉDIATRIQUES","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"3002","98-11-12","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN ANALGÉSIQUE","",""
"3003","98-06-22","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"3004","98-06-22","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"3005","98-06-22","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"3006","98-05-04","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3007","98-01-29","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3008","98-01-29","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3009","98-01-29","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3010","98-01-28","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3011","98-01-16","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT, TUMOR IMAGING AGENT","AGENT RADIODIAGNOSTIQUE, AGENT POUR L'IMAGERIE DES CANCERS","",""
"3012","98-12-30","ICN CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"3013","98-12-14","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING OF CURRENT APPROVED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3